0001274737-24-000092.txt : 20241112 0001274737-24-000092.hdr.sgml : 20241112 20241112091548 ACCESSION NUMBER: 0001274737-24-000092 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241112 DATE AS OF CHANGE: 20241112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EXAGEN INC. CENTRAL INDEX KEY: 0001274737 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39049 FILM NUMBER: 241444071 BUSINESS ADDRESS: STREET 1: 1261 LIBERTY WAY CITY: VISTA STATE: CA ZIP: 92081 BUSINESS PHONE: (760) 560-1501 MAIL ADDRESS: STREET 1: 1261 LIBERTY WAY CITY: VISTA STATE: CA ZIP: 92081 FORMER COMPANY: FORMER CONFORMED NAME: EXAGEN DIAGNOSTICS INC DATE OF NAME CHANGE: 20031230 10-Q 1 exdx-20240930.htm 10-Q exdx-20240930
000127473712-312024Q3FALSExbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureexdx:segmentexdx:installment00012747372024-01-012024-09-3000012747372024-11-0800012747372024-09-3000012747372023-12-3100012747372024-07-012024-09-3000012747372023-07-012023-09-3000012747372023-01-012023-09-300001274737us-gaap:CommonStockMember2023-12-310001274737us-gaap:AdditionalPaidInCapitalMember2023-12-310001274737us-gaap:RetainedEarningsMember2023-12-310001274737us-gaap:CommonStockMember2024-01-012024-03-310001274737us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100012747372024-01-012024-03-310001274737us-gaap:RetainedEarningsMember2024-01-012024-03-310001274737us-gaap:CommonStockMember2024-03-310001274737us-gaap:AdditionalPaidInCapitalMember2024-03-310001274737us-gaap:RetainedEarningsMember2024-03-3100012747372024-03-310001274737us-gaap:CommonStockMember2024-04-012024-06-300001274737us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000012747372024-04-012024-06-300001274737us-gaap:RetainedEarningsMember2024-04-012024-06-300001274737us-gaap:CommonStockMember2024-06-300001274737us-gaap:AdditionalPaidInCapitalMember2024-06-300001274737us-gaap:RetainedEarningsMember2024-06-3000012747372024-06-300001274737us-gaap:CommonStockMember2024-07-012024-09-300001274737us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001274737us-gaap:RetainedEarningsMember2024-07-012024-09-300001274737us-gaap:CommonStockMember2024-09-300001274737us-gaap:AdditionalPaidInCapitalMember2024-09-300001274737us-gaap:RetainedEarningsMember2024-09-300001274737us-gaap:CommonStockMember2022-12-310001274737us-gaap:AdditionalPaidInCapitalMember2022-12-310001274737us-gaap:RetainedEarningsMember2022-12-3100012747372022-12-310001274737us-gaap:CommonStockMember2023-01-012023-03-310001274737us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100012747372023-01-012023-03-310001274737us-gaap:RetainedEarningsMember2023-01-012023-03-310001274737us-gaap:CommonStockMember2023-03-310001274737us-gaap:AdditionalPaidInCapitalMember2023-03-310001274737us-gaap:RetainedEarningsMember2023-03-3100012747372023-03-310001274737us-gaap:CommonStockMember2023-04-012023-06-300001274737us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000012747372023-04-012023-06-300001274737us-gaap:RetainedEarningsMember2023-04-012023-06-300001274737us-gaap:CommonStockMember2023-06-300001274737us-gaap:AdditionalPaidInCapitalMember2023-06-300001274737us-gaap:RetainedEarningsMember2023-06-3000012747372023-06-300001274737us-gaap:CommonStockMember2023-07-012023-09-300001274737us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001274737us-gaap:RetainedEarningsMember2023-07-012023-09-300001274737us-gaap:CommonStockMember2023-09-300001274737us-gaap:AdditionalPaidInCapitalMember2023-09-300001274737us-gaap:RetainedEarningsMember2023-09-3000012747372023-09-300001274737exdx:MedicareAdvantageMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001274737exdx:MedicareAdvantageMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001274737exdx:MedicareAdvantageMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300001274737exdx:MedicareAdvantageMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001274737exdx:MedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001274737exdx:MedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001274737exdx:MedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300001274737exdx:MedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001274737exdx:MedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-09-300001274737exdx:MedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001274737exdx:MedicareAdvantageMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-09-300001274737exdx:MedicareAdvantageMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001274737us-gaap:ProductConcentrationRiskMemberexdx:AVISECTDTestMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001274737us-gaap:ProductConcentrationRiskMemberexdx:AVISECTDTestMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001274737us-gaap:ProductConcentrationRiskMemberexdx:AVISECTDTestMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300001274737us-gaap:ProductConcentrationRiskMemberexdx:AVISECTDTestMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001274737exdx:TwoMajorSuppliersMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001274737exdx:TwoMajorSuppliersMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001274737exdx:TwoMajorSuppliersMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300001274737exdx:TwoMajorSuppliersMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001274737exdx:HealthcareInsurersMember2024-07-012024-09-300001274737exdx:HealthcareInsurersMember2023-07-012023-09-300001274737exdx:HealthcareInsurersMember2024-01-012024-09-300001274737exdx:HealthcareInsurersMember2023-01-012023-09-300001274737exdx:Government1Member2024-07-012024-09-300001274737exdx:Government1Member2023-07-012023-09-300001274737exdx:Government1Member2024-01-012024-09-300001274737exdx:Government1Member2023-01-012023-09-300001274737exdx:ClientMember2024-07-012024-09-300001274737exdx:ClientMember2023-07-012023-09-300001274737exdx:ClientMember2024-01-012024-09-300001274737exdx:ClientMember2023-01-012023-09-300001274737us-gaap:OtherCustomerMember2024-07-012024-09-300001274737us-gaap:OtherCustomerMember2023-07-012023-09-300001274737us-gaap:OtherCustomerMember2024-01-012024-09-300001274737us-gaap:OtherCustomerMember2023-01-012023-09-300001274737us-gaap:ShippingAndHandlingMember2024-07-012024-09-300001274737us-gaap:ShippingAndHandlingMember2023-07-012023-09-300001274737us-gaap:ShippingAndHandlingMember2024-01-012024-09-300001274737us-gaap:ShippingAndHandlingMember2023-01-012023-09-300001274737us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001274737us-gaap:WarrantMember2024-01-012024-09-300001274737us-gaap:WarrantMember2023-01-012023-09-300001274737us-gaap:StockOptionMember2024-01-012024-09-300001274737us-gaap:StockOptionMember2023-01-012023-09-300001274737us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001274737us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001274737us-gaap:EmployeeStockMember2024-01-012024-09-300001274737us-gaap:EmployeeStockMember2023-01-012023-09-300001274737us-gaap:FurnitureAndFixturesMember2024-09-300001274737us-gaap:FurnitureAndFixturesMember2023-12-310001274737exdx:LaboratoryEquipmentMember2024-09-300001274737exdx:LaboratoryEquipmentMember2023-12-310001274737exdx:ComputerEquipmentAndSoftwareMember2024-09-300001274737exdx:ComputerEquipmentAndSoftwareMember2023-12-310001274737us-gaap:LeaseholdImprovementsMember2024-09-300001274737us-gaap:LeaseholdImprovementsMember2023-12-310001274737us-gaap:ConstructionInProgressMember2024-09-300001274737us-gaap:ConstructionInProgressMember2023-12-310001274737exdx:InnovatusLifeSciencesLendingFundMemberexdx:Term2017Memberus-gaap:LoansPayableMember2017-09-012017-09-300001274737exdx:InnovatusLifeSciencesLendingFundMemberexdx:Term2017Memberus-gaap:LoansPayableMember2024-09-300001274737exdx:InnovatusLifeSciencesLendingFundMemberexdx:Term2017Memberus-gaap:LoansPayableMember2023-04-282023-04-280001274737exdx:InnovatusLifeSciencesLendingFundMemberexdx:Term2017Memberus-gaap:LoansPayableMember2023-04-280001274737exdx:InnovatusLifeSciencesLendingFundMemberexdx:Term2017Memberus-gaap:LoansPayableMember2024-01-012024-09-300001274737exdx:InnovatusLifeSciencesLendingFundMemberexdx:Term2017Memberus-gaap:PaymentInKindPIKNoteMember2023-07-012023-09-300001274737exdx:InnovatusLifeSciencesLendingFundMemberexdx:Term2017Memberus-gaap:PaymentInKindPIKNoteMember2024-07-012024-09-300001274737exdx:InnovatusLifeSciencesLendingFundMemberexdx:Term2017Memberus-gaap:PaymentInKindPIKNoteMember2024-01-012024-09-300001274737exdx:InnovatusLifeSciencesLendingFundMemberexdx:Term2017Memberus-gaap:PaymentInKindPIKNoteMember2023-01-012023-09-300001274737exdx:EquipmentNotesPayableMember2024-09-300001274737us-gaap:LicenseAgreementTermsMembersrt:MinimumMember2024-09-300001274737us-gaap:LicenseAgreementTermsMembersrt:MaximumMember2024-09-300001274737exdx:AlleghenyHealthNetworkResearchInstituteMember2021-05-012021-05-310001274737exdx:AHNCollaborationMember2024-07-012024-09-300001274737exdx:AHNCollaborationMember2023-07-012023-09-300001274737exdx:AHNCollaborationMember2024-01-012024-09-300001274737exdx:AHNCollaborationMember2023-01-012023-09-3000012747372024-08-310001274737exdx:USDepartmentOfJusticeCaseMemberus-gaap:SettledLitigationMember2023-10-012023-10-310001274737us-gaap:FairValueInputsLevel2Memberexdx:Term2017Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001274737us-gaap:FairValueInputsLevel2Memberexdx:Term2017Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001274737exdx:EquipmentNotesPayableMember2023-12-310001274737us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-09-300001274737us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-09-300001274737us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-09-300001274737us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-09-300001274737us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001274737us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001274737us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001274737us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001274737exdx:ShelfRegistrationStatementMember2023-11-170001274737exdx:ShelfRegistrationStatementMember2024-09-300001274737exdx:CowenEquityDistributionAgreementMember2022-09-152022-09-150001274737exdx:ExpirationJan192026Member2024-09-300001274737exdx:ExpirationMar312026Member2024-09-300001274737exdx:ExpirationApr12026Member2024-09-300001274737exdx:ExpirationDec72025Member2024-09-300001274737exdx:NoExpirationMember2024-09-300001274737us-gaap:EmployeeStockOptionMemberexdx:IncentiveAwardPlan2019Member2024-01-012024-09-300001274737us-gaap:EmployeeStockOptionMemberexdx:IncentiveAwardPlan2019Member2024-09-300001274737us-gaap:RestrictedStockUnitsRSUMember2023-12-310001274737us-gaap:RestrictedStockUnitsRSUMember2024-09-300001274737us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001274737us-gaap:EmployeeStockOptionMember2023-12-310001274737us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001274737us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001274737us-gaap:EmployeeStockOptionMember2024-09-300001274737us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001274737us-gaap:EmployeeStockMember2024-09-300001274737us-gaap:CostOfSalesMember2024-07-012024-09-300001274737us-gaap:CostOfSalesMember2023-07-012023-09-300001274737us-gaap:CostOfSalesMember2024-01-012024-09-300001274737us-gaap:CostOfSalesMember2023-01-012023-09-300001274737us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300001274737us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001274737us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300001274737us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001274737us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001274737us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001274737us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001274737us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 FORM 10-Q

(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


Commission File Number: 001-39049

EXAGEN INC.
(Exact name of registrant as specified in its charter)
Delaware20-0434866
(State or Other Jurisdiction of
Incorporation or Organization)		(I.R.S. Employer
Identification No.)
1261 Liberty Way
Vista,
CA92081
(Address of Principal Executive Offices)(Zip Code)
(760)
560-1501
(Registrant's Telephone Number, Including Area Code)
 Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareXGNThe Nasdaq Global Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Total shares of common stock outstanding as of the close of business on November 8, 2024 was 17,637,278.


TABLE OF CONTENTS
 
 Page
Part I.Financial Information
Item 1.
Item 2.
Item 3.
Item 4.
Part II.Other Information
Item 1.
Item 1A.
Item 5.
Item 6.





Part I. Financial Information
Item 1. Unaudited Condensed Financial Statements
Exagen Inc.
Unaudited Condensed Balance Sheets
(in thousands, except share and per share data)
 September 30, 2024December 31, 2023
 
Assets
Current assets:
Cash and cash equivalents$22,035 $36,493 
Accounts receivable, net9,387 6,551 
Prepaid expenses and other current assets4,135 4,797 
Total current assets35,557 47,841 
Property and equipment, net4,855 5,201 
Operating lease right-of-use assets2,630 3,286 
Other assets563 616 
Total assets$43,605 $56,944 
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$1,105 $3,131 
Accrued and other current liabilities6,177 7,531 
Operating lease liabilities1,065 976 
Borrowings-current portion430 264 
Total current liabilities8,777 11,902 
Borrowings-non-current portion, net of discounts and debt issuance costs19,823 19,231 
Operating lease liabilities - non-current portion1,952 2,760 
Other non-current liabilities185 357 
Total liabilities30,737 34,250 
Commitments and contingencies (Note 5)
Stockholders' equity:
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized, no shares issued or outstanding as of September 30, 2024 and December 31, 2023
— — 
Common stock, $0.001 par value per share; 200,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 17,520,335 and 17,045,954 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively
18 17 
        Additional paid-in capital
303,420 301,893 
Accumulated deficit(290,570)(279,216)
Total stockholders' equity12,868 22,694 
Total liabilities and stockholders' equity$43,605 $56,944 
The accompanying notes are an integral part of these condensed financial statements

1

Exagen Inc.
Unaudited Condensed Statements of Operations
(in thousands, except share and per share data)
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Revenue$12,507 $13,416 $41,986 $38,783 
Operating expenses:
Costs of revenue5,526 5,710 17,351 17,472 
Selling, general and administrative expenses10,163 11,375 31,169 35,212 
Research and development expenses1,481 1,400 3,719 3,789 
Total operating expenses17,170 18,485 52,239 56,473 
Loss from operations(4,663)(5,069)(10,253)(17,690)
Interest expense(562)(557)(1,671)(1,769)
Interest income197 211 570 1,343 
Net loss$(5,028)$(5,415)$(11,354)$(18,116)
Net loss per share, basic and diluted$(0.28)$(0.31)$(0.63)$(1.03)
Weighted-average number of shares used to compute net loss per share, basic and diluted18,254,937 17,692,603 18,127,549 17,626,686 
The accompanying notes are an integral part of these condensed financial statements

2

Exagen Inc.
Unaudited Condensed Statements of Stockholders' Equity
(in thousands, except share data)

 Common StockAdditional
Paid-In
Capital		Accumulated
Deficit		Total
Stockholders'
Equity
 SharesAmount
Balances as of December 31, 202317,045,954 $17 $301,893 $(279,216)$22,694 
Issuance of stock from vested restricted stock units217,056 — — — — 
Issuance of stock under Employee Stock Purchase Plan54,605 — 104 — 104 
Exercise of stock options326 — — — — 
Stock-based compensation— — 553 — 553 
Net loss— — — (3,360)(3,360)
Balances as of March 31, 202417,317,941 17 302,550 (282,576)19,991 
Issuance of stock from vested restricted stock units62,998 — — — — 
Exercise of stock options636 — — — — 
Stock-based compensation— — 560 — 560 
Net loss— — — (2,966)(2,966)
Balances as of June 30, 2024
17,381,575 17 303,110 (285,542)17,585 
Issuance of stock from vested restricted stock units13,155 — — — — 
Issuance of stock under Employee Stock Purchase Plan41,443 1 71 — 72 
Exercise of stock options84,162 — 22 — 22 
Stock-based compensation— — 217 — 217 
Net loss— — — (5,028)(5,028)
Balances as of September 30, 2024
17,520,335 $18 $303,420 $(290,570)$12,868 
The accompanying notes are an integral part of these condensed financial statements
3

Exagen Inc.
Unaudited Condensed Statements of Stockholders' Equity
(in thousands, except share data)

 Common StockAdditional
Paid-In
Capital		Accumulated
Deficit		Total
Stockholders'
Equity
 SharesAmount
Balances as of December 31, 202216,549,984 $17 $297,970 $(255,527)$42,460 
Issuance of stock from vested restricted stock units113,378 — — — — 
Exercise of stock options93,335 — 27 — 27 
Issuance of stock under Employee Stock Purchase Plan70,317 — 152 — 152 
Stock-based compensation— — 986 — 986 
Net loss— — — (7,688)(7,688)
Balances as of March 31, 202316,827,014 17 299,135 (263,215)35,937 
Issuance of stock from vested restricted stock units31,180 — — — — 
Stock-based compensation— — 978 — 978 
Net loss— — — (5,013)(5,013)
Balances as of June 30, 202316,858,194 17 300,113 (268,228)31,902 
Issuance of stock from vested restricted stock units14,424 — — — — 
Issuance of stock under Employee Stock Purchase Plan59,276 — 127 — 127 
Stock-based compensation— — 890 — 890 
Net loss— — — (5,415)(5,415)
Balances as of September 30, 202316,931,894 $17 $301,130 $(273,643)$27,504 
The accompanying notes are an integral part of these condensed financial statements
 
4

Exagen Inc.
Unaudited Condensed Statements of Cash Flows
(in thousands)
 
 Nine Months Ended September 30,
 20242023
 
Cash flows from operating activities:
Net loss$(11,354)$(18,116)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization1,309 1,661 
Amortization of debt discount and debt issuance costs112 119 
Non-cash interest expense
206 294 
Loss on disposal of assets111 209 
Non-cash lease expense656 717 
Stock-based compensation1,330 2,854 
Changes in assets and liabilities:
Accounts receivable, net(2,836)(10,967)
Prepaid expenses and other current assets662 727 
Other assets50 (120)
Operating lease liabilities(720)(767)
Accounts payable(2,028)(1,422)
Accrued and other current liabilities(1,140)2,000 
Net cash used in operating activities(13,642)(22,811)
Cash flows from investing activities:
Purchases of property and equipment(369)(722)
Proceeds from disposal of property and equipment— 2 
Net cash used in investing activities(369)(720)
Cash flows from financing activities:
Proceeds from exercise of stock options22 27 
Proceeds from common stock issued under Employee Stock Purchase Plan176 279 
Principal payments on finance lease obligations(379)(541)
Principal payment on note payable obligations(266)(177)
Principal payment on long-term debt— (10,000)
Net cash used in financing activities(447)(10,412)
Net change in cash, cash equivalents and restricted cash(14,458)(33,943)
Cash, cash equivalents and restricted cash, beginning of period36,693 62,591 
Cash, cash equivalents and restricted cash, end of period$22,235 $28,648 
Supplemental disclosure of cash flow information:
Cash paid for interest$1,307 $1,336 
Supplemental disclosure of non-cash items:
Equipment purchased under notes payable obligations$706 $250 
Costs incurred, but not paid, in connection with capital expenditures$20 $81 

The accompanying notes are an integral part of these condensed financial statements
5


Exagen Inc.
Notes to Unaudited Interim Condensed Financial Statements
Note 1. Organization
Description of Business
Exagen Inc. (the Company) is a commercial-stage diagnostics company which exists to provide clarity in autoimmune disease decision making with the goal of improving patients' clinical outcomes.
Liquidity
The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses. As of September 30, 2024, the Company had cash and cash equivalents of $22.0 million and had an accumulated deficit of $290.6 million. Since inception, the Company has financed its operations primarily through a combination of equity financings, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these condensed financial statements.
To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it may need to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.
Note 2. Summary of Significant Accounting Policies
Basis of Presentation and Use of Estimates
The accompanying interim condensed balance sheet as of September 30, 2024, condensed statements of operations and stockholders' equity for the three and nine months ended September 30, 2024 and 2023, cash flows for the nine months ended September 30, 2024 and 2023 and the related footnote disclosures are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. These unaudited condensed financial statements and related footnote disclosures should be read in conjunction with the Company’s audited financial statements for the fiscal year ended December 31, 2023, included in its Annual Report on Form 10-K filed with the SEC on March 18, 2024. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all normal adjustments necessary for the fair presentation of the Company's financial position as of September 30, 2024 and its results of operations for the periods presented. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.
Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the recoverability of its long-lived assets and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.
6

Concentration of Credit Risk and Other Risk and Uncertainties
Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.
Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:
 
 Revenue
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2024202320242023
Medicare Advantage22 %15 %21 %17 %
Medicare20 %37 %24 %35 %
*Less than 10%.

Accounts Receivable, Net
 September 30, 2024December 31, 2023
Medicare23 %42 %
Medicare Advantage22 %16 %
*Less than 10%.
For the three months ended September 30, 2024 and 2023, approximately 93% and 89%, respectively, of the Company's revenue was related to the AVISE® CTD test. Revenue related to the AVISE® CTD test for the nine months ended September 30, 2024 and 2023 was approximately 91% and 88%, respectively.
The Company is dependent on key suppliers for certain laboratory materials. For the three months ended September 30, 2024 and 2023, approximately 98% and 98%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. For the nine months ended September 30, 2024 and 2023, approximately 97% and 97%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.
Disaggregation of Revenue
The following table includes the Company's revenues as disaggregated by payor and customer category (in thousands):
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Revenue:
Commercial$6,779 $6,090 $22,314 $17,789 
Government2,633 4,955 10,276 13,570 
Client(1)2,981 2,319 9,175 6,999 
Other(2)114 52 221 425 
Total revenue$12,507 $13,416 $41,986 $38,783 
7

(1)Includes hospitals, other laboratories, etc.
(2)Includes patient self-pay.
Cash, Cash Equivalents and Restricted Cash
The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.
The Company has an arrangement with a financial institution with which it has an existing banking relationship, whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a certificate of deposit with this financial institution in the amount of $0.2 million as collateral for the balances borrowed on these cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).
Cash, cash equivalents, and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):
 
 September 30, 2024December 31, 2023
Cash and cash equivalents$22,035 $36,493 
Restricted cash200 200 
$22,235 $36,693 
Long-lived Assets
The Company’s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, the Company combines its intangible assets and other long-lived assets, into groupings, a determination which is made principally on the basis of whether the assets are specific to a particular test offered or technology being developed. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset’s carrying amount. Management’s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.
Revenue Recognition
Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (hospitals, other laboratories, etc.) and patient self-pay.
The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers and follows a five-step process to determine the amount and timing of revenue recognized: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligation is satisfied. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.
8

Payors are generally billed at the Company's list price unless a separate pricing contract is in place. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the three months ended September 30, 2024 and 2023 was a $0.6 million net revenue increase and a $2.5 million net revenue increase, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. Included in revenues for the nine months ended September 30, 2024 and 2023 was a $6.2 million net revenue increase and a $2.6 million net revenue increase, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.
Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company’s balance sheet.
Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information, along with any requested medical or other claims-related information to the healthcare insurers. This generally occurs within 30 to 90 days of billing, however, the amount and timing of any reimbursements or collections for the Company's billed tests may vary by payor and other circumstances. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.
Accounts Receivable and Allowance for Credit Losses
We accrue an allowance for credit losses against our accounts receivable based on management’s current estimate of amounts that will not be collected. Management’s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was zero as of September 30, 2024 and 2023. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.
Research and Development
Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense; materials; laboratory supplies; consulting costs; costs associated with setting up and conducting clinical studies; depreciation; amortization and allocated overhead, including rent and utilities.
Advertising and Marketing Costs
Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.4 million and $0.5 million for the three months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024 and 2023, total advertising and marketing costs were approximately $1.0 million and $1.2 million, respectively. These costs are included in selling, general and administrative expenses in the accompanying condensed statements of operations.
Shipping and Handling Costs
9

Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and were approximately $0.9 million and $0.6 million for the three months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024 and 2023, shipping and handling costs were approximately $2.5 million and $1.9 million, respectively.
Stock-Based Compensation
The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.
The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method, as we have concluded that our stock option exercise history does not provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.
The fair value of each restricted stock unit (RSU) is determined on the grant date using the closing price of the Company's common stock on that date. The Company's RSUs generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of the RSU is subject to the holder's continued service with the Company. The Company issues new shares of common stock to satisfy the RSUs upon vesting.
Comprehensive Loss
Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.
Net Loss Per Share
Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, RSUs outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three and nine months ended September 30, 2024 and 2023, there is no difference in the number of shares used to calculate basic and diluted shares outstanding, as the inclusion of the potentially dilutive securities would be antidilutive.
Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):
 
 September 30, 2024September 30, 2023
Warrants to purchase common stock325,330 409,108 
Common stock options576,151 1,004,855 
Restricted stock units1,810,468 1,568,112 
Employee stock purchase plan12,570 12,542 
Total2,724,519 2,994,617 
10

Segment Reporting
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.
Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, Accounting Standards Updates (ASU) not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company's financial statements or disclosures.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), which requires public entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (CODM) and details of how the CODM uses financial reporting to assess the performance of a segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU will likely result in additional required disclosure when adopted.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which requires additional income tax disclosures in the rate reconciliation table for federal, state and foreign income taxes, in addition to more details about the reconciling items in some categories when items meet a certain quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 with early adoption permitted. The Company does not expect that this standard will have a material impact on its financial statements.
Note 3. Other Financial Information
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following (in thousands):
                                                                     
 September 30, 2024December 31, 2023
Diagnostic testing supplies$2,934 $2,871 
Prepaid product royalties32 35 
Prepaid maintenance and insurance contracts1,169 1,860 
Other prepaid expenses and other current assets— 31 
Prepaid expenses and other current assets$4,135 $4,797 
Property and Equipment
Property and equipment consist of the following (in thousands):
11

 
 September 30, 2024December 31, 2023
Furniture and fixtures$98 $98 
Laboratory equipment4,209 5,312 
Computer equipment and software2,113 2,185 
Leasehold improvements3,089 3,316 
Construction in progress945 59 
Total property and equipment10,454 10,970 
Less: accumulated depreciation and amortization(5,599)(5,769)
Property and equipment, net$4,855 $5,201 
Depreciation and amortization expense for the three months ended September 30, 2024 and 2023 was approximately $0.4 million and $0.6 million, respectively. For the nine months ended September 30, 2024 and 2023, depreciation and amortization expense was approximately $1.3 million and $1.7 million, respectively.
Accrued and Other Current Liabilities
Accrued and other current liabilities consist of the following (in thousands):
 
 September 30, 2024December 31, 2023
Accrued payroll and related expenses$4,413 $4,738 
Accrued purchases of goods and services547 720 
Finance lease obligations, current portion283 490 
Refund liability266 302 
Other accrued liabilities668 1,281 
Accrued and other current liabilities$6,177 $7,531 
Note 4. Borrowings
2017 Term Loan
In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), as amended (the Amended Loan Agreement), pursuant to which the Company borrowed $25.0 million. As of September 30, 2024, no additional amounts remained available to borrow under the Amended Loan Agreement.
On April 28, 2023, the Company entered into the Amended Loan Agreement. The Amended Loan Agreement was treated as a modification. In connection with the Amended Loan Agreement, the Company repaid $10.0 million of the principal balance outstanding, for which the prepayment premium was waived. Pursuant to the Amended Loan Agreement, the interest rate on all borrowings under the Amended Loan Agreement is the sum (the Basic Rate) of (a) the greater of 8.0% or The Wall Street Journal prime rate (the Prime Rate), plus (b) 2.0%, which is paid-in-kind in the form of additional term loans (PIK Loans). Under the Amended Loan Agreement, an amount equal to 1.5% of the Basic Rate will be payable in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until April 1, 2026, after which interest is scheduled to accrue at the Basic Rate. The maturity date of the loan was extended to December 31, 2026. The Company estimated the effective interest rate of this loan to be approximately 10.6% as of September 30, 2024. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest under the Amended Loan Agreement is to be repaid in ten equal monthly installments commencing in April 2026. Upon repayment of the final installment under the Amended Loan Agreement, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of the loan using the effective interest method. For each of the three months ended September 30, 2024 and 2023, the Company issued PIK Loans totaling $0.1 million. For the nine months ended September 30, 2024 and 2023, the Company issued PIK Loans totaling $0.2 million and $0.3 million, respectively. The issuances of the PIK Loans are included in borrowings-non-current portion on the accompanying balance sheet.
12

The Amended Loan Agreement requires a prepayment premium of 1% of the aggregate outstanding principal for any prepayments made prior to November 1, 2024.
The Amended Loan Agreement is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Amended Loan Agreement require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.
The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis, however the Company is not required to comply with the revenue covenant for any quarter during which it maintains a minimum aggregate cash balance equal to fifty percent of the aggregate principal amount of the Amended Loan Agreement (excluding any capitalized interest paid-in-kind) at all times during such quarter. The consequences of failing to achieve the performance covenants, when applicable, will be cured if, (i) within thirty days of failing to achieve the performance covenant, the Company submits a new financial plan approved by the Company's board of directors (the Board) to Innovatus under which the Company is expected to break even on a cash flow basis prior to the maturity date, and (ii) within thirty days of the submission of such financial plan, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined in the Amended Loan Agreement. The Amended Loan Agreement requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.
The negative covenants provide, among other things, that without the prior consent of Innovatus, subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Amended Loan Agreement provides that an event of default will occur if, among other triggers, (i) the Company defaults in the payment of any amount payable under the agreement when due, (ii) there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii) the Company becomes insolvent, (iv) the Company undergoes a change in control or (v) the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.
As of September 30, 2024, the Company was in compliance with all covenants of the Amended Loan Agreement.
Upon an event of default in any of the Amended Loan Agreement covenants, the repayment of the 2017 Term Loan may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the 2017 Term Loan can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the Amended Loan Agreement due beyond twelve months of the balance sheet date as non-current.
Equipment Notes Payable
In April 2024, the Company purchased additional laboratory equipment using notes payable. At September 30, 2024, the total notes payable balance related to the financed equipment was $1.2 million, with $0.4 million classified within borrowings-current portion and $0.8 million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. The notes related to the financed equipment are subject to a 5.28% effective interest rate and will mature between October 1, 2026 and April 1, 2028.
Future Minimum Payments on the Outstanding Borrowings
As of September 30, 2024, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):
13

 
2024 (remaining)$517 
20252,097 
202621,400 
2027215 
202867 
Total24,296 
Less:
Unamortized debt discount and issuance costs(80)
Interest(3,963)
Total borrowings, net of discounts and debt issuance costs20,253 
Less: Borrowings-current portion(430)
Borrowings-non-current portion, net of discounts and debt issuance costs$19,823 
Note 5. Commitments and Contingencies
Licensing Agreements
The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements, individual license agreements generally provide for ongoing royalty payments ranging from 2.0% to 7.0% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when incurred and recorded in costs of revenue in the accompanying condensed statements of operations.
Collaboration Obligations
In May 2021, the Company entered into a master research collaboration agreement with Allegheny Health Network Research Institute (AHN), pursuant to which the Company is required to pay AHN a collaboration fee of $0.4 million per year. Collaboration expenses under the master research collaboration agreement were $0.1 million for each of the three months ended September 30, 2024 and 2023. For each of the nine months ended September 30, 2024 and 2023, collaboration expenses under the master research collaboration agreement were $0.3 million. Collaboration expenses under the AHN collaboration are included in research and development expenses.
Supply Agreements
In August 2024, the Company amended a supply agreement with one supplier for reagents, which includes pricing terms and minimum purchase commitments, through December 31, 2025, for new consumable products related to the Company's launch of the RA Sub-Profile Biomarkers. Aggregate minimum annual purchase commitments related to such agreement for the years ending December 31, 2024 and 2025 are $8.4 million and $10.4 million, respectively.
Contingencies
In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including for subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
Litigation
From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities. The Company does not believe the outcome of any such matters will have a material effect on its financial position or results of operations.
14

In addition, in October 2023, the Company resolved an investigation with the U.S. Attorney’s Office for the District of Massachusetts that was initiated by a qui tam lawsuit. Pursuant to a settlement agreement entered into by and between the Company and the U.S. Department of Justice (the Settlement Agreement), the Company made a single lump-sum remittance to the government in the amount of $0.7 million, including interest, in connection with specimen processing arrangements that Exagen historically had with physicians. The U.S. Attorney’s Office dismissed this “covered conduct” in the qui tam lawsuit with prejudice, while non-covered conduct was dismissed without prejudice. The Department of Justice excused itself from the case in connection with the settlement. In November 2023, the complaint was unsealed by the court and served on Exagen by the relator. Exagen filed a motion to dismiss the complaint. In December 2023, the Company's insurance carrier provided reimbursement for certain defense costs the Company incurred in the October 2023 qui tam lawsuit. In February 2024, the relator filed a motion for leave to amend the complaint. Exagen opposed this motion, and all motions are still pending. The Company cannot predict when these matters will be resolved, the outcome of these matters, or their potential impact, which may materially and adversely affect the Company’s business, prospects, and financial condition. The Company intends to vigorously defend against the claims being asserted in the complaint.
The Company's participation in federal healthcare programs is not affected by the Settlement Agreement.
Note 6. Fair Value Measurements
The carrying value of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature, which are determined to be a Level 1 measurement. The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for the same or similar issues. As of September 30, 2024, the 2017 Term Loan had a carrying value of $19.0 million and a fair value of $18.5 million. As of December 31, 2023, the 2017 Term Loan had a carrying value of $18.7 million and a fair value of $19.7 million. The estimated fair value of the 2017 Term Loan was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The carrying value of the Company's other long-term borrowing at September 30, 2024 was $1.2 million and approximated its fair value. At December 31, 2023, the carrying value of the Company's other long-term borrowing was $0.8 million and approximated its fair value.
Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:
Level 1 -    Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2 -    Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and
Level 3 -    Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.
The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):
 
 September 30, 2024
 TotalLevel 1Level 2Level 3
Assets:
Money market funds, included in cash and cash equivalents$14,963 $14,963 $— $— 
15

 
 December 31, 2023
 TotalLevel 1Level 2Level 3
Assets:
Money market funds, included in cash and cash equivalents$14,386 $14,386 $— $— 
The fair value of the Company's money market funds is based on quoted market prices.
Note 7. Stockholders' Equity
Common Stock
Shelf Registration Statement
On November 17, 2023, the Company filed a registration statement on Form S-3, as amended (the 2023 Shelf Registration Statement), covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units. The 2023 Shelf Registration Statement became effective on November 29, 2023, and all $150.0 million remain available for sale as of September 30, 2024.
At The Market Sales Agreement
On September 15, 2022, the Company entered into a sales agreement, as amended on November 17, 2023 (the Sales Agreement) with Cowen and Company, LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $50.0 million. The Company is not obligated to sell any shares of Company common stock in the offering. As of September 30, 2024, the Company has not sold any shares of its common stock pursuant to the Sales Agreement.
Outstanding Warrants
The following equity classified warrants to purchase common stock were outstanding as of September 30, 2024:
SharesExercise PriceIssuance dateExpiration date
Common stock warrants237,169$1.84 January 19, 2016January 19, 2026
Common stock warrants67,086$1.84 March 31, 2016March 31, 2026
Common stock warrants131$1.84 April 1, 2016April 1, 2026
Common stock warrants20,944$14.32 December 7, 2018December 7, 2025
Common stock warrants804,951$0.001 June 22, 2021None
1,130,281
During the three and nine months ended September 30, 2024, no warrants to purchase common stock were exercised.
Note 8. Stock Option Plan
2019 Incentive Award Plan
In September 2019, the Board adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board and is generally four years from the date of grant or, for grants to new hires, date of hire. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) 4% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board. As of September 30, 2024, 2,122,271 shares of common stock remained available for future awards under the 2019 Plan.
16

Restricted Stock Units
RSU activity under the Company's 2019 Plan is set forth below:
Number of
Shares		Weighted-
Average
Grant Date Fair Value
Outstanding, December 31, 20231,387,459 $4.24 
Awards granted1,287,225 $2.09 
Awards released(293,209)$5.87 
Awards canceled(571,007)$4.16 
Outstanding, September 30, 2024
1,810,468 $2.47 
As of September 30, 2024, all of the outstanding RSUs were unvested. The fair value of RSUs vested in the nine months ended September 30, 2024 and 2023 was $0.5 million and $0.4 million, respectively. The weighted average grant date fair value for RSUs granted in the nine months ended September 30, 2024 and 2023 was $2.09 and $2.42, respectively. As of September 30, 2024, total unrecognized compensation cost related to RSUs was $3.7 million, which is expected to be recognized over a remaining weighted-average vesting period of 3.0 years.
Stock Options
Stock option activity under the 2019 Plan is set forth below:
 
Number of
Options		Weighted-
Average
Exercise Price		Weighted-
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic
Value (in thousands)
Outstanding, December 31, 2023986,819 $11.87 6.44$228 
Granted55,500 $1.99 
Exercised(85,124)$0.26 
Forfeited(9,518)$16.70 
Expired(371,526)$15.48 
Outstanding, September 30, 2024
576,151 $10.23 6.57$197 
Vested and expected to vest, September 30, 2024
576,151 $10.23 6.57$197 
Options exercisable, September 30, 2024
552,686 $10.56 6.45$177 
There were 55,500 and 73,500 stock options granted in the nine months ended September 30, 2024 and 2023, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The aggregate intrinsic value of options exercised during the nine months ended September 30, 2024 was $0.3 million. The aggregate intrinsic value of options exercised during the nine months ended September 30, 2023 was $0.2 million. As of September 30, 2024, total unrecognized compensation cost related to option awards was less than $0.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.29 years.
2019 Employee Stock Purchase Plan
In September 2019, the Board adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Board. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the lesser of (i) 1% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board. As of September 30, 2024, 523,744 shares of common stock remained available for issuance under the ESPP.
Stock-Based Compensation Expense
17

Total non-cash stock-based compensation expense recorded related to options granted, RSUs granted and stock purchase rights granted under the ESPP in the condensed statements of operations is as follows (in thousands):
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Costs of revenue$47 $45 $103 $161 
Selling, general and administrative114 792 1,058 2,497 
Research and development56 53 169 196 
Total$217 $890 $1,330 $2,854 
18

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion of our financial condition and results of operations in conjunction with the unaudited condensed financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023.
Forward Looking Statements
The following discussion and other parts of this quarterly report contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements other than statements of historical facts contained in this quarterly report, including statements regarding our future results of operations and financial position, estimates regarding profitability and the time that may elapse before we may become profitable, business strategy, current and future product offerings, reimbursement and coverage, the expected benefits from our partnership or promotion arrangements with third parties, research and development costs, timing and likelihood of success and plans and objectives of management for future operations, are forward-looking statements. These statements are often identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “estimate,” or “continue,” and similar expressions or variations. The forward-looking statements in this quarterly report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, operating results, business strategy, and short-term and long-term business operations and objectives. These forward-looking statements speak only as of the date of this quarterly report and are subject to a number of risks, uncertainties and assumptions, including those described in Part I, Item IA, "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and Part II, Item 1A, “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Overview
We exist to provide clarity in autoimmune disease decision making with the goal of improving patients' clinical outcomes. We have developed and are commercializing a portfolio of innovative testing products under our AVISE® brand, which allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases. We believe our focus on and experience in the field of rheumatology, combined with our commitment to excellent customer service and support, position us very well to respond to the needs of rheumatologists and the patients they serve. There is an unmet need for rheumatologists to add clarity in their connective tissue disease (CTD) clinical evaluation, and we believe there is a significant opportunity for our tests in this market, particularly for potentially life-threatening diseases such as systemic lupus erythematosus (SLE).
Since inception we have devoted substantially all of our efforts to developing and marketing products for the diagnosis, prognosis and monitoring of autoimmune diseases. We commercially launched our lead testing product, AVISE® CTD, in 2012. Our proprietary AVISE® Lupus test is included as part of the AVISE® CTD panel and employs a patent-protected method for diagnosing patients with SLE based on levels of CB-CAPs (e.g. EC4d and BC4d), ANA, and ds-DNA. The AVISE® Lupus test also employs patent-protected algorithms used to generate risk scores to diagnose patients with SLE based on the levels of the biomarkers. These proprietary, patent-protected methods vastly improve the diagnostic sensitivity of our test compared to the current standard of care. AVISE® CTD enables differential diagnosis for patients presenting with symptoms indicative of a wide variety of CTDs and other related diseases with overlapping symptoms. Revenue from this product comprised 91% and 88% of our revenue for the nine months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024 and 2023, we incurred net losses of $11.4 million and $18.1 million, respectively, and we expect to continue to incur operating losses in the near term. Our operations have been funded primarily through equity financings, debt financings and revenue from product sales. We have never been profitable and, as of September 30, 2024, we had $22.0 million of cash and cash equivalents and an accumulated deficit of $290.6 million.
Reimbursement for our testing services comes from several sources, including commercial payors (such as insurance companies and health maintenance organizations), government payors (such as Medicare and
19

Medicaid), client payors (such as hospitals, other laboratories, etc.) and patients. Reimbursement rates vary by product and payor.
All of our AVISE® tests are performed in our approximately 13,000 square-foot laboratory located in Vista, California, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). Our laboratory is certified for performance of high-complexity testing by the Centers for Medicare & Medicaid Services (CMS) in accordance with CLIA and is licensed by all states requiring out-of-state licensure. Our clinical laboratory typically reports all AVISE® testing product results within five business days
In addition to providing diagnostic testing, we are leveraging our clinical laboratory to enter into agreements in the normal course of business with leading pharmaceutical companies and contract research organizations for the use of our testing products and/or the data generated from such tests. We believe the quality of our testing, proprietary offerings and specialized knowledge give us an advantage in this space. We plan to continue to pursue additional partnerships with leading pharmaceutical companies and academic research centers that are synergistic with our evolving portfolio of testing products, as more of these organizations realize the extent of the service we can provide.
We market our AVISE® testing products using our specialized sales force covering 40 territories in the United States. Many diagnostic sales forces are trained only to understand the comparative benefits of the tests they promote. In contrast, the specialized backgrounds of our sales personnel, coupled with our comprehensive training, enables our sales representatives to interpret results from our de-identified patient test reports and provide unique insights in a highly tailored discussion with rheumatologists. We believe our focus on and experience in the field of rheumatology, combined with our commitment to excellent customer service and support, position us very well to respond to the needs of rheumatologists and the patients they serve.
Recent Developments
TC4d, TIgG and TIgM Biomarkers
Our collaborative efforts with the Allegheny Health Network Research Institute (AHN) have resulted in further development of three innovative biomarkers, TC4d, TIgG, and TIgM (the T-Cell Biomarkers), for which we obtained an exclusive, worldwide license from AHN in May 2021. These biomarkers have been clinically validated, exhibit a high degree of specificity for lupus and are more sensitive for lupus compared to conventional biomarkers. TC4d is patent protected through 2035, representing a proprietary expansion of CB-CAPs, involving a biochemical process wherein complement activation products are measured on T-cells. We currently plan to incorporate these three biomarkers into our AVISE® CTD test towards the end of 2024. Once incorporated, we believe these biomarkers will significantly enhance the diagnostic sensitivity for lupus of our AVISE® CTD tests beyond its current 80% sensitivity.
RA Sub-Profile
Approximately 70% of rheumatoid arthritis (RA) patients show serological evidence of RA, identified by key biomarkers: anti-CCP and Rheumatoid Factor. The remaining 30% of patients, despite lacking these serological markers, are clinically diagnosed with RA; this subgroup is referred to as “seronegative RA.” These patients often face delays in diagnosis due to the absence of serological evidence. In cases of early inflammatory arthritis, differential diagnosis is broad, including conditions like reactive arthritis, crystal arthropathy, spondyloarthropathy, and other systemic rheumatic diseases such as SLE and Sjogren’s syndrome, alongside seronegative RA. We have identified three unique biomarkers specific to seronegative RA (the RA Sub-Profile Biomarkers) that help bridge this diagnostic gap and would enable AVISE® CTD to correctly identify approximately a third of the traditional seronegative RA subgroup. We currently plan to incorporate these new biomarkers into our AVISE® CTD test toward the end of 2024, allowing for more timely and targeted treatment plans for these patients. We’ve submitted our validation for our rheumatoid arthritis assay utilizing RA33 antibodies to the New York State Department of Health for conditional approval. We intend to commercialize the assay once conditional approval is received in accordance with the FDA final rule on laboratory developed tests.
We believe that the addition of the biomarkers discussed above will further differentiate our core test offerings in the market and be accretive to our financial performance, as well as have a positive impact on the average sales price of AVISE® CTD and revenue. Additionally, we anticipate progressive incremental improvements in demand for AVISE® CTD over time, as we educate physicians about the benefits these new markers provide. Given the financial impact we expect from the planned launch of these new biomarkers, we estimate that we will achieve positive cash flows within a year of launching both the T-Cell Biomarkers and the RA Sub-Profile Biomarkers. This estimate
20

assumes, among other things, that we are able to incrementally increase the average selling price per test. This estimate may ultimately be incorrect.
Factors Affecting Our Performance
We believe there are several important factors that have impacted, and that we expect will impact, our operating performance and results of operations, including:
 
▪Reimbursement for Our Testing Products. Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payors, including both commercial payors and government payors. Payment from third-party payors differs depending on whether we are considered a "participating provider" (have entered into a contract with the payors as a participating provider) or a "non-participating provider" (do not have a contract and are considered a "non-participating provider"). Payors will often reimburse non-participating providers at a lower amount than participating providers, if at all. We have received a substantial portion of our revenue from a limited number of commercial payors, most of which have not contracted with us to be a participating provider. Historically, we have experienced situations where commercial payors proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payors have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract to serve as a participating provider, reimbursements are made pursuant to a negotiated fee schedule and are limited to only covered indications. If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payors, we may not be able to effectively increase our testing volume and revenue as expected. Additionally, changes in our estimated reimbursements for tests performed in prior periods can positively or negatively impact our revenue in the current period and cause our financial results to fluctuate. In addition, in connection with our revenue cycle management initiatives, we've held claims in the first half of the year which has resulted in increases in our accounts receivable and an accelerated decrease in our cash in the first half of the year. As expected, this trend has begun to reverse in the third quarter of 2024 and we expect it to continue to reverse, as cash is collected on billed tests through the remainder of the year.
▪Continued Growth of Our Testing Products. Since the launch of AVISE® CTD in 2012 and through September 30, 2024, we have delivered approximately 980,714 of these tests. During the three months ended September 30, 2024, the number of AVISE® CTD tests delivered declined by approximately 6% over the same period in 2023. Revenue growth for our testing products will depend, in part, on our ability to continue to expand our base of ordering healthcare providers and increase our penetration with existing healthcare providers, in addition to our ability to successfully and timely launch the T-Cell Biomarkers and RA Sub-Profile Biomarkers we plan to add to our AVISE® CTD test.
▪Development of Additional Testing Products. We rely on sales of our AVISE® CTD test to generate the significant majority of our revenue. We expect to continue to invest in research and development in order to develop additional testing products. Our success in developing new testing products will be important in our efforts to grow our business by expanding the potential market for our products and diversifying our sources of revenue.
▪Maintain Meaningful Margin. We seek to maintain meaningful margin through a continued focus on increasing operating leverage through the implementation of certain internal initiatives, such as leveraging validation, utility and reimbursement oriented clinical studies to facilitate payor coverage of our testing products. We center our efforts around long-term reimbursement and average sales price (ASP) growth and seek to improve our per-test costs by focusing on profitable, core test offerings and limiting fixed costs and overhead.
▪Timing of Our Research and Development Expenses. We conduct clinical studies to validate our new testing products, as well as ongoing clinical and outcome studies to further expand the published evidence that supports our commercialized AVISE® testing products. We also expend funds to secure clinical samples that can be used in discovery, product development, clinical validation, utility and outcome studies. Our spending on experiments and clinical studies may vary substantially from quarter to quarter, and the timing of these research and development activities is difficult to predict. If a substantial number of clinical samples are obtained in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses will affect our financial results.
21

▪How We Recognize Revenue. We record revenue on an accrual basis, using an estimate of the amount that we will ultimately realize, as determined based on a historical analysis of amounts collected by test and by payor, among other factors. Changes to such estimates may increase or decrease revenue recognized in future periods.
While each of these areas present significant opportunities for us, they also pose significant risks and challenges that we must address. We discuss many of these risks, uncertainties and other factors in the section entitled "Risk Factors" in our Quarterly Report on Form 10-Q for the six months ended June 30, 2024, filed with the SEC on August 5, 2024 and our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 18, 2024.
Seasonality
Based on our experience to date, we expect some seasonal variations in our financial results due to a variety of factors, such as: the year-end holiday period and other major holidays, vacation patterns of both patients and healthcare providers (including medical conferences), climate and weather conditions in our markets (for example, excess sun exposure can cause flares in SLE), seasonal conditions that may affect medical practices and provider activity (for example, influenza outbreaks that may reduce the percentage of patients that can be seen) and other factors relating to the timing of patient benefit changes, as well as patient deductibles and co-insurance limits.
Inflationary Environment
The current inflationary environment has resulted in higher prices, which have impacted our costs incurred to generate revenue from our laboratory testing services, costs to attract and retain personnel, and other operating costs. The severity and duration of the current inflationary environment remains uncertain and may continue to impact our financial condition and results of operations.
Financial Overview
Revenue
We recognize revenue in accordance with the provisions of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers. We record revenue on an accrual basis, using an estimate of the amount we will ultimately receive, as determined based on a historical analysis of amounts collected by test and by payor, among other factors. These assessments require significant judgment by management.
To date, we have derived nearly all of our revenue from the sale of our testing products, most of which is attributable to our AVISE® CTD test. We primarily market our testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order our testing products, and to whom results are reported, are generally not responsible for payment for these products. The parties that pay for these services (payors) consist of commercial payors (insurance companies, health maintenance organizations, etc.), government payors (primarily Medicare and Medicaid), client payors (hospitals, other laboratories, etc.), and patient self-pay. Our service is completed upon the delivery of test results to the prescribing rheumatologists which triggers billing for the service.
Our ability to increase our revenue will depend on our ability to further penetrate the market for our current and future testing products and increase our reimbursement and collection rates for tests delivered.
In April 2022, we were granted a Proprietary Laboratory Code (PLA) code for our protein-based test, AVISE® Lupus. Noridian, our Medicare Administrative Contractor, has set the current pricing for this PLA code at $840.65 per test through December 31, 2025. The process for obtaining and maintaining consistent reimbursement for new tests can be uncertain, lengthy and time consuming. A pricing determination is not synonymous with a coverage determination. Having a price associated with the PLA code for any particular test does not secure coverage or reimbursement for that PLA code from Medicare or any other third-party payor.
We submitted a formal request to Noridian for coverage of our AVISE® Lupus test under the new PLA Code, and on September 27, 2022, we received notice that Noridian has deemed our application for a Local Coverage Determination (LCD) to be valid, but our application is still pending. Ultimately receiving a favorable LCD is uncertain and may be time-consuming, resource intensive and require multiple quarterly or annual periods to
22

complete and is subject to risks and uncertainties described in the section entitled "Risk Factors" in this Quarterly Report on Form 10-Q. In the meantime, we have continued to submit Medicare claims for AVISE® Lupus, appeal denials and respond to requests for additional information. On January 31, 2024, CMS released a coverage article under which all multi-analyte proteomic testing will be considered within the scope of molecular diagnostic services (MolDX) and reviewed through their technology assessment process. The article listed several such tests, including the AVISE® Lupus test, and requires all laboratories furnishing multi-analyte proteomics testing in MolDX jurisdictions to register with the DEX® Diagnostics Exchange Registry and obtain a Z-Code® identifier. We were issued a Z-Code® in May 2024. To determine if the submitted tests are compliant with relevant policy requirements, these tests will undergo technical assessment by Palmetto GBA as part of the MolDX program.
We face consistent challenges relating to commercial payor claim processing and revenue. While collectability has improved with certain plans year-over-year, we continue to experience denials due to unfavorable medical policy with certain plans, and we expect this situation to persist.
During the year ended December 31, 2023, we implemented several revenue cycle management initiatives, including among others, withholding the submission of commercial payor claims for reimbursement until subsequent quarters, increasing appeals efforts, adjusting the documentation required of physicians when ordering our tests and implementing increases to our patient payment rates. Additionally, in November 2023, we increased the list price billed for our tests. These ongoing revenue cycle management initiatives aim to optimize our appeals process and the potential for cash collections. We've experienced moderate declines in test volume since the second half of 2023, as rheumatologists and patients adjust to these changes. The number of AVISE® CTD tests delivered during the three months ended September 30, 2024 declined by approximately 6% as compared to the number of AVISE® CTD tests delivered during the three months ended June 30, 2024 due to seasonal factors, including increased out-of-office time for physicians and weather-related events in the south-east of the United States.
Operating Expenses
Costs of Revenue
Costs of revenue represents the expenses associated with obtaining and testing patient specimens. The components of our costs of revenue include materials costs, direct labor, equipment, infrastructure expenses, shipping charges to transport specimens, blood specimen collections fees, royalties, depreciation and allocated overhead (including rent and utilities).
Each payor, whether commercial, government, or individual, reimburses us at different amounts. These differences can be significant. As a result, our costs of revenue as a percentage of revenue may vary significantly from period to period due to the composition of payors for each period's billings.
We expect that our costs of revenue will increase in the near-term, primarily due to projected increases in cost-per-test resulting from the expected additions of our T-Cell Biomarkers and RA Sub-Profile Biomarkers to AVISE® CTD.
Selling, General and Administrative Expenses
Selling, general and administrative expenses consist of personnel costs (including stock-based compensation expense), direct marketing expenses, accounting and legal expenses, consulting costs and allocated overhead (including rent, information technology, depreciation and utilities).
We expect that our selling, general and administrative expenses will increase in the near-term, primarily due to expected additions to headcount and associated increases for personnel costs, including stock-based compensation.
Research and Development Expenses
Research and development expenses include costs incurred to develop our technology, test products and product candidates, in addition to costs incurred to collect clinical specimens and conduct clinical studies to develop and support those products and product candidates. These costs consist of personnel-related expenses (including stock-based compensation expense), materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead (including rent and utilities). We expense all research and development costs in the periods in which they are incurred.
23

We expect that our research and development expenses will remain relatively consistent in the near-term.
Interest Expense
Interest expense consists of cash and non-cash interest expense associated with our financing arrangements, including the borrowings under our Amended Loan Agreement with Innovatus.
Interest Income
Interest income consists of interest income earned on our cash and cash equivalents.
Results of Operations
Comparison of the Three Months Ended September 30, 2024 and 2023 (in thousands):
 Three Months Ended September 30,
 20242023Change
Revenue$12,507 $13,416 $(909)
Operating expenses:
Costs of revenue5,526 5,710 (184)
Selling, general and administrative expenses10,163 11,375 (1,212)
Research and development expenses1,481 1,400 81 
Total operating expenses17,170 18,485 (1,315)
Loss from operations(4,663)(5,069)406 
Interest expense(562)(557)(5)
Interest income197 211 (14)
Net loss$(5,028)$(5,415)$387 
Revenue
Revenue decreased $0.9 million, or 6.8%, for the three months ended September 30, 2024 compared to the three months ended September 30, 2023, primarily due to a $1.2 million decrease related to revenue and accounts receivable adjustments recorded in the third quarter of 2024. Excluding these adjustments, revenue increased $0.3 million due to improved ASP (including prior period cash collections), partially offset by decreased AVISE® CTD year-over-year volume. The $1.2 million decrease in revenue and accounts receivable adjustments were comprised of a $0.9 million reserve recognized related to accounts receivable for AVISE® CTD testing, in addition to a $0.3 million reversal of other testing revenue relating to a current procedural terminology coding discrepancy for AVISE® Vasculitis. The number of AVISE® CTD tests delivered, which accounted for 93% of revenue and 89% of revenue in the three months ended September 30, 2024 and 2023, respectively, declined by approximately 6% in the three months ended September 30, 2024 as compared to the same period in 2023.
Costs of Revenue
Costs of revenue decreased $0.2 million, or 3.2%, for the three months ended September 30, 2024 compared to the three months ended September 30, 2023. This decrease was primarily due to a decrease of $0.3 million in facilities and allocated overhead expenses, a decrease of $0.2 million in royalty expenses, and a decrease of $0.1 million in materials and supplies expenses, partially offset by an increase of $0.3 million in shipping and handling costs resulting from increased cost-per-shipment, offset in-part by reduced shipping volume; and an increase of $0.1 million in direct labor. Gross margin as a percentage of revenue decreased to 55.8% for the three months ended September 30, 2024, compared to 57.4% for the three months ended September 30, 2023, primarily due to the changes to revenue and costs of revenue described above, including the $1.2 million in revenue adjustments, which impacted gross margin by approximately 400 basis points.
Selling, General and Administrative Expenses
Selling, general and administrative expenses decreased $1.2 million, or 10.7%, for the three months ended September 30, 2024 compared to the three months ended September 30, 2023. This decrease was primarily due to decreases of $0.7 million in employee-related expenses (including salaries, benefits and stock-based
24

compensation) resulting from reduced headcount, $0.4 million in professional service expenses, $0.2 million in facilities and allocated overhead expenses, $0.2 million in insurance expenses, and $0.1 million in legal expenses, partially offset by an increase of $0.4 million in commissions.
Research and Development Expenses
Research and development expenses increased $0.1 million, or 5.8%, for the three months ended September 30, 2024 compared to the three months ended September 30, 2023, primarily due to an increase of $0.2 million in employee-related expenses (including salaries, benefits and stock-based compensation), partially offset by a decrease of $0.1 million in clinical trial expenses.
Interest Expense
Interest expense remained relatively consistent for the three months ended September 30, 2024 compared to the three months ended September 30, 2023.
Interest Income
Interest income remained relatively consistent for the three months ended September 30, 2024 compared to the three months ended September 30, 2023.
Comparison of the Nine Months Ended September 30, 2024 and 2023 (in thousands):
 Nine Months Ended September 30,
 20242023Change
Revenue$41,986 $38,783 $3,203 
Operating expenses:
Costs of revenue17,351 17,472 (121)
Selling, general and administrative expenses31,169 35,212 (4,043)
Research and development expenses3,719 3,789 (70)
Total operating expenses52,239 56,473 (4,234)
Loss from operations(10,253)(17,690)7,437 
Interest expense(1,671)(1,769)98 
Interest income570 1,343 (773)
Net loss$(11,354)$(18,116)$6,762 
Revenue
Revenue increased $3.2 million, or 8.3%, for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023, primarily due to improved ASP (including prior period cash collections), partially offset by decreased AVISE® CTD year-over-year volume. The number of AVISE® CTD tests delivered, which accounted for 91% of revenue and 88% of revenue in the nine months ended September 30, 2024 and 2023, respectively, declined by approximately 13% in the nine months ended September 30, 2024 as compared to the same period in 2023.
Costs of Revenue
Costs of revenue decreased $0.1 million, or 0.7%, for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023. This decrease was primarily due to a decrease of $1.0 million in materials and supplies expenses, and a decrease of $0.2 million in facilities and allocated overhead expenses, partially offset by an increase of $0.6 million in shipping and handling costs resulting from increased cost-per-shipment, offset in-part by reduced shipping volume; and an increase of $0.5 million in direct labor. Gross margin as a percentage of revenue increased to 58.7% for the nine months ended September 30, 2024, compared to 54.9% for the nine months ended September 30, 2023, primarily due to the changes to revenue and costs of revenue described above.
Selling, General and Administrative Expenses
25

Selling, general and administrative expenses decreased $4.0 million, or 11.5%, for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023. This decrease was primarily due to decreases of $1.9 million in employee-related expenses (including salaries, benefits and stock-based compensation) resulting from reduced headcount, $0.9 million in legal expenses and settlement costs, $0.5 million in insurance expenses, $0.4 million in professional services, $0.4 million in facilities and allocated overhead expenses, and $0.2 million in audit and tax services, partially offset by an increase of $0.3 million in commissions.
Research and Development Expenses
Research and development expenses decreased $0.1 million, or 1.8%, for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023. This decrease was primarily due to a decrease of $0.4 million in clinical trial expenses and a decrease of $0.1 million in facilities and allocated overhead expenses, partially offset by an increase of $0.4 million in employee-related expenses (including salaries, benefits and stock-based compensation).
Interest Expense
Interest expense decreased by $0.1 million, or 5.5%, for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023. This decrease was due to interest savings related to the term loan agreement entered into in September 2017 (the 2017 Term Loan), by and between the Company and Innovatus Life Sciences Lending Fund I, LP, as amended.
Interest Income
Interest income decreased by $0.8 million, or 57.6%, for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023, primarily due to lower cash and cash equivalents balances of interest-earning accounts.
Liquidity and Capital Resources
We have incurred net losses since our inception. For the nine months ended September 30, 2024 and 2023, we incurred a net loss of $11.4 million and $18.1 million, respectively, and we expect to incur additional losses in future periods. To date, we have generated only limited revenue, and, despite any estimates we may make regarding our ability to become profitable, we may never achieve revenue sufficient to offset our expenses. As of September 30, 2024, we had an accumulated deficit of $290.6 million and cash and cash equivalents of $22.0 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our funds are held in cash and money market funds.
Since becoming a public company, our primary sources of capital have been cash inflows from product sales, sales of our common stock and, to a lesser extent, borrowings under our 2017 Term Loan. In April 2023, we further amended the 2017 Term Loan, pursuant to which we prepaid $10.0 million of principal and amended additional terms of the agreement. See Note 4, Borrowings, to the unaudited condensed financial statements included in this Quarterly Report on Form 10-Q for additional information.
Our obligations under the Amended Loan Agreement are secured by a security interest in substantially all of our assets, including our intellectual property. The Amended Loan Agreement contains customary conditions to borrowing, events of default, and covenants, including covenants requiring us to maintain minimum liquidity of $2.0 million, covenants to achieve certain minimum amounts of revenue, and covenants limiting our ability to dispose of assets, undergo a change in control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of our capital stock, repurchase stock and make investments, in each case subject to certain exceptions. Per the Amended Loan Agreement, we are not required to comply with the revenue covenant for any quarter during which we maintain a minimum aggregate cash balance equal to fifty percent of the aggregate principal amount of the 2017 Term Loan funded (excluding any capitalized interest paid-in-kind) at all times during such quarter. The consequences of failing to achieve the performance covenants, when applicable, will be cured if, (i) within thirty days of failing to achieve the performance covenant, we submit a new financial plan approved by our Board of Directors to Innovatus under which we are expected to break even on a cash flow basis prior to the maturity date, and (ii) within thirty days of the submission of such financial plan, we issue additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined in the Amended Loan Agreement. In addition, upon the occurrence of an
26

event of default, Innovatus, among other things, can declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working capital needs, capital expenditures and other general corporate purposes. As of September 30, 2024, we were in compliance with all covenants of the Amended Loan Agreement with Innovatus.
On November 17, 2023, we filed a registration statement on Form S-3 covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units, all of which remained unsold at September 30, 2024.
On September 15, 2022, we entered into a sales agreement, as amended on November 17, 2023 (the Sales Agreement) with Cowen and Company, LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $50.0 million. The Company is not obligated to sell any shares of Company common stock in the offering. As of September 30, 2024, the Company has not sold any shares of its common stock pursuant to the Sales Agreement.
Funding Requirements
Our primary use of cash is to fund our operations as we continue to grow our business. We expect to continue to incur operating losses in the near term. We believe we have sufficient laboratory capacity to support increased test volume. Cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.
We expect that our near- and longer-term liquidity requirements will continue to consist of working capital and general corporate expenses associated with the growth of our business, including payments we may be required to make upon the achievement of previously negotiated milestones associated with intellectual property we have licensed, payments related to non-cancelable purchase obligations for reagents, payments related to our principal and interest under our long term borrowing arrangements, payments for operating leases related to our office and laboratory space in Vista, California and our office space in Carlsbad, California and payments for finance leases related to our laboratory equipment (see Note 4, Borrowings, and Note 5, Commitments and Contingencies, to our unaudited financial statements included in this Quarterly Report on Form 10-Q). Based on our current business plan, we believe that our existing cash and cash equivalents and our anticipated future revenue, will be sufficient to meet our anticipated cash requirements for at least the next 12 months from the date of this filing.
Our estimate of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties. Actual results could vary as a result of a number of factors, including:
•our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for our testing products;
•our ability to maintain and grow sales of our AVISE® testing products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our products and support reimbursement efforts;
•fluctuations in working capital;
•the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation, utility and outcome studies as well as the success of our development efforts; and
•the extent to which we establish additional partnerships or in-license, acquire or invest in complementary businesses or products as well as the success of our existing partnerships and/or in-licenses.
Until such time, if ever, as we can generate revenue to support our costs structure, we expect to finance our operations through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. If additional funding is required or desired, there can be no assurance that additional funds will be available to us on acceptable terms on a timely basis, if at all, or that we will generate sufficient cash from operations to adequately fund our operating needs or achieve or sustain profitability. If we are unable to raise additional capital or generate sufficient cash from operations to adequately fund our operations, we will need to delay, reduce or eliminate some
27

or all of our research and development programs, product portfolio expansion plans or commercialization efforts. Doing so will likely have an unfavorable effect on our ability to execute on our business plan and could have a negative impact on our commercial and strategic relationships. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition, and results of operations could be adversely affected.
Cash Flows
The following table summarizes our cash flows for the periods indicated (in thousands):
 Nine Months Ended September 30,
 20242023
Net cash used in:
Operating activities$(13,642)$(22,811)
Investing activities(369)(720)
Financing activities(447)(10,412)
Net change in cash, cash equivalents and restricted cash$(14,458)$(33,943)
Cash Flows from Operating Activities
Net cash used in operating activities for the nine months ended September 30, 2024 was $13.6 million, primarily resulting from (i) our net loss of $11.4 million adjusted for non-cash charges of $3.7 million primarily related to stock-based compensation, depreciation, amortization and non-cash lease expense and (ii) changes in our net operating assets of $6.0 million primarily related to net increases in accounts receivable and net decreases in accounts payable, operating lease liabilities and accrued and other current liabilities, partially offset by net decreases in prepaid expenses. The increase in accounts receivable was primarily due to delays in claim submission as part of our revenue cycle management initiatives.
Net cash used in operating activities for the nine months ended September 30, 2023 was $22.8 million, primarily resulting from (i) our net loss of $18.1 million adjusted for non-cash charges of $5.9 million primarily related to stock-based compensation, depreciation, amortization, non-cash lease expense and non-cash interest and (ii) changes in our net operating assets of $10.5 million primarily related to net increases in accounts receivable and accrued and other current liabilities, partially offset by net decreases in accounts payable, prepaid expenses, other current assets and operating lease liabilities. The increase in accounts receivable was primarily due to delays in claim submission as part of our revenue cycle management initiatives and delayed claim processing by Medicare due to a request for medical records on submitted claims.
Cash Flows from Investing Activities
Net cash used in investing activities for the nine months ended September 30, 2024 and 2023 was $0.4 million and $0.7 million, respectively, due to purchases of property and equipment.
Cash Flows from Financing Activities
Net cash used in financing activities for the nine months ended September 30, 2024 was $0.4 million, primarily resulting from payments on finance lease and notes payable obligations, partially offset by proceeds from purchases under the Company's 2019 Employee Stock Purchase Plan.
Net cash used in financing activities for the nine months ended September 30, 2023 was $10.4 million, primarily resulting from the Term Loan Prepayment of $10.0 million.
Critical Accounting Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The year-end condensed balance sheets data was derived from audited
28

financial statements, but does not include all disclosures required by GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions, and any such differences may be material.
For a description of our critical accounting estimates, please see the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Estimates" contained in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on March 18, 2024. There have been no significant changes in our critical accounting policies and estimates during the nine months ended September 30, 2024 as compared to the critical accounting policies and estimates disclosed in the Management’s Discussion and Analysis of Financial Condition and Operations included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 18, 2024.
Recent Accounting Pronouncements
Please see Note 2, Summary of Significant Accounting Policies, to the unaudited condensed financial statements included in this Quarterly Report on Form 10-Q for a summary of recent accounting pronouncements.
JOBS Act Accounting Election
The Jumpstart Our Business Startups Act of 2012 (the JOBS Act), contains provisions that, among other things, reduce certain reporting requirements for an "emerging growth company." The JOBS Act permits an "emerging growth company" like us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our audited financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.
We will remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended, which will occur on December 31, 2024. However, if certain events occur prior to the end of this five-year period, including if we become a "large accelerated filer" as defined in Rule 12b-2 under the Exchange Act, our annual gross revenues exceed $1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to this anniversary.

Item 3. Quantitative and Qualitative Disclosures About Market Risk
Not applicable.

29

Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that the information we are required to disclose in such reports is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate.
Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer have concluded that as of September 30, 2024, our disclosure controls and procedures were effective at a reasonable level of assurance.
Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting during the three months ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations on Effectiveness of Controls and Procedures
Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

30


Part II. Other Information

Item 1. Legal Proceedings
From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on our business resulting from defense and settlement costs, diversion of resources and other factors. There can be no assurances that favorable outcomes will be obtained.
In October 2023, we resolved an investigation with the U.S. Attorney’s Office for the District of Massachusetts that was initiated by a qui tam lawsuit. Pursuant to a settlement agreement entered into by and between us and the U.S. Department of Justice (the Settlement Agreement), we made a single lump-sum remittance to the government in the amount of $0.7 million, including interest, in connection with specimen processing arrangements that we historically had with physicians. The U.S. Attorney’s Office dismissed this “covered conduct” in the qui tam lawsuit with prejudice, while non-covered conduct was dismissed without prejudice. The Department of Justice excused itself from the case in connection with the settlement. In November 2023, the complaint was unsealed by the court and served on us by the relator. We filed a motion to dismiss the complaint. In February 2024, the relator filed a motion for leave to amend the complaint. We opposed this motion, and all motions are still pending. We cannot predict when these matters will be resolved, the outcome of these matters, or their potential impact, which may materially and adversely affect our business, prospects, and financial condition. We intend to vigorously defend against the claims being asserted in the complaint.
Our participation in federal healthcare programs is not affected by the Settlement Agreement.
Item 1A. Risk Factors
There have been no material changes to the risk factors disclosed in Part I, Item 1A, "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2023 and Part II, Item 1A, “Risk Factors” of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.


Item 5. Other Information
Rule 10b5-1 trading arrangements
During the nine months ended September 30, 2024, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408 of Regulation S-K.
31

Item 6. Exhibits
Incorporated by Reference
Exhibit NumberExhibit DescriptionFormFile No.ExhibitExhibit Filing DateFiled/Furnished Herewith
3.18-K001-390493.19/23/2019
3.28-K001-390493.13/22/2021
3.38-K001-390493.11/23/2023
4.1S-1/A333-2334464.19/9/2019
4.2S-1/A333-2334464.29/9/2019
4.3S-1/A333-2334464.39/9/2019
4.4S-1/A333-2334464.49/9/2019
4.5S-1/A333-2334464.89/9/2019
4.610-Q001-390494.58/9/2021
10.2#8-K/A001-3904910.18/2/2024
31.1X
31.2X
32.1*X
101.INSInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.X
101.SCHInline XBRL Taxonomy Extension Schema Document.X
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.X
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.X
101.LABInline XBRL Taxonomy Extension Labels Linkbase Document.X
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.X
104
The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, has been formatted in Inline XBRL.
X

*     This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
#     Management Compensation Plan or Arrangement.
32


Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



EXAGEN INC.
Date: November 12, 2024
by:/s/ John Aballi
John Aballi
President and Chief Executive Officer
(Principal Executive Officer)
Date: November 12, 2024
by:/s/ Jeffrey G. Black
Jeffrey G. Black
Chief Financial Officer
(Principal Financial and Accounting Officer)

33
 EX-31.1 2 xgn311-093024.htm EX-31.1 Document

Exhibit 31.1

EXAGEN INC.
CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John Aballi, certify that:
1.                I have reviewed this Quarterly Report on Form 10-Q of Exagen Inc.;
2.              Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.              Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.              The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)              Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)              Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)              Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)               Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.              The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


(a)              All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)              Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 12, 2024
/s/ John Aballi

John Aballi

President and Chief Executive Officer

(Principal Executive Officer)


 EX-31.2 3 xgn312-093024.htm EX-31.2 Document

Exhibit 31.2

EXAGEN INC.
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jeffrey G. Black, certify that:
1.                 I have reviewed this Quarterly Report on Form 10-Q of Exagen Inc.;
2.              Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.              Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.              The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)              Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)              Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)              Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)               Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.              The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


(a)              All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)              Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 12, 2024
/s/ Jeffrey G. Black

Jeffrey G. Black

Chief Financial Officer

(Principal Financial and Accounting Officer)


 EX-32.1 4 xgn321-093024.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the "Company") hereby certifies, to such officer's knowledge, that:
1.                   The accompanying quarterly report on Form 10-Q of the Company for the quarterly period ended September 30, 2024 (the "Report") fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2.                   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.

Dated: November 12, 2024
/s/ John Aballi
John Aballi
President and Chief Executive Officer
(Principal Executive Officer)
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
CERTIFICATION OF CHIEF FINANCIAL OFFICER

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the "Company") hereby certifies, to such officer's knowledge, that:
1.                   The accompanying quarterly report on Form 10-Q of the Company for the quarterly period ended September 30, 2024 (the "Report") fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2.                   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.

Dated: November 12, 2024


/s/ Jeffrey G. Black
Jeffrey G. Black
Chief Financial Officer
(Principal Financial and Accounting Officer)
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


 EX-101.SCH 5 exdx-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Unaudited Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Unaudited Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Unaudited Condensed Statements of Operations link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Unaudited Condensed Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Unaudited Condensed Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 9952156 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Other Financial Information link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Borrowings link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Commitment and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Stock Option Plan link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Other Financial Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Stock Option Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Summary of Significant Accounting Policies - Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Other Financial Information - Prepaid Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Other Financial Information - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Other Financial Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Other Financial Information - Accrued and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Borrowings - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Borrowings - Future Minimum Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Commitment and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Stockholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Stockholders' Equity - Outstanding Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Stock Option Plan - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Stock Option Plan - Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Stock Option Plan - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 exdx-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 exdx-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 exdx-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Vested and expected to vest, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Maximum employee payroll deduction percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Refund liability Customer Refund Liability, Current Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Principal payment on long-term debt Loan repayment Repayments of Long-Term Debt Schedule of Prepaid Expenses and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Cover [Abstract] Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Notes payable, current Notes Payable, Current Innovatus Life Sciences Lending Fund Innovatus Life Sciences Lending Fund [Member] Innovatus Life Sciences Lending Fund Trading Symbol Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Number of monthly installments Debt Instrument, Number Of Monthly Installments Debt Instrument, Number Of Monthly Installments Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Stock options, vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Accounts receivable, net Increase (Decrease) in Accounts Receivable Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Licensing Agreements License Agreement Terms [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Fair Value Measurements Fair Value Disclosures [Text Block] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Award Timing Disclosures [Line Items] Common stock Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Other Performance Measure, Amount Other Performance Measure, Amount Royalty obligation, percent of net sales Royalty Obligation, Percentage of Sales Royalty Obligation, Percentage of Sales Shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Other Other Customer [Member] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Shares that remain available for future awards (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Operating lease liabilities - non-current portion Operating Lease, Liability, Noncurrent Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Segment Reporting Segment Reporting, Policy [Policy Text Block] Plan Name [Domain] Plan Name [Domain] Loan payable Loans Payable [Member] Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Settlement payment Payments for Legal Settlements Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Money market funds, included in cash and cash equivalents Money Market Funds [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Supplier [Domain] Supplier [Domain] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Proceeds from sale of stock Sale of Stock, Consideration Received on Transaction Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Diagnostic testing supplies Other Assets, Current Award Timing Method Award Timing Method [Text Block] Accrued purchases of goods and services Accrued Purchase, Goods and Services, Current Accrued Purchase, Goods and Services, Current Research and Development Research and Development Expense, Policy [Policy Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Options exercised, end of period (in shares), Weighted Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Total operating expenses Costs and Expenses Adjustment to Compensation, Amount Adjustment to Compensation Amount Outstanding, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Compensation Amount Outstanding Recovery Compensation Amount Term loan, paid in-kind loans issued Debt Instrument, Paid In Kind Loans Issued Debt Instrument, Paid In Kind Loans Issued Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Issuance of stock under Employee Stock Purchase Plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Accrued and other current liabilities Accrued and other current liabilities Accrued Liabilities, Current Anti-dilutive securities excluded from computation (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Long-lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Warrant expiration March 31, 2026 Expiration Mar 31, 2026 [Member] Expiration Mar 31, 2026 Shipping and Handling Costs Cost of Goods and Service [Policy Text Block] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Stock options, unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current assets: Assets, Current [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Medicare Medicare [Member] Medicare Product and Service [Domain] Product and Service [Domain] Stock options Share-Based Payment Arrangement, Option [Member] Awards released (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Fair Value Disclosures [Abstract] Prepaid product royalties Prepaid Royalties Shares outstanding (in shares) Preferred Stock, Shares Outstanding Warrants to purchase common stock Warrant [Member] Security Exchange Name Security Exchange Name Variable rate Debt Instrument, Basis Spread on Variable Rate Non-cash interest expense Paid-in-Kind Interest Award Type [Axis] Award Type [Axis] Warrant expiration December 7, 2025 Expiration Dec 7, 2025 [Member] Expiration Dec 7, 2025 Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Settled Litigation Settled Litigation [Member] Total liabilities Liabilities Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Current Other Assets Increase (Decrease) in Prepaid Expense and Current Other Assets Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development expenses Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Operating lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Shares issued (in shares) Common Stock, Shares, Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Percent of total revenue Concentration Risk, Percentage Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Exercise of stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Common stock offering, remaining authorized amount Sale Of Stock, Remaining Authorized Amount Sale Of Stock, Remaining Authorized Amount Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development Research and Development Expense [Member] Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Shares authorized (in shares) Common Stock, Shares Authorized Debt instrument, minimum cash balance Debt Instrument, Minimum Cash Balance Required, Not Required To Comply With Covenant Debt Instrument, Minimum Cash Balance Required, Not Required To Comply With Covenant Less: accumulated depreciation and amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Weighted-average number of shares used to compute net loss per share, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Purchase obligation, year one Purchase Obligation, to be Paid, Year One Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Interest expense Interest Expense, Nonoperating Accrued payroll and related expenses Accrued Salaries, Current Concentration Risk Type [Domain] Concentration Risk Type [Domain] Common stock offering, authorized amount Sale Of Stock, Authorized Amount Sale Of Stock, Authorized Amount New Accounting Pronouncement, Early Adoption [Table] Accounting Standards Update and Change in Accounting Principle [Table] Selling, general and administrative expenses Selling, General and Administrative Expense 2019 Incentive Award Plan Incentive Award Plan, 2019 [Member] Incentive Award Plan, 2019 Recurring Fair Value, Recurring [Member] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Costs of revenue Cost of Sales [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Sale of Stock [Domain] Sale of Stock [Domain] Total borrowings, net of discounts and debt issuance costs Long-term debt Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Interest Long-term Debt, Undiscounted Interest Amount Long-term Debt, Undiscounted Interest Amount Document Fiscal Period Focus Document Fiscal Period Focus 2028 Long-Term Debt, Maturity, Year Four All Executive Categories All Executive Categories [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate U.S. Department Of Justice Case U.S. Department Of Justice Case [Member] U.S. Department Of Justice Case Document Type Document Type Term loan, effective interest rate Debt Instrument, Interest Rate, Effective Percentage Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Term loan, paid in-kind, interest rate Debt Instrument, Stated Interest Rate, Paid In-Kind Debt Instrument, Stated Interest Rate, Paid In-Kind Issuance of stock from vested restricted stock units (in shares) Awards released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Furniture and fixtures Furniture and Fixtures [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Leasehold improvements Leasehold Improvements [Member] Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Warrants issued to purchase redeemable convertible preferred stock (in shares) Class of Warrant or Right, Outstanding Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Prepaid maintenance and insurance contracts Prepaid Maintenance and Insurance Contracts Prepaid Maintenance and Insurance Contracts Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Supplier Concentration Risk Supplier Concentration Risk [Member] Non-PEO NEO Non-PEO NEO [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Notes payable Notes Payable Class of Stock [Line Items] Class of Stock [Line Items] Recent Accounting Pronouncements and Recently Adopted Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Net loss per share, diluted (in dollars per share) Earnings Per Share, Diluted Collaboration agreement, collaboration expenses Collaboration Agreement, Collaboration Expenses Collaboration Agreement, Collaboration Expenses Counterparty Name [Domain] Counterparty Name [Domain] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Commercial Healthcare Insurers [Member] Healthcare Insurers Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Options exercisable, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Schedule of Outstanding Warrants Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Number of operating segments Number of Operating Segments Shares issued (in shares) Preferred Stock, Shares Issued New Accounting Pronouncement, Early Adoption [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Customer [Axis] Customer [Axis] Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Notes payable, noncurrent Notes Payable, Noncurrent Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Proceeds from disposal of property and equipment Proceeds from Sale of Property, Plant, and Equipment Term loan, interest rate Debt Instrument, Interest Rate, Stated Percentage Aggregate intrinsic value, vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Stock options, cost not yet recognized, remaining weighted average vesting period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Exercise of common stock warrants (in shares) Stock Issued During Period, Shares, Warrants Exercised, Net Stock Issued During Period, Shares, Warrants Exercised, Net Revenue Revenue from Contract with Customer, Excluding Assessed Tax Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Total liabilities and stockholders' equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Additional paid-in capital Additional Paid in Capital Computer equipment and software Computer Equipment and Software [Member] Computer Equipment and Software Commitments and Contingencies Disclosure [Abstract] Interest income Investment Income, Interest Shipping and Handling Shipping and Handling [Member] Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings Schedule of Maturities of Long-Term Debt [Table Text Block] Organization Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Restricted cash Restricted Cash Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Allegheny Health Network Research Institute Allegheny Health Network Research Institute [Member] Allegheny Health Network Research Institute Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Outstanding, beginning of period (in dollars per share) Outstanding, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Unamortized debt discount and issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Vested and expected to vest, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number 2017 Term loan Term 2017 [Member] Term 2017 Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Outstanding, beginning of period (in dollars per share) Outstanding, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Outstanding, beginning of period (in shares) Outstanding, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Exercise Price Award Exercise Price Term loan, covenant, number of days to cure covenant if performance measure is not met Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met Arrangement Duration Trading Arrangement Duration Issuance of stock under Employee Stock Purchase Plan Stock Issued During Period, Value, Employee Stock Purchase Plan Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Operating expenses: Costs and Expenses [Abstract] Stockholders' equity: Equity, Attributable to Parent [Abstract] Awards granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] PEO PEO [Member] Debt instrument Debt Instrument, Fair Value Disclosure Name Trading Arrangement, Individual Name Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Other assets Increase (Decrease) in Other Noncurrent Assets Options exercisable, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number AHN Collaboration AHN Collaboration [Member] AHN Collaboration 2024 (remaining) Long-Term Debt, Maturity, Remainder of Fiscal Year Schedule of Concentration of Risk, by Risk Factor and Significant Payer Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Lender Name [Axis] Lender Name [Axis] Assets: Assets, Fair Value Disclosure [Abstract] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Money market funds, included in cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Depreciation and amortization Cost, Depreciation and Amortization Local Phone Number Local Phone Number Supplier [Axis] Supplier [Axis] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Term loan covenant, minimum unrestricted cash balance Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance Schedule of Restricted Stock Unit Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Stock Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Schedule of Accrued and Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Entity Ex Transition Period Entity Ex Transition Period Vested and expected to vest, end of period (in shares), Weighted Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Policy [Policy Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Two Major Suppliers Two Major Suppliers [Member] Two Major Suppliers Debt Disclosure [Abstract] Common Stock Common Stock [Member] Measure: Measure [Axis] Government Government1 [Member] Government1 Shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Entity Emerging Growth Company Entity Emerging Growth Company Equipment purchased under notes payable obligations Equipment Purchased Under Notes Payable Obligations Equipment Purchased Under Notes Payable Obligations Entity Central Index Key Entity Central Index Key Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Other Financial Information Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block] Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities Stockholders' Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Financial Instrument [Axis] Financial Instrument [Axis] Borrowings-current portion Less: Borrowings-current portion Long-Term Debt, Current Maturities Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Shelf Registration Statement Shelf Registration Statement [Member] Shelf Registration Statement Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Measurement Frequency [Domain] Measurement Frequency [Domain] Counterparty Name [Axis] Counterparty Name [Axis] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Medicare Advantage Medicare Advantage [Member] Medicare Advantage City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Term loan, covenant, revenue performance period Debt Instrument, Covenant, Revenue Performance Period Debt Instrument, Covenant, Revenue Performance Period Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Total property and equipment Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Revenue Recognition Revenue [Policy Text Block] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Term loan, prepayment premium percentage Debt Instrument, Prepayment Premium Percentage Debt Instrument, Prepayment Premium Percentage Loss on disposal of assets Gain (Loss) on Disposition of Assets Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity 2027 Long-Term Debt, Maturity, Year Three Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Borrowings-non-current portion, net of discounts and debt issuance costs Borrowings-non-current portion, net of discounts and debt issuance costs Long-Term Debt, Excluding Current Maturities Accounts Receivable and Allowance for Credit Losses Receivable [Policy Text Block] Weighted- Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Equity [Abstract] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Supplemental disclosure of non-cash items: Supplemental Cash Flow Elements [Abstract] 2026 Long-Term Debt, Maturity, Year Two Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Non-cash lease expense Non-Cash Lease Expense Non-Cash Lease Expense Term loan, fee incurred upon payment of final installment Debt Instrument, Fee Amount Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Preferred stock Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Amendment Flag Amendment Flag AVISE CTD Test AVISE CTD Test [Member] AVISE CTD Test Entity Registrant Name Entity Registrant Name Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation, Depletion and Amortization Laboratory equipment Laboratory Equipment [Member] Laboratory Equipment Schedule of Restricted Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Vested and expected to vest, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Warrant expiration January 19, 2026 Expiration Jan 19, 2026 [Member] Expiration Jan 19, 2026 Level 2 Fair Value, Inputs, Level 2 [Member] Borrowings Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Prepaid expenses and other current assets Prepaid Expense and Other Assets Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Advertising expense Advertising Expense Schedule of Non-Cash Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, $0.001 par value per share; 200,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 17,520,335 and 17,045,954 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Share-Based Payment Arrangement [Abstract] Equipment Notes Payable Equipment Notes Payable [Member] Equipment Notes Payable Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Litigation Status [Axis] Litigation Status [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Options exercisable, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Awards canceled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Term loan covenant, increase to interest rate Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease) Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease) Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, $0.001 par value per share; 10,000,000 shares authorized, no shares issued or outstanding as of September 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Employee stock purchase plan Employee Stock [Member] No expiration No expiration [Member] No expiration Net loss per share, basic (in dollars per share) Earnings Per Share, Basic Paid in-kind note Payment in Kind (PIK) Note [Member] Client Client [Member] Client Accounts payable Increase (Decrease) in Accounts Payable Proceeds from common stock issued under Employee Stock Purchase Plan Proceeds from Stock Plans Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Stock options, expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Common stock options Equity Option [Member] Property and equipment, net Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Other prepaid expenses and other current assets Other Prepaid Expense, Current Principal payments on finance lease obligations Finance Lease, Principal Payments Costs incurred, but not paid, in connection with capital expenditures Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total assets Assets Concentration of Credit Risk and Other Risk and Uncertainties Concentration Risk, Credit Risk, Policy [Policy Text Block] Costs of revenue Cost of Goods and Services Sold Advertising and Marketing Costs Advertising Cost [Policy Text Block] Awards granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Principal payment on note payable obligations Repayments of Notes Payable Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Other non-current liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Total Long-term Debt, Including Undiscounted Interest Long-term Debt, Including Undiscounted Interest Commitments and contingencies (Note 5) Commitments and Contingencies Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Termination Date Trading Arrangement Termination Date Collaboration fee Collaboration Agreement, Annual Collaboration Fee Collaboration Agreement, Annual Collaboration Fee Other Financial Information [Abstract] Other Financial Information Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Class of warrant or right, exercise price of warrants or rights (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights 2025 Long-Term Debt, Maturity, Year One Stock Option Plan Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Term loan borrowings Proceeds from Issuance of Long-Term Debt Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Allowance for credit losses Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest Stock-based compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Awards canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Loss Contingencies [Table] Loss Contingencies [Table] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Document Fiscal Year Focus Document Fiscal Year Focus Cowen Equity Distribution Agreement Cowen Equity Distribution Agreement [Member] Cowen Equity Distribution Agreement Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Product Concentration Risk Product Concentration Risk [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Other accrued liabilities Other Accrued Liabilities, Current Accrued and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Name Forgone Recovery, Individual Name Intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Shares authorized, percentage Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Finance lease obligations, current portion Finance Lease, Liability, Current Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Outstanding, beginning of period (in shares) Outstanding, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Insider Trading Arrangements [Line Items] Warrant expiration April 1, 2026 Expiration Apr 1, 2026 [Member] Expiration Apr 1, 2026 Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Cost of revenue Cost of Revenue Revenue recognized in previous periods Contract with Customer, Liability, Revenue Recognized Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Accounts Receivable, Net Accounts Receivable [Member] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Litigation Case [Domain] Litigation Case [Domain] Customer [Domain] Customer [Domain] Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Litigation Status [Domain] Litigation Status [Domain] Weighted-average number of shares used to compute net loss per share, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Purchase obligation, remainder of fiscal year Purchase Obligation, to be Paid, Remainder of Fiscal Year Restricted stock units Restricted Stock Units (RSUs) [Member] Amortization of debt discount and debt issuance costs Amortization of Debt Issuance Costs and Discounts Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Construction in progress Construction in Progress [Member] Revenue Revenue Benchmark [Member] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 9 exdx-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Cover - shares
 9 Months Ended
Sep. 30, 2024
Nov. 08, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2024  
Document Transition Report false  
Entity File Number 001-39049  
Entity Registrant Name EXAGEN INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 20-0434866  
Entity Address, Address Line One 1261 Liberty Way  
Entity Address, City or Town Vista  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92081  
City Area Code 760  
Local Phone Number 560-1501  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol XGN  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   17,637,278
Entity Central Index Key 0001274737  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.3
Unaudited Condensed Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 22,035 $ 36,493
Accounts receivable, net 9,387 6,551
Prepaid expenses and other current assets 4,135 4,797
Total current assets 35,557 47,841
Property and equipment, net 4,855 5,201
Operating lease right-of-use assets 2,630 3,286
Other assets 563 616
Total assets 43,605 56,944
Current liabilities:    
Accounts payable 1,105 3,131
Accrued and other current liabilities 6,177 7,531
Operating lease liabilities 1,065 976
Borrowings-current portion 430 264
Total current liabilities 8,777 11,902
Borrowings-non-current portion, net of discounts and debt issuance costs 19,823 19,231
Operating lease liabilities - non-current portion 1,952 2,760
Other non-current liabilities 185 357
Total liabilities 30,737 34,250
Commitments and contingencies (Note 5)
Stockholders' equity:    
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized, no shares issued or outstanding as of September 30, 2024 and December 31, 2023 0 0
Common stock, $0.001 par value per share; 200,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 17,520,335 and 17,045,954 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 18 17
Additional paid-in capital 303,420 301,893
Accumulated deficit (290,570) (279,216)
Total stockholders' equity 12,868 22,694
Total liabilities and stockholders' equity $ 43,605 $ 56,944
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.3
Unaudited Condensed Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2024
Dec. 31, 2023
Preferred stock    
Par value (in dollars per share) $ 0.001 $ 0.001
Shares authorized (in shares) 10,000,000 10,000,000
Shares outstanding (in shares) 0 0
Shares issued (in shares) 0 0
Common stock    
Par value (in dollars per share) $ 0.001 $ 0.001
Shares authorized (in shares) 200,000,000 200,000,000
Shares issued (in shares) 17,520,335 17,045,954
Shares outstanding (in shares) 17,520,335 17,045,954
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Unaudited Condensed Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Revenue $ 12,507 $ 13,416 $ 41,986 $ 38,783
Operating expenses:        
Costs of revenue 5,526 5,710 17,351 17,472
Selling, general and administrative expenses 10,163 11,375 31,169 35,212
Research and development expenses 1,481 1,400 3,719 3,789
Total operating expenses 17,170 18,485 52,239 56,473
Loss from operations (4,663) (5,069) (10,253) (17,690)
Interest expense (562) (557) (1,671) (1,769)
Interest income 197 211 570 1,343
Net loss $ (5,028) $ (5,415) $ (11,354) $ (18,116)
Net loss per share, basic (in dollars per share) $ (0.28) $ (0.31) $ (0.63) $ (1.03)
Net loss per share, diluted (in dollars per share) $ (0.28) $ (0.31) $ (0.63) $ (1.03)
Weighted-average number of shares used to compute net loss per share, basic (in shares) 18,254,937 17,692,603 18,127,549 17,626,686
Weighted-average number of shares used to compute net loss per share, diluted (in shares) 18,254,937 17,692,603 18,127,549 17,626,686
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Unaudited Condensed Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022   16,549,984    
Beginning balance at Dec. 31, 2022 $ 42,460 $ 17 $ 297,970 $ (255,527)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of stock from vested restricted stock units (in shares)   113,378    
Issuance of stock under Employee Stock Purchase Plan (in shares)   70,317    
Issuance of stock under Employee Stock Purchase Plan 152   152  
Exercise of stock options (in shares)   93,335    
Exercise of stock options 27   27  
Stock-based compensation 986   986  
Net loss (7,688)     (7,688)
Ending balance (in shares) at Mar. 31, 2023   16,827,014    
Ending balance at Mar. 31, 2023 35,937 $ 17 299,135 (263,215)
Beginning balance (in shares) at Dec. 31, 2022   16,549,984    
Beginning balance at Dec. 31, 2022 42,460 $ 17 297,970 (255,527)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net loss (18,116)      
Ending balance (in shares) at Sep. 30, 2023   16,931,894    
Ending balance at Sep. 30, 2023 27,504 $ 17 301,130 (273,643)
Beginning balance (in shares) at Mar. 31, 2023   16,827,014    
Beginning balance at Mar. 31, 2023 35,937 $ 17 299,135 (263,215)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of stock from vested restricted stock units (in shares)   31,180    
Stock-based compensation 978   978  
Net loss (5,013)     (5,013)
Ending balance (in shares) at Jun. 30, 2023   16,858,194    
Ending balance at Jun. 30, 2023 31,902 $ 17 300,113 (268,228)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of stock from vested restricted stock units (in shares)   14,424    
Issuance of stock under Employee Stock Purchase Plan (in shares)   59,276    
Issuance of stock under Employee Stock Purchase Plan 127   127  
Stock-based compensation 890   890  
Net loss (5,415)     (5,415)
Ending balance (in shares) at Sep. 30, 2023   16,931,894    
Ending balance at Sep. 30, 2023 $ 27,504 $ 17 301,130 (273,643)
Beginning balance (in shares) at Dec. 31, 2023 17,045,954 17,045,954    
Beginning balance at Dec. 31, 2023 $ 22,694 $ 17 301,893 (279,216)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of stock from vested restricted stock units (in shares)   217,056    
Issuance of stock under Employee Stock Purchase Plan (in shares)   54,605    
Issuance of stock under Employee Stock Purchase Plan 104   104  
Exercise of stock options (in shares)   326    
Stock-based compensation 553   553  
Net loss (3,360)     (3,360)
Ending balance (in shares) at Mar. 31, 2024   17,317,941    
Ending balance at Mar. 31, 2024 $ 19,991 $ 17 302,550 (282,576)
Beginning balance (in shares) at Dec. 31, 2023 17,045,954 17,045,954    
Beginning balance at Dec. 31, 2023 $ 22,694 $ 17 301,893 (279,216)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net loss $ (11,354)      
Ending balance (in shares) at Sep. 30, 2024 17,520,335 17,520,335    
Ending balance at Sep. 30, 2024 $ 12,868 $ 18 303,420 (290,570)
Beginning balance (in shares) at Mar. 31, 2024   17,317,941    
Beginning balance at Mar. 31, 2024 19,991 $ 17 302,550 (282,576)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of stock from vested restricted stock units (in shares)   62,998    
Exercise of stock options (in shares)   636    
Stock-based compensation 560   560  
Net loss (2,966)     (2,966)
Ending balance (in shares) at Jun. 30, 2024   17,381,575    
Ending balance at Jun. 30, 2024 17,585 $ 17 303,110 (285,542)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of stock from vested restricted stock units (in shares)   13,155    
Issuance of stock under Employee Stock Purchase Plan (in shares)   41,443    
Issuance of stock under Employee Stock Purchase Plan 72 $ 1 71  
Exercise of stock options (in shares)   84,162    
Exercise of stock options 22   22  
Stock-based compensation 217   217  
Net loss $ (5,028)     (5,028)
Ending balance (in shares) at Sep. 30, 2024 17,520,335 17,520,335    
Ending balance at Sep. 30, 2024 $ 12,868 $ 18 $ 303,420 $ (290,570)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.3
Unaudited Condensed Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities:    
Net loss $ (11,354) $ (18,116)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,309 1,661
Amortization of debt discount and debt issuance costs 112 119
Non-cash interest expense 206 294
Loss on disposal of assets 111 209
Non-cash lease expense 656 717
Stock-based compensation 1,330 2,854
Changes in assets and liabilities:    
Accounts receivable, net (2,836) (10,967)
Prepaid expenses and other current assets 662 727
Other assets 50 (120)
Operating lease liabilities (720) (767)
Accounts payable (2,028) (1,422)
Accrued and other current liabilities (1,140) 2,000
Net cash used in operating activities (13,642) (22,811)
Cash flows from investing activities:    
Purchases of property and equipment (369) (722)
Proceeds from disposal of property and equipment 0 2
Net cash used in investing activities (369) (720)
Cash flows from financing activities:    
Proceeds from exercise of stock options 22 27
Proceeds from common stock issued under Employee Stock Purchase Plan 176 279
Principal payments on finance lease obligations (379) (541)
Principal payment on note payable obligations (266) (177)
Principal payment on long-term debt 0 (10,000)
Net cash used in financing activities (447) (10,412)
Net change in cash, cash equivalents and restricted cash (14,458) (33,943)
Cash, cash equivalents and restricted cash, beginning of period 36,693 62,591
Cash, cash equivalents and restricted cash, end of period 22,235 28,648
Supplemental disclosure of cash flow information:    
Cash paid for interest 1,307 1,336
Supplemental disclosure of non-cash items:    
Equipment purchased under notes payable obligations 706 250
Costs incurred, but not paid, in connection with capital expenditures $ 20 $ 81
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3
Organization
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization Organization
Description of Business
Exagen Inc. (the Company) is a commercial-stage diagnostics company which exists to provide clarity in autoimmune disease decision making with the goal of improving patients' clinical outcomes.
Liquidity
The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses. As of September 30, 2024, the Company had cash and cash equivalents of $22.0 million and had an accumulated deficit of $290.6 million. Since inception, the Company has financed its operations primarily through a combination of equity financings, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these condensed financial statements.
To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it may need to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation and Use of Estimates
The accompanying interim condensed balance sheet as of September 30, 2024, condensed statements of operations and stockholders' equity for the three and nine months ended September 30, 2024 and 2023, cash flows for the nine months ended September 30, 2024 and 2023 and the related footnote disclosures are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. These unaudited condensed financial statements and related footnote disclosures should be read in conjunction with the Company’s audited financial statements for the fiscal year ended December 31, 2023, included in its Annual Report on Form 10-K filed with the SEC on March 18, 2024. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all normal adjustments necessary for the fair presentation of the Company's financial position as of September 30, 2024 and its results of operations for the periods presented. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.
Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the recoverability of its long-lived assets and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.
Concentration of Credit Risk and Other Risk and Uncertainties
Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.
Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:
 
 Revenue
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2024202320242023
Medicare Advantage22 %15 %21 %17 %
Medicare20 %37 %24 %35 %
*Less than 10%.

Accounts Receivable, Net
 September 30, 2024December 31, 2023
Medicare23 %42 %
Medicare Advantage22 %16 %
*Less than 10%.
For the three months ended September 30, 2024 and 2023, approximately 93% and 89%, respectively, of the Company's revenue was related to the AVISE® CTD test. Revenue related to the AVISE® CTD test for the nine months ended September 30, 2024 and 2023 was approximately 91% and 88%, respectively.
The Company is dependent on key suppliers for certain laboratory materials. For the three months ended September 30, 2024 and 2023, approximately 98% and 98%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. For the nine months ended September 30, 2024 and 2023, approximately 97% and 97%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.
Disaggregation of Revenue
The following table includes the Company's revenues as disaggregated by payor and customer category (in thousands):
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Revenue:
Commercial$6,779 $6,090 $22,314 $17,789 
Government2,633 4,955 10,276 13,570 
Client(1)2,981 2,319 9,175 6,999 
Other(2)114 52 221 425 
Total revenue$12,507 $13,416 $41,986 $38,783 
(1)Includes hospitals, other laboratories, etc.
(2)Includes patient self-pay.
Cash, Cash Equivalents and Restricted Cash
The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.
The Company has an arrangement with a financial institution with which it has an existing banking relationship, whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a certificate of deposit with this financial institution in the amount of $0.2 million as collateral for the balances borrowed on these cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).
Cash, cash equivalents, and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):
 
 September 30, 2024December 31, 2023
Cash and cash equivalents$22,035 $36,493 
Restricted cash200 200 
$22,235 $36,693 
Long-lived Assets
The Company’s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, the Company combines its intangible assets and other long-lived assets, into groupings, a determination which is made principally on the basis of whether the assets are specific to a particular test offered or technology being developed. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset’s carrying amount. Management’s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.
Revenue Recognition
Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (hospitals, other laboratories, etc.) and patient self-pay.
The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers and follows a five-step process to determine the amount and timing of revenue recognized: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligation is satisfied. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.
Payors are generally billed at the Company's list price unless a separate pricing contract is in place. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the three months ended September 30, 2024 and 2023 was a $0.6 million net revenue increase and a $2.5 million net revenue increase, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. Included in revenues for the nine months ended September 30, 2024 and 2023 was a $6.2 million net revenue increase and a $2.6 million net revenue increase, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.
Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company’s balance sheet.
Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information, along with any requested medical or other claims-related information to the healthcare insurers. This generally occurs within 30 to 90 days of billing, however, the amount and timing of any reimbursements or collections for the Company's billed tests may vary by payor and other circumstances. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.
Accounts Receivable and Allowance for Credit Losses
We accrue an allowance for credit losses against our accounts receivable based on management’s current estimate of amounts that will not be collected. Management’s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was zero as of September 30, 2024 and 2023. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.
Research and Development
Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense; materials; laboratory supplies; consulting costs; costs associated with setting up and conducting clinical studies; depreciation; amortization and allocated overhead, including rent and utilities.
Advertising and Marketing Costs
Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.4 million and $0.5 million for the three months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024 and 2023, total advertising and marketing costs were approximately $1.0 million and $1.2 million, respectively. These costs are included in selling, general and administrative expenses in the accompanying condensed statements of operations.
Shipping and Handling Costs
Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and were approximately $0.9 million and $0.6 million for the three months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024 and 2023, shipping and handling costs were approximately $2.5 million and $1.9 million, respectively.
Stock-Based Compensation
The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.
The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method, as we have concluded that our stock option exercise history does not provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.
The fair value of each restricted stock unit (RSU) is determined on the grant date using the closing price of the Company's common stock on that date. The Company's RSUs generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of the RSU is subject to the holder's continued service with the Company. The Company issues new shares of common stock to satisfy the RSUs upon vesting.
Comprehensive Loss
Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.
Net Loss Per Share
Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, RSUs outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three and nine months ended September 30, 2024 and 2023, there is no difference in the number of shares used to calculate basic and diluted shares outstanding, as the inclusion of the potentially dilutive securities would be antidilutive.
Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):
 
 September 30, 2024September 30, 2023
Warrants to purchase common stock325,330 409,108 
Common stock options576,151 1,004,855 
Restricted stock units1,810,468 1,568,112 
Employee stock purchase plan12,570 12,542 
Total2,724,519 2,994,617 
Segment Reporting
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.
Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, Accounting Standards Updates (ASU) not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company's financial statements or disclosures.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), which requires public entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (CODM) and details of how the CODM uses financial reporting to assess the performance of a segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU will likely result in additional required disclosure when adopted.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which requires additional income tax disclosures in the rate reconciliation table for federal, state and foreign income taxes, in addition to more details about the reconciling items in some categories when items meet a certain quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 with early adoption permitted. The Company does not expect that this standard will have a material impact on its financial statements.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3
Other Financial Information
 9 Months Ended
Sep. 30, 2024
Other Financial Information [Abstract]  
Other Financial Information Other Financial Information
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following (in thousands):
                                                                     
 September 30, 2024December 31, 2023
Diagnostic testing supplies$2,934 $2,871 
Prepaid product royalties32 35 
Prepaid maintenance and insurance contracts1,169 1,860 
Other prepaid expenses and other current assets— 31 
Prepaid expenses and other current assets$4,135 $4,797 
Property and Equipment
Property and equipment consist of the following (in thousands):
 
 September 30, 2024December 31, 2023
Furniture and fixtures$98 $98 
Laboratory equipment4,209 5,312 
Computer equipment and software2,113 2,185 
Leasehold improvements3,089 3,316 
Construction in progress945 59 
Total property and equipment10,454 10,970 
Less: accumulated depreciation and amortization(5,599)(5,769)
Property and equipment, net$4,855 $5,201 
Depreciation and amortization expense for the three months ended September 30, 2024 and 2023 was approximately $0.4 million and $0.6 million, respectively. For the nine months ended September 30, 2024 and 2023, depreciation and amortization expense was approximately $1.3 million and $1.7 million, respectively.
Accrued and Other Current Liabilities
Accrued and other current liabilities consist of the following (in thousands):
 
 September 30, 2024December 31, 2023
Accrued payroll and related expenses$4,413 $4,738 
Accrued purchases of goods and services547 720 
Finance lease obligations, current portion283 490 
Refund liability266 302 
Other accrued liabilities668 1,281 
Accrued and other current liabilities$6,177 $7,531 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.3
Borrowings
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Borrowings Borrowings
2017 Term Loan
In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), as amended (the Amended Loan Agreement), pursuant to which the Company borrowed $25.0 million. As of September 30, 2024, no additional amounts remained available to borrow under the Amended Loan Agreement.
On April 28, 2023, the Company entered into the Amended Loan Agreement. The Amended Loan Agreement was treated as a modification. In connection with the Amended Loan Agreement, the Company repaid $10.0 million of the principal balance outstanding, for which the prepayment premium was waived. Pursuant to the Amended Loan Agreement, the interest rate on all borrowings under the Amended Loan Agreement is the sum (the Basic Rate) of (a) the greater of 8.0% or The Wall Street Journal prime rate (the Prime Rate), plus (b) 2.0%, which is paid-in-kind in the form of additional term loans (PIK Loans). Under the Amended Loan Agreement, an amount equal to 1.5% of the Basic Rate will be payable in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until April 1, 2026, after which interest is scheduled to accrue at the Basic Rate. The maturity date of the loan was extended to December 31, 2026. The Company estimated the effective interest rate of this loan to be approximately 10.6% as of September 30, 2024. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest under the Amended Loan Agreement is to be repaid in ten equal monthly installments commencing in April 2026. Upon repayment of the final installment under the Amended Loan Agreement, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of the loan using the effective interest method. For each of the three months ended September 30, 2024 and 2023, the Company issued PIK Loans totaling $0.1 million. For the nine months ended September 30, 2024 and 2023, the Company issued PIK Loans totaling $0.2 million and $0.3 million, respectively. The issuances of the PIK Loans are included in borrowings-non-current portion on the accompanying balance sheet.
The Amended Loan Agreement requires a prepayment premium of 1% of the aggregate outstanding principal for any prepayments made prior to November 1, 2024.
The Amended Loan Agreement is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Amended Loan Agreement require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.
The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis, however the Company is not required to comply with the revenue covenant for any quarter during which it maintains a minimum aggregate cash balance equal to fifty percent of the aggregate principal amount of the Amended Loan Agreement (excluding any capitalized interest paid-in-kind) at all times during such quarter. The consequences of failing to achieve the performance covenants, when applicable, will be cured if, (i) within thirty days of failing to achieve the performance covenant, the Company submits a new financial plan approved by the Company's board of directors (the Board) to Innovatus under which the Company is expected to break even on a cash flow basis prior to the maturity date, and (ii) within thirty days of the submission of such financial plan, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined in the Amended Loan Agreement. The Amended Loan Agreement requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.
The negative covenants provide, among other things, that without the prior consent of Innovatus, subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Amended Loan Agreement provides that an event of default will occur if, among other triggers, (i) the Company defaults in the payment of any amount payable under the agreement when due, (ii) there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii) the Company becomes insolvent, (iv) the Company undergoes a change in control or (v) the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.
As of September 30, 2024, the Company was in compliance with all covenants of the Amended Loan Agreement.
Upon an event of default in any of the Amended Loan Agreement covenants, the repayment of the 2017 Term Loan may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the 2017 Term Loan can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the Amended Loan Agreement due beyond twelve months of the balance sheet date as non-current.
Equipment Notes Payable
In April 2024, the Company purchased additional laboratory equipment using notes payable. At September 30, 2024, the total notes payable balance related to the financed equipment was $1.2 million, with $0.4 million classified within borrowings-current portion and $0.8 million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. The notes related to the financed equipment are subject to a 5.28% effective interest rate and will mature between October 1, 2026 and April 1, 2028.
Future Minimum Payments on the Outstanding Borrowings
As of September 30, 2024, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):
 
2024 (remaining)$517 
20252,097 
202621,400 
2027215 
202867 
Total24,296 
Less:
Unamortized debt discount and issuance costs(80)
Interest(3,963)
Total borrowings, net of discounts and debt issuance costs20,253 
Less: Borrowings-current portion(430)
Borrowings-non-current portion, net of discounts and debt issuance costs$19,823 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.3
Commitment and Contingencies
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Licensing Agreements
The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements, individual license agreements generally provide for ongoing royalty payments ranging from 2.0% to 7.0% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when incurred and recorded in costs of revenue in the accompanying condensed statements of operations.
Collaboration Obligations
In May 2021, the Company entered into a master research collaboration agreement with Allegheny Health Network Research Institute (AHN), pursuant to which the Company is required to pay AHN a collaboration fee of $0.4 million per year. Collaboration expenses under the master research collaboration agreement were $0.1 million for each of the three months ended September 30, 2024 and 2023. For each of the nine months ended September 30, 2024 and 2023, collaboration expenses under the master research collaboration agreement were $0.3 million. Collaboration expenses under the AHN collaboration are included in research and development expenses.
Supply Agreements
In August 2024, the Company amended a supply agreement with one supplier for reagents, which includes pricing terms and minimum purchase commitments, through December 31, 2025, for new consumable products related to the Company's launch of the RA Sub-Profile Biomarkers. Aggregate minimum annual purchase commitments related to such agreement for the years ending December 31, 2024 and 2025 are $8.4 million and $10.4 million, respectively.
Contingencies
In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including for subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
Litigation
From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities. The Company does not believe the outcome of any such matters will have a material effect on its financial position or results of operations.
In addition, in October 2023, the Company resolved an investigation with the U.S. Attorney’s Office for the District of Massachusetts that was initiated by a qui tam lawsuit. Pursuant to a settlement agreement entered into by and between the Company and the U.S. Department of Justice (the Settlement Agreement), the Company made a single lump-sum remittance to the government in the amount of $0.7 million, including interest, in connection with specimen processing arrangements that Exagen historically had with physicians. The U.S. Attorney’s Office dismissed this “covered conduct” in the qui tam lawsuit with prejudice, while non-covered conduct was dismissed without prejudice. The Department of Justice excused itself from the case in connection with the settlement. In November 2023, the complaint was unsealed by the court and served on Exagen by the relator. Exagen filed a motion to dismiss the complaint. In December 2023, the Company's insurance carrier provided reimbursement for certain defense costs the Company incurred in the October 2023 qui tam lawsuit. In February 2024, the relator filed a motion for leave to amend the complaint. Exagen opposed this motion, and all motions are still pending. The Company cannot predict when these matters will be resolved, the outcome of these matters, or their potential impact, which may materially and adversely affect the Company’s business, prospects, and financial condition. The Company intends to vigorously defend against the claims being asserted in the complaint.
The Company's participation in federal healthcare programs is not affected by the Settlement Agreement.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The carrying value of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature, which are determined to be a Level 1 measurement. The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for the same or similar issues. As of September 30, 2024, the 2017 Term Loan had a carrying value of $19.0 million and a fair value of $18.5 million. As of December 31, 2023, the 2017 Term Loan had a carrying value of $18.7 million and a fair value of $19.7 million. The estimated fair value of the 2017 Term Loan was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The carrying value of the Company's other long-term borrowing at September 30, 2024 was $1.2 million and approximated its fair value. At December 31, 2023, the carrying value of the Company's other long-term borrowing was $0.8 million and approximated its fair value.
Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:
Level 1 -    Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2 -    Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and
Level 3 -    Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.
The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):
 
 September 30, 2024
 TotalLevel 1Level 2Level 3
Assets:
Money market funds, included in cash and cash equivalents$14,963 $14,963 $— $— 
 
 December 31, 2023
 TotalLevel 1Level 2Level 3
Assets:
Money market funds, included in cash and cash equivalents$14,386 $14,386 $— $— 
The fair value of the Company's money market funds is based on quoted market prices.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders' Equity
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Stockholders' Equity Stockholders' Equity
Common Stock
Shelf Registration Statement
On November 17, 2023, the Company filed a registration statement on Form S-3, as amended (the 2023 Shelf Registration Statement), covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units. The 2023 Shelf Registration Statement became effective on November 29, 2023, and all $150.0 million remain available for sale as of September 30, 2024.
At The Market Sales Agreement
On September 15, 2022, the Company entered into a sales agreement, as amended on November 17, 2023 (the Sales Agreement) with Cowen and Company, LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $50.0 million. The Company is not obligated to sell any shares of Company common stock in the offering. As of September 30, 2024, the Company has not sold any shares of its common stock pursuant to the Sales Agreement.
Outstanding Warrants
The following equity classified warrants to purchase common stock were outstanding as of September 30, 2024:
SharesExercise PriceIssuance dateExpiration date
Common stock warrants237,169$1.84 January 19, 2016January 19, 2026
Common stock warrants67,086$1.84 March 31, 2016March 31, 2026
Common stock warrants131$1.84 April 1, 2016April 1, 2026
Common stock warrants20,944$14.32 December 7, 2018December 7, 2025
Common stock warrants804,951$0.001 June 22, 2021None
1,130,281
During the three and nine months ended September 30, 2024, no warrants to purchase common stock were exercised.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.3
Stock Option Plan
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Stock Option Plan Stock Option Plan
2019 Incentive Award Plan
In September 2019, the Board adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board and is generally four years from the date of grant or, for grants to new hires, date of hire. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) 4% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board. As of September 30, 2024, 2,122,271 shares of common stock remained available for future awards under the 2019 Plan.
Restricted Stock Units
RSU activity under the Company's 2019 Plan is set forth below:
Number of
Shares		Weighted-
Average
Grant Date Fair Value
Outstanding, December 31, 20231,387,459 $4.24 
Awards granted1,287,225 $2.09 
Awards released(293,209)$5.87 
Awards canceled(571,007)$4.16 
Outstanding, September 30, 2024
1,810,468 $2.47 
As of September 30, 2024, all of the outstanding RSUs were unvested. The fair value of RSUs vested in the nine months ended September 30, 2024 and 2023 was $0.5 million and $0.4 million, respectively. The weighted average grant date fair value for RSUs granted in the nine months ended September 30, 2024 and 2023 was $2.09 and $2.42, respectively. As of September 30, 2024, total unrecognized compensation cost related to RSUs was $3.7 million, which is expected to be recognized over a remaining weighted-average vesting period of 3.0 years.
Stock Options
Stock option activity under the 2019 Plan is set forth below:
 
Number of
Options		Weighted-
Average
Exercise Price		Weighted-
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic
Value (in thousands)
Outstanding, December 31, 2023986,819 $11.87 6.44$228 
Granted55,500 $1.99 
Exercised(85,124)$0.26 
Forfeited(9,518)$16.70 
Expired(371,526)$15.48 
Outstanding, September 30, 2024
576,151 $10.23 6.57$197 
Vested and expected to vest, September 30, 2024
576,151 $10.23 6.57$197 
Options exercisable, September 30, 2024
552,686 $10.56 6.45$177 
There were 55,500 and 73,500 stock options granted in the nine months ended September 30, 2024 and 2023, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The aggregate intrinsic value of options exercised during the nine months ended September 30, 2024 was $0.3 million. The aggregate intrinsic value of options exercised during the nine months ended September 30, 2023 was $0.2 million. As of September 30, 2024, total unrecognized compensation cost related to option awards was less than $0.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.29 years.
2019 Employee Stock Purchase Plan
In September 2019, the Board adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Board. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the lesser of (i) 1% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board. As of September 30, 2024, 523,744 shares of common stock remained available for issuance under the ESPP.
Stock-Based Compensation Expense
Total non-cash stock-based compensation expense recorded related to options granted, RSUs granted and stock purchase rights granted under the ESPP in the condensed statements of operations is as follows (in thousands):
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Costs of revenue$47 $45 $103 $161 
Selling, general and administrative114 792 1,058 2,497 
Research and development56 53 169 196 
Total$217 $890 $1,330 $2,854 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure                
Net loss $ (5,028) $ (2,966) $ (3,360) $ (5,415) $ (5,013) $ (7,688) $ (11,354) $ (18,116)
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Concentration of Credit Risk and Other Risk and Uncertainties
Concentration of Credit Risk and Other Risk and Uncertainties
Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.
Cash, Cash Equivalents and Restricted Cash
Cash, Cash Equivalents and Restricted Cash
The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.
Long-lived Assets
Long-lived Assets
The Company’s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, the Company combines its intangible assets and other long-lived assets, into groupings, a determination which is made principally on the basis of whether the assets are specific to a particular test offered or technology being developed. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset’s carrying amount. Management’s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.
Revenue Recognition
Revenue Recognition
Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (hospitals, other laboratories, etc.) and patient self-pay.
The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers and follows a five-step process to determine the amount and timing of revenue recognized: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligation is satisfied. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.
Payors are generally billed at the Company's list price unless a separate pricing contract is in place. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the three months ended September 30, 2024 and 2023 was a $0.6 million net revenue increase and a $2.5 million net revenue increase, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. Included in revenues for the nine months ended September 30, 2024 and 2023 was a $6.2 million net revenue increase and a $2.6 million net revenue increase, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.
Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company’s balance sheet.
Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information, along with any requested medical or other claims-related information to the healthcare insurers. This generally occurs within 30 to 90 days of billing, however, the amount and timing of any reimbursements or collections for the Company's billed tests may vary by payor and other circumstances. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.
Accounts Receivable and Allowance for Credit Losses
Accounts Receivable and Allowance for Credit Losses
We accrue an allowance for credit losses against our accounts receivable based on management’s current estimate of amounts that will not be collected. Management’s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was zero as of September 30, 2024 and 2023. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.
Research and Development
Research and Development
Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense; materials; laboratory supplies; consulting costs; costs associated with setting up and conducting clinical studies; depreciation; amortization and allocated overhead, including rent and utilities.
Advertising and Marketing Costs
Advertising and Marketing Costs
Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.4 million and $0.5 million for the three months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024 and 2023, total advertising and marketing costs were approximately $1.0 million and $1.2 million, respectively. These costs are included in selling, general and administrative expenses in the accompanying condensed statements of operations.
Shipping and Handling Costs
Shipping and Handling Costs
Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations
Stock-Based Compensation
Stock-Based Compensation
The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.
The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method, as we have concluded that our stock option exercise history does not provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.
The fair value of each restricted stock unit (RSU) is determined on the grant date using the closing price of the Company's common stock on that date. The Company's RSUs generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of the RSU is subject to the holder's continued service with the Company. The Company issues new shares of common stock to satisfy the RSUs upon vesting.
Comprehensive Loss
Comprehensive Loss
Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.
Net Loss Per Share
Net Loss Per Share
Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, RSUs outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three and nine months ended September 30, 2024 and 2023, there is no difference in the number of shares used to calculate basic and diluted shares outstanding, as the inclusion of the potentially dilutive securities would be antidilutive.
Segment Reporting
Segment Reporting
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.
Recent Accounting Pronouncements and Recently Adopted Accounting Standards
Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, Accounting Standards Updates (ASU) not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company's financial statements or disclosures.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), which requires public entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (CODM) and details of how the CODM uses financial reporting to assess the performance of a segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU will likely result in additional required disclosure when adopted.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which requires additional income tax disclosures in the rate reconciliation table for federal, state and foreign income taxes, in addition to more details about the reconciling items in some categories when items meet a certain quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 with early adoption permitted. The Company does not expect that this standard will have a material impact on its financial statements.
Fair Value Measurements
The carrying value of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature, which are determined to be a Level 1 measurement. The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for the same or similar issues. As of September 30, 2024, the 2017 Term Loan had a carrying value of $19.0 million and a fair value of $18.5 million. As of December 31, 2023, the 2017 Term Loan had a carrying value of $18.7 million and a fair value of $19.7 million. The estimated fair value of the 2017 Term Loan was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The carrying value of the Company's other long-term borrowing at September 30, 2024 was $1.2 million and approximated its fair value. At December 31, 2023, the carrying value of the Company's other long-term borrowing was $0.8 million and approximated its fair value.
Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:
Level 1 -    Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2 -    Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and
Level 3 -    Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.
The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Schedule of Concentration of Risk, by Risk Factor and Significant Payer For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:
 
 Revenue
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2024202320242023
Medicare Advantage22 %15 %21 %17 %
Medicare20 %37 %24 %35 %
*Less than 10%.

Accounts Receivable, Net
 September 30, 2024December 31, 2023
Medicare23 %42 %
Medicare Advantage22 %16 %
*Less than 10%.
Schedule of Disaggregation of Revenue
The following table includes the Company's revenues as disaggregated by payor and customer category (in thousands):
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Revenue:
Commercial$6,779 $6,090 $22,314 $17,789 
Government2,633 4,955 10,276 13,570 
Client(1)2,981 2,319 9,175 6,999 
Other(2)114 52 221 425 
Total revenue$12,507 $13,416 $41,986 $38,783 
(1)Includes hospitals, other laboratories, etc.
(2)Includes patient self-pay.
Schedule of Cash and Cash Equivalents
Cash, cash equivalents, and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):
 
 September 30, 2024December 31, 2023
Cash and cash equivalents$22,035 $36,493 
Restricted cash200 200 
$22,235 $36,693 
Schedule of Restricted Cash and Cash Equivalents
Cash, cash equivalents, and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):
 
 September 30, 2024December 31, 2023
Cash and cash equivalents$22,035 $36,493 
Restricted cash200 200 
$22,235 $36,693 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):
 
 September 30, 2024September 30, 2023
Warrants to purchase common stock325,330 409,108 
Common stock options576,151 1,004,855 
Restricted stock units1,810,468 1,568,112 
Employee stock purchase plan12,570 12,542 
Total2,724,519 2,994,617 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.3
Other Financial Information (Tables)
 9 Months Ended
Sep. 30, 2024
Other Financial Information [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following (in thousands):
                                                                     
 September 30, 2024December 31, 2023
Diagnostic testing supplies$2,934 $2,871 
Prepaid product royalties32 35 
Prepaid maintenance and insurance contracts1,169 1,860 
Other prepaid expenses and other current assets— 31 
Prepaid expenses and other current assets$4,135 $4,797 
Schedule of Property and Equipment
Property and equipment consist of the following (in thousands):
 
 September 30, 2024December 31, 2023
Furniture and fixtures$98 $98 
Laboratory equipment4,209 5,312 
Computer equipment and software2,113 2,185 
Leasehold improvements3,089 3,316 
Construction in progress945 59 
Total property and equipment10,454 10,970 
Less: accumulated depreciation and amortization(5,599)(5,769)
Property and equipment, net$4,855 $5,201 
Schedule of Accrued and Other Current Liabilities
Accrued and other current liabilities consist of the following (in thousands):
 
 September 30, 2024December 31, 2023
Accrued payroll and related expenses$4,413 $4,738 
Accrued purchases of goods and services547 720 
Finance lease obligations, current portion283 490 
Refund liability266 302 
Other accrued liabilities668 1,281 
Accrued and other current liabilities$6,177 $7,531 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.3
Borrowings (Tables)
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings
As of September 30, 2024, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):
 
2024 (remaining)$517 
20252,097 
202621,400 
2027215 
202867 
Total24,296 
Less:
Unamortized debt discount and issuance costs(80)
Interest(3,963)
Total borrowings, net of discounts and debt issuance costs20,253 
Less: Borrowings-current portion(430)
Borrowings-non-current portion, net of discounts and debt issuance costs$19,823 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):
 
 September 30, 2024
 TotalLevel 1Level 2Level 3
Assets:
Money market funds, included in cash and cash equivalents$14,963 $14,963 $— $— 
 
 December 31, 2023
 TotalLevel 1Level 2Level 3
Assets:
Money market funds, included in cash and cash equivalents$14,386 $14,386 $— $— 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Schedule of Outstanding Warrants
The following equity classified warrants to purchase common stock were outstanding as of September 30, 2024:
SharesExercise PriceIssuance dateExpiration date
Common stock warrants237,169$1.84 January 19, 2016January 19, 2026
Common stock warrants67,086$1.84 March 31, 2016March 31, 2026
Common stock warrants131$1.84 April 1, 2016April 1, 2026
Common stock warrants20,944$14.32 December 7, 2018December 7, 2025
Common stock warrants804,951$0.001 June 22, 2021None
1,130,281
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3
Stock Option Plan (Tables)
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Restricted Stock Unit Activity
RSU activity under the Company's 2019 Plan is set forth below:
Number of
Shares		Weighted-
Average
Grant Date Fair Value
Outstanding, December 31, 20231,387,459 $4.24 
Awards granted1,287,225 $2.09 
Awards released(293,209)$5.87 
Awards canceled(571,007)$4.16 
Outstanding, September 30, 2024
1,810,468 $2.47 
Schedule of Stock Option Activity
Stock option activity under the 2019 Plan is set forth below:
 
Number of
Options		Weighted-
Average
Exercise Price		Weighted-
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic
Value (in thousands)
Outstanding, December 31, 2023986,819 $11.87 6.44$228 
Granted55,500 $1.99 
Exercised(85,124)$0.26 
Forfeited(9,518)$16.70 
Expired(371,526)$15.48 
Outstanding, September 30, 2024
576,151 $10.23 6.57$197 
Vested and expected to vest, September 30, 2024
576,151 $10.23 6.57$197 
Options exercisable, September 30, 2024
552,686 $10.56 6.45$177 
Schedule of Non-Cash Stock-Based Compensation Expense
Total non-cash stock-based compensation expense recorded related to options granted, RSUs granted and stock purchase rights granted under the ESPP in the condensed statements of operations is as follows (in thousands):
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Costs of revenue$47 $45 $103 $161 
Selling, general and administrative114 792 1,058 2,497 
Research and development56 53 169 196 
Total$217 $890 $1,330 $2,854 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3
Organization (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Cash and cash equivalents $ 22,035 $ 36,493
Accumulated deficit $ 290,570 $ 279,216
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies - Revenue by Major Payers (Details) - Customer Concentration Risk
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Medicare Advantage | Revenue          
Disaggregation of Revenue [Line Items]          
Percent of total revenue 22.00% 15.00% 21.00% 17.00%  
Medicare Advantage | Accounts Receivable, Net          
Disaggregation of Revenue [Line Items]          
Percent of total revenue     22.00%   16.00%
Medicare | Revenue          
Disaggregation of Revenue [Line Items]          
Percent of total revenue 20.00% 37.00% 24.00% 35.00%  
Medicare | Accounts Receivable, Net          
Disaggregation of Revenue [Line Items]          
Percent of total revenue     23.00%   42.00%
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
segment
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
New Accounting Pronouncement, Early Adoption [Line Items]          
Restricted cash $ 200   $ 200   $ 200
Revenue recognized in previous periods 600 $ 2,500 6,200 $ 2,600  
Allowance for credit losses 0 0 0 0  
Advertising expense 400 500 $ 1,000 1,200  
Number of operating segments | segment     1    
Restricted stock units          
New Accounting Pronouncement, Early Adoption [Line Items]          
Dividend yield     0.00%    
Stock options, vesting period     4 years    
Shipping and Handling          
New Accounting Pronouncement, Early Adoption [Line Items]          
Cost of revenue $ 900 $ 600 $ 2,500 $ 1,900  
Revenue | Product Concentration Risk | AVISE CTD Test          
New Accounting Pronouncement, Early Adoption [Line Items]          
Percent of total revenue 93.00% 89.00% 91.00% 88.00%  
Revenue | Supplier Concentration Risk | Two Major Suppliers          
New Accounting Pronouncement, Early Adoption [Line Items]          
Percent of total revenue 98.00% 98.00% 97.00% 97.00%  
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Revenue $ 12,507 $ 13,416 $ 41,986 $ 38,783
Commercial        
Disaggregation of Revenue [Line Items]        
Revenue 6,779 6,090 22,314 17,789
Government        
Disaggregation of Revenue [Line Items]        
Revenue 2,633 4,955 10,276 13,570
Client        
Disaggregation of Revenue [Line Items]        
Revenue 2,981 2,319 9,175 6,999
Other        
Disaggregation of Revenue [Line Items]        
Revenue $ 114 $ 52 $ 221 $ 425
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Sep. 30, 2023
Dec. 31, 2022
Accounting Policies [Abstract]        
Cash and cash equivalents $ 22,035 $ 36,493    
Restricted cash 200 200    
Total cash, cash equivalents and restricted cash $ 22,235 $ 36,693 $ 28,648 $ 62,591
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies - Securities (Details) - shares
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Class of Stock [Line Items]    
Anti-dilutive securities excluded from computation (in shares) 2,724,519 2,994,617
Warrants to purchase common stock    
Class of Stock [Line Items]    
Anti-dilutive securities excluded from computation (in shares) 325,330 409,108
Common stock options    
Class of Stock [Line Items]    
Anti-dilutive securities excluded from computation (in shares) 576,151 1,004,855
Restricted stock units    
Class of Stock [Line Items]    
Anti-dilutive securities excluded from computation (in shares) 1,810,468 1,568,112
Employee stock purchase plan    
Class of Stock [Line Items]    
Anti-dilutive securities excluded from computation (in shares) 12,570 12,542
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.3
Other Financial Information - Prepaid Expenses (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Other Financial Information [Abstract]    
Diagnostic testing supplies $ 2,934 $ 2,871
Prepaid product royalties 32 35
Prepaid maintenance and insurance contracts 1,169 1,860
Other prepaid expenses and other current assets 0 31
Prepaid expenses and other current assets $ 4,135 $ 4,797
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.3
Other Financial Information - Property and Equipment (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 10,454 $ 10,970
Less: accumulated depreciation and amortization (5,599) (5,769)
Property and equipment, net 4,855 5,201
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Total property and equipment 98 98
Laboratory equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 4,209 5,312
Computer equipment and software    
Property, Plant and Equipment [Line Items]    
Total property and equipment 2,113 2,185
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment 3,089 3,316
Construction in progress    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 945 $ 59
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.3
Other Financial Information - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Other Financial Information [Abstract]        
Depreciation and amortization $ 0.4 $ 0.6 $ 1.3 $ 1.7
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.3
Other Financial Information - Accrued and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Other Financial Information [Abstract]    
Accrued payroll and related expenses $ 4,413 $ 4,738
Accrued purchases of goods and services 547 720
Finance lease obligations, current portion 283 490
Refund liability 266 302
Other accrued liabilities 668 1,281
Accrued and other current liabilities $ 6,177 $ 7,531
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.3
Borrowings - Narrative (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Apr. 28, 2023
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
installment
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Debt Instrument [Line Items]              
Loan repayment         $ 0 $ 10,000,000  
2017 Term loan | Innovatus Life Sciences Lending Fund | Loan payable              
Debt Instrument [Line Items]              
Term loan borrowings   $ 25,000,000          
Remaining borrowing capacity     $ 0   $ 0    
Loan repayment $ 10,000,000            
Variable rate 8.00%            
Term loan, interest rate 2.00%            
Term loan, paid in-kind, interest rate 1.50%            
Term loan, effective interest rate     10.60%   10.60%    
Number of monthly installments | installment         10    
Term loan, fee incurred upon payment of final installment     $ 1,000,000   $ 1,000,000    
Term loan, prepayment premium percentage     1.00%   1.00%    
Term loan, covenant, revenue performance period         12 months    
Debt instrument, minimum cash balance         50.00%    
Term loan, covenant, number of days to cure covenant if performance measure is not met         30 days    
Term loan covenant, minimum unrestricted cash balance     $ 2,000,000.0   $ 2,000,000.0    
Term loan covenant, increase to interest rate     4.00%   4.00%    
2017 Term loan | Innovatus Life Sciences Lending Fund | Paid in-kind note              
Debt Instrument [Line Items]              
Term loan, paid in-kind loans issued     $ 100,000 $ 100,000 $ 200,000 $ 300,000  
Equipment Notes Payable              
Debt Instrument [Line Items]              
Term loan, effective interest rate     5.28%   5.28%    
Notes payable     $ 1,200,000   $ 1,200,000   $ 800,000
Notes payable, current     400,000   400,000    
Notes payable, noncurrent     $ 800,000   $ 800,000    
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.3
Borrowings - Future Minimum Payments (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Debt Disclosure [Abstract]    
2024 (remaining) $ 517  
2025 2,097  
2026 21,400  
2027 215  
2028 67  
Total 24,296  
Unamortized debt discount and issuance costs (80)  
Interest (3,963)  
Total borrowings, net of discounts and debt issuance costs 20,253  
Less: Borrowings-current portion (430) $ (264)
Borrowings-non-current portion, net of discounts and debt issuance costs $ 19,823 $ 19,231
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.3
Commitment and Contingencies (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2023
May 31, 2021
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Aug. 31, 2024
Loss Contingencies [Line Items]              
Purchase obligation, remainder of fiscal year             $ 8.4
Purchase obligation, year one             $ 10.4
U.S. Department Of Justice Case | Settled Litigation              
Loss Contingencies [Line Items]              
Settlement payment $ 0.7            
AHN Collaboration              
Loss Contingencies [Line Items]              
Collaboration agreement, collaboration expenses     $ 0.1 $ 0.1 $ 0.3 $ 0.3  
Allegheny Health Network Research Institute              
Loss Contingencies [Line Items]              
Collaboration fee   $ 0.4          
Minimum | Licensing Agreements              
Loss Contingencies [Line Items]              
Royalty obligation, percent of net sales     2.00%   2.00%    
Maximum | Licensing Agreements              
Loss Contingencies [Line Items]              
Royalty obligation, percent of net sales     7.00%   7.00%    
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Long-term debt $ 20,253  
Equipment Notes Payable    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Notes payable 1,200 $ 800
Recurring | Money market funds, included in cash and cash equivalents    
Assets:    
Money market funds, included in cash and cash equivalents 14,963 14,386
Recurring | Level 1 | Money market funds, included in cash and cash equivalents    
Assets:    
Money market funds, included in cash and cash equivalents 14,963 14,386
Recurring | Level 2 | 2017 Term loan    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Long-term debt 19,000 18,700
Debt instrument 18,500 19,700
Recurring | Level 2 | Money market funds, included in cash and cash equivalents    
Assets:    
Money market funds, included in cash and cash equivalents 0 0
Recurring | Level 3 | Money market funds, included in cash and cash equivalents    
Assets:    
Money market funds, included in cash and cash equivalents $ 0 $ 0
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders' Equity - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 15, 2022
Sep. 30, 2024
Sep. 30, 2024
Nov. 17, 2023
Class of Stock [Line Items]        
Exercise of common stock warrants (in shares)   0 0  
Shelf Registration Statement        
Class of Stock [Line Items]        
Common stock offering, authorized amount       $ 150.0
Common stock offering, remaining authorized amount   $ 150.0 $ 150.0  
Cowen Equity Distribution Agreement        
Class of Stock [Line Items]        
Proceeds from sale of stock $ 50.0      
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders' Equity - Outstanding Warrants (Details)
Sep. 30, 2024
$ / shares
shares
Class of Stock [Line Items]  
Warrants issued to purchase redeemable convertible preferred stock (in shares) 1,130,281
Warrant expiration January 19, 2026  
Class of Stock [Line Items]  
Warrants issued to purchase redeemable convertible preferred stock (in shares) 237,169
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares $ 1.84
Warrant expiration March 31, 2026  
Class of Stock [Line Items]  
Warrants issued to purchase redeemable convertible preferred stock (in shares) 67,086
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares $ 1.84
Warrant expiration April 1, 2026  
Class of Stock [Line Items]  
Warrants issued to purchase redeemable convertible preferred stock (in shares) 131
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares $ 1.84
Warrant expiration December 7, 2025  
Class of Stock [Line Items]  
Warrants issued to purchase redeemable convertible preferred stock (in shares) 20,944
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares $ 14.32
No expiration  
Class of Stock [Line Items]  
Warrants issued to purchase redeemable convertible preferred stock (in shares) 804,951
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares $ 0.001
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.3
Stock Option Plan - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Intrinsic value $ 0.3 $ 0.2
Stock options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock options, unrecognized compensation cost $ 0.1  
Stock options, cost not yet recognized, remaining weighted average vesting period 2 years 3 months 14 days  
Granted (in shares) 55,500 73,500
Stock options | 2019 Incentive Award Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock options, expiration period 10 years  
Stock options, vesting period 4 years  
Shares authorized, percentage 4.00%  
Shares that remain available for future awards (in shares) 2,122,271  
Restricted stock units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock options, vesting period 4 years  
Aggregate intrinsic value, vested $ 0.5 $ 0.4
Awards granted (in dollars per share) $ 2.09 $ 2.42
Stock options, unrecognized compensation cost $ 3.7  
Stock options, cost not yet recognized, remaining weighted average vesting period 3 years  
Employee stock purchase plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares authorized, percentage 1.00%  
Shares that remain available for future awards (in shares) 523,744  
Maximum employee payroll deduction percentage 20.00%  
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.3
Stock Option Plan - Restricted Stock Units (Details) - Restricted stock units - $ / shares
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Number of Shares    
Outstanding, beginning of period (in shares) 1,387,459  
Awards granted (in shares) 1,287,225  
Awards released (in shares) (293,209)  
Awards canceled (in shares) (571,007)  
Outstanding, end of period (in shares) 1,810,468  
Weighted- Average Grant Date Fair Value    
Outstanding, beginning of period (in dollars per share) $ 4.24  
Awards granted (in dollars per share) 2.09 $ 2.42
Awards released (in dollars per share) 5.87  
Awards canceled (in dollars per share) 4.16  
Outstanding, end of period (in dollars per share) $ 2.47  
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.3
Stock Option Plan - Stock Option Activity (Details) - Stock options - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Number of Options      
Outstanding, beginning of period (in shares) 986,819    
Granted (in shares) 55,500 73,500  
Exercised (in shares) (85,124)    
Forfeited (in shares) (9,518)    
Expired (in shares) (371,526)    
Outstanding, end of period (in shares) 576,151   986,819
Vested and expected to vest, end of period (in shares) 576,151    
Options exercisable, end of period (in shares) 552,686    
Weighted- Average Exercise Price      
Outstanding, beginning of period (in dollars per share) $ 11.87    
Granted (in dollars per share) 1.99    
Exercised (in dollars per share) 0.26    
Forfeited (in dollars per share) 16.70    
Expired (in dollars per share) 15.48    
Outstanding, end of period (in dollars per share) 10.23   $ 11.87
Vested and expected to vest, end of period (in shares), Weighted Average Exercise Price (in dollars per share) 10.23    
Options exercised, end of period (in shares), Weighted Average Exercise Price (in dollars per share) $ 10.56    
Stock Options, Additional Disclosures [Abstract]      
Outstanding, Weighted Average Remaining Contractual Term 6 years 6 months 25 days   6 years 5 months 8 days
Vested and expected to vest, Weighted Average Remaining Contractual Term 6 years 6 months 25 days    
Options exercisable, Weighted Average Remaining Contractual Term 6 years 5 months 12 days    
Outstanding, Aggregate Intrinsic Value $ 197   $ 228
Vested and expected to vest, Aggregate Intrinsic Value 197    
Options exercisable, Aggregate Intrinsic Value $ 177    
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.3
Stock Option Plan - Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 217 $ 890 $ 1,330 $ 2,854
Costs of revenue        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 47 45 103 161
Selling, general and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 114 792 1,058 2,497
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 56 $ 53 $ 169 $ 196
EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /5);%D'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #U26Q9M_=ZC>X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>NFD'AZC+96BG(2$Q"<0M2KPMHDFCQ*C=VY.6K1."!^ 8^\_G MSY);'83N(S['/F DB^EN=)U/0H^"V@6XES]$SMW@%V28[)+:AB&M[ ^ MD?(:\Z]D!9T#KMEU\FNS>=QOF:RK>E5P7O!ZSU>"WXNF>9]621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M /5);%E-$)<1W04 *8? 8 >&PO=V]R:W-H965T&UL MM9EK<^(V&(7_BH9V.KLS(5@RMVP),X1I8OP;=SHD<7^TCJK:3ZGLR%T.0Y"N/DLC;7>O&NT4B\N8AX('D8B30,9$B>EE;4#? M#5W7"+(G/@=BE>P<$X/R).5WX/Y5(H4B?)G"N1]!H:/,V= MAK?17^5ZMD=_03[(6,\3/Y/*<.%V;_$5QW*)^W,S/1>OGK\%3HA5TN;]M-90[-.T.9AR^2Q;<$Y.0/J5<::'"-7D0"ZFT#0^WTBJU5/PQD(%TC>C MD,![P-IXN%,Q[O8./%1?D;-3<':.[)F*PR2<[T&.0'_DSN?=A= ;3P,NXD2Y\P)(Y M=:?I-KOMMI47%5?E924O.X9WX/O@GIQM#\A[>(Y\C.WMBEM2UJ:@A\H"XR]\ M;:5&+:I2EPF(HIGC/]1#S96Q?W' ZLH*<(1+1,1!3/,:]!QQ(:)"1_!HO]+R?<\8(Y76HE/44V MHF4XHGBFR7KJ &:W^\%P@T[;L6*=(@K1,@M1/,"\EQZTUW@N8RPK'#!IM9TZ M;3GV9CM%$J)E%*)XCGD,-*0@.264O7EZ2R;"2Q6TI!42=QK**(*OT41+[_L9 M67!%ECQ,!?G9.8>P1!8PML4*8F5*8GA.6;;F.3FV9OS>";V1L$#1J/!Y'I@G6[BPJJ$92AB1X6B M8:J4F;#DLY2L)>&#DEJ76 XX?K,NS QQ557.,@RQH\+0?0RSZGPQSLP\^1;< MRHD[[N,\1?QA9?QA1\4?,S.#% ^98":5]5UTP&4^0@ M5N8@=E0.FD0\#,E5FL#MQ-YK<9]]RR6XK"I>F7[84>GG)A)J9D;E'3CH.02$ M:,%C>[M66Q;"954YR^S#\.BRY7S>73+)5XFLD+C;WC437%>5LHQ"#$\QV\XZ M%]!9L3:LN"2$ZZKBE4F(';4J]#+&3+*E>O(QU9#;XRPDO GBS0K^6RO]#XHR MFSK)W5J9F]DF6O9II^UV6*?;:RQMO&7H84,FZ7X_92XW2?7RGB* M$.3N[(+AX64 @'X.&?*9E0HWV/N&Q77_%ZRQLQ-JOO#9!G%"/+/XFF^*%E>+ M3>A!MO7:*!_/=[ _<&[08Y&7^G*T,::ZF$QTNN$%T^>RXB6\64M5, .WZFZB*\59UB@5^81B M'$T*)LK18MX\NU&+N:Q-+DI^HY"NBX*IIRN>RX?+$1D]/_@H[C;&/I@LYA6[ MXRMN/ERN9*'BIA2R1XNO+T0=RL:2)56@D_A;\01]<(^O*K91?[,WO MV>4(6T0\YZFQ)AC\N>=+GN?6$N#XNC,ZVG_3*AY>/UO_M7$>G+EEFB]E_H_( MS.9RE(Q0QM>LSLU'^? ;WSD46GNIS'7S&SWL9/$(I;4VLM@I X)"E-N_['$7 MB ,%,NU1H#L%>JI"L%,(&D>WR!JWKIEAB[F2#TA9:;!F+YK8--K@C2CM,JZ, M@K<"],SB<\GJ3!B>H:4L,U@>N+IB.2M3CE;6JD9GZ//J&KU]\PZ]0:)$GS:R MUJS,]'QB ( U,TEW'[O:?HSV?&S%JW,4X#&BF$X]ZLMA]6N>@CIIU(-C]0FX MO?>=[GVGC;V@Q]ZR5HJ7!C&MP<\+GS]; U._ ;O%+G3%4GXY@CVDN;KGH\7/ M/Y$(O_=Y]TK&CGP-]KX&0]872Z8W"%8-I?:"?ZW%/>\J;DU%C2E;!^X7 ME.(@G$_N#]UQI8)H.@OV4D-MSL>HY,8'Y#A(,@;Q2LF,L0?*[MC=!-8:390XQ?""SP MDS)/34!MDE; &*8W 6(70Q)V0^D*A13WX$SV.)-!G'\!2F9$>8=R#AR"E"6+ M,[D^J^&F/[*) X5& >[@=84"FD1^O+,]WMDPWB8W^X'-W!A%00>7*Q.1'E@$ MM^R#3\C)?F []:,E#B+<76./6!C-IM,>> ?D2$YBB%RP6Y$+([B?)G9F7HDG M7LO:L=,M*Y)!(FI+<,6>;/WU.DR=@!/B+HLK%9"@9^^1ELK(,)U&WQ$:&F:U;,U["ZA(7P9$380\'QGV[LJ4W,LQO M5U*!#D#59\^1K:2R;;<7J8>LG*KF$:)1W_YL&8U\"Z6]%%&7LI+877U7BI 9 MICU06V8CP]1V$--2EMVX-A2'Y!IE0N]VG\WNC-\:)+2NFWX\E;JG2KH<1V8) M[59PKQCMS>R6#,FWL>'!.L#PX/'6ZX/+>V06TJX+'@J-(]SC04N/Y!1^/$3Z M4BZY;$@29W.Z0D'8T\31EC+I*93Y C[J$F* XZ";[#ZQ*0U[XDE;WJ2#%+58 MRJ(0QO9NVSQ.96GS@Y>IS8FW?TK#4?C."_P[N ]YAZT?-W3L_,%4.3Q6KHQ, MOVQDGG&E?VFZ6//D'RY?=[K\/\9+VI(R'29EF(G6'/9.AK3U?XS>X'.,"301 M"L&H67,$50+I#5/\/2)XC''SLWT"65*;C53B7YY!*93/3VWI XM2(5D;;2"5 M;)5AVE;*%:\,+VZYVCKQ?*S0Y-LU#(_V5<]IP2[\+L]W66M0Y#A0;1] A_L MNS=D>4J4*!X(T_=$ 0(?CV'Z&0=!V$C +9Z&XUDX[42\::U^+.1C&.%UQ9MC MNOS)NP">%B?IKH!'IJ^$MOT-'>YO/F29L#P$==3.\6>B1"FK!-15+TRW=0DP ME$DG67QR).D[$:%MET.'NQSH=^NBSID]IPIQ^!4==) 5>,4ICN>L"V;0L=;EL<(FWR^&3P MB7/\Y9M,/6*^R71R<()KC\__8.I.E!H:JC7HX?,8O%?;$^GMC9%5TZ\_[_ XC]02P,$% @ ]4EL6377K #C @ MM H !@ !X;"]W;W)K+6^7A('F+ ]QS. 2Z^ MLYV03RH'T.BY8%S-O5SK\L;W59I#0=1 E,#-F[60!=&F*S>^*B60S($*YH<8 MC_R"4.XE,S>VE,E,5)I1#DN)5%441/ZY!29VW+!DM@"LJ.)*PGGM?@IM%X NXB>%G=IK(VOE48@GV_F>S3UL%0&# M5%L*8AY;6 !CELGH^-V0>NV<%KC??F'_ZLP;,X]$P4*P7S33^=R;>"B#-:F8 MOA>[;] 8BBU?*IAR_VA7QXZ&'DHKI471@(V"@O+Z29Z;A=@#!(< 80,(SP5$ M#2!R1FMESM8=T2292;%#TD8;-MMP:^/0Q@WE=AM76IJWU.!T\L!)E5$-&5H( MGIGM,:U;P@A/ :TLJT)72R*!ZQPT30F[1I_0>^0CE9M1-?.U$6&I_+29\+:> M,#PPX0K* 8KP1Q3B<-@#7QR'WT%JX(UVX;ZRW_L/6?^CXH@-\2W-J0$KC MVBQU^M3GIR88]A/8-+M1)4EA[ID\4B"WX"4?W@4C_+G/W87(.EZCUFMTC#TQ M^XBVA%6 KBA'F6",2(5*D/5F7O>9KQG'CM%>"=L$#S .9OYVW]6IJ([<82MW M>%3NRITP1"J="TG_FBVRLNMSUZNUIHOW5 2X_KV2>T9@1W'<*H[/46QN2Z4) MSRC?G)(DE')_4=B^CH&[?ZQD#I.SDK'4U$=N=-6[O2RZ3A]*>R/Q,)[&PP.*]S[(P84OD8;P'-E]D;VR_;V2 MPM9S/XC<4*X0@[6!XL'8<,BZ1*H[6I2NRG@4VM0LKIF;LA*D#3#OUT+HEXXM M7-I"-?D'4$L#!!0 ( /5);%DH]:EN 04 ) 5 8 >&PO=V]R:W-H M965T&ULK5A=<^(V%/TK&G>GLSN3Q);\24J828!.,]-M,V'3 M?>CT0<$"/&M;5!*0_OM*-AB0K]VTY07\<>Z5SM'Q];6&.RZ^R15C"KT5>2GO MG)52ZUO7E?,5*ZB\X6M6ZCL++@JJ]*E8NG(M&$VKH")WB>=%;D&STAD-JVM/ M8C3D&Y5G)7L22&Z*@HJ_'EC.=W<.=@X7GK/E2ID+[FBXIDLV8^IE_23TF=MD M2;."E3+C)1)L<>?GS(_F-%7I-YI9*->?XU2]7JSDD3J MF>]^8GM"HR7DFS11+T9B7J3: /IHIJI@V@Y*(+]"O:R:H652)KM'+;((^ M?OB$/J"L1%]6?"-IFN)=+4&C SGH\$!Z$\[8^@;YWA4B'@F ^8S?'^Y#=/[?Z-/_//J9&'YC"K_* MYW?D>RSGO&!''Z#?[U^E$OJA_@-:ZCI9 "Y6KNFRHK@/(#')VC)FU4@ >)A9JV47X2)WZ#.F,8-@S#7L_MRTRY1.QM;>J0O(78 MAI?TVB6332Z9;'JA9&Y;E MVB <^R&V+ >A@IC EHL;HG$OT9EN3[3AKM"2E=I\.=+O,D13_9;-3+4S'4QC M1DB$N#TI#T>^I0* PGX<6C*T43[&T<"2 4"%!'?(D#0R)/]06R2C8KZJZ*=Z MS7.^KJI^'_>DS2I(K%4;0R#/-D ;Y,?8)@Z!D@',>]#P'O3R_L*57G/>JCL0 MW0'@/QQ;5,8 *@D2>ZG;J) 0WV8,H*(@[BBRV#NV>UXOZ9^YE&@A>'$@KOLZ ML'WS6N-?!U'+W! L]&S?3B 8]DAHI9N"N#@:>!VT3[I1S>K.CF0+6F;=6!W#0"(8&QS M;8-"^]&80L/Y09>=CXTJ[NVZ1K_H3^E<6QIDZ+?Z%.U-DM@<(5B [:<6@NE" M'@8V40B7X)-6ZYSJL0/$_2W@@2K2SRV2*RK8E?E$SN;HH_X62WF>4W%R\Q,H M23U$ZN"\9*C?%JZ:OF[E* 8DVY@-? M<:3+PEHKA5]5!L&Y 2Y:0,!CXK2("-6_1@$2>;ZL'Y<0DUEEM <&<)(J2 MKN?LV!3B_J[P,AJ>&K%/1: [[% 10':H".6$501S0BJZ)SM,!1/+:FM/:@4V MI:KW%9JKS?;A?;5I9EU_P+=C#%R?F.W&:D?KF+[>J_Q,Q3(K)_JM/%%]7^UNO7"E>5(&PO=V]R:W-H965T&UL MO9U=<]NX%8;_"D?=:3V8CH=-T9CN>9-->='K!2+3-B21J2FC;[;O) MI%D\%.N\>5MMBXWZS5U5K_-6?:WO)\VV+O+EOM)Z-:%QG$S6>;D9W5SM?W9; MWUQ5NW95;HK;.FIVZW5>?W]?K*JGZQ$9_?C!Q_+^H>U^,+FYVN;WQ:>B_;R] MK=6WR5%E6:Z+35-6FZ@N[JY'OY!W,MU7V)?X=UD\-2>?H^Y4OE35U^[+A^7U M*.Z.J%@5B[:3R-5_C\6L6*TZ)7487<73SS_4_[X_>74R7_*FF%6K M_Y3+]N%Z-!U%R^(NWZW:C]73/XK#"8E.;U&MFOV_T=.A;#R*%KNFK=:'RNH( MUN7F^?_\V\&(DPJ$G:E #Q7HT KL4(%9%6AZI@(_5.!VA7/G( X5]J<^>3[W MO7'SO,UOKNKJ*:J[TDJM^[!W?U];^55NNH;RJ:W5;TM5K[WYO,EWR[(MEM&L MVBQ5 U"?/K5Y6ZC&T#91=:>^58NO#]5J6=3-7R+Y^ZYLOT?CZ/.G>?3S3V^B MGZ)R$_WV4.V:?+-LKB:M.JA.>K(X',#[YP.@9P[@MZK-5YYJ,[C:K%JOJ\V? M_T22^&_[(_1(S&&)7Y;JQ%5CS5?1;5XNQQ\VT2S?EO[#D3U:B\5NO5OEG9'S MXJY?;4EY%G,;$7ZSJ@ MQQN2")YE4WXU>3SU'3.J1!(S$L"."6"!"1AB^K-FAK5Z-09[S^]Z:YU;W_P MWX_5:A6IKOLIKY?_\YG",5LBIM@<4TPBB1D)$\>$";"U?FB:W;Z1JEZ[Z;(4 MW=75.GHLFJY;4O':NEQT'Y]_N=N4JH<_Z5%\:0,CAJ9-N!T(82R=6LT>,Z9$ M$C,2DAP3D@0F9*?NL74DU]M5];THGJ^EZ'97+QZZ"^U6]3%]"0$CAB8D<1*2 MQLSIAC!#2B0Q(Q_I,1\I>CY\.4C==BRHU;V#1Q+:10T(*)$"&L9.C\9.06/E MMZ)>E,V)L=6V&UKU=B^@;&AKGCHN98PQ8;5FS) 22,- MM2[S&1@MM,7VQY-(\0SO2*RY)P;=VU_JXXXQE]&B6BOP;O+./2_!Q&[+FB:6 M?7"\4/^&A)18(4T+3]"1@!;^JVBC5=7XH8\XQS].D^G4-@V,$&P:IIKL/073 M-@UU!*8ZN5D"2/=K7A_I@GF=164ZXH.Z*4UC8D,=:ER)I6;F0',=@<'.RL$@ MWYGC%!,9LWM1,H#K/%(TRXA]JY*>\4@Z<<.,= -"*1Y(*S# 05 MCU#5YJAJ$DO-3)LF*0*C%'CO=W%E3*:$.",F5$9"59-8:J:]FJ=(#U"!8X1/ MQ5;U$#%PKT+E*N*"%4DR1J:9TSFCPA66FID#C5>DAZ^<,4*_[S[L$3&W&WXV MH&=VI5A,"'-Z9K? 8<,3IZ'Z0B9QO85@!E48JF96='H1V'T"YGXHBZ6 M9?9RS0R.%WP%# @IL4*:%FILHS"V08-?ZB$E$1-FFX:YR#5'59.]IV#:IE&/ MPLMA\*#VG[L-/+B"U8,O?7?M2XTFQ)0X@UK4N!)+SWAR"I&NO1,Y.O5(,5G5YR*('*6:AJ UW'(:[$#[F+BD)82^5P/&"V^Z D!(K MI&GAR8-W,.A!?,Q=[AHSYFS^@R,$FX:*<+VG8-JFV8P'L1FP6X5[G45]UHU[ M'G9+&4DS3NRK'W7Q#DO-S('F0QZTQC?(]\1%DBS+B-VB/<5L=A+S\?#RXYAP\ZN(F]QMY(KN&0PWLC7\;' M!]$^/O84>< MPT<<[.]K()702"6"'EP;Y"EUNU,Z3>PM9+YBSEL!/"05,T[M>[NGW)AFL4C/ MC"^%)AL1^C:0T"$F'"#X=0HNRIP98J+&E5AJ9AHT'0F8CGHW1/NM]ZQ7>4:9 MAV+@_=\CY1UE>LJ!HTQQ\J(/<<'[O\!]R0?JSD94-8FE9J9-PY$(?1\(P@M: M4'=%"A>,$IIE3E^,NMZ&I69F12.;Z-D2^=*90E@WV'J7YA)FSQ2BAI18:J;Q M&N0$#'(A,X7"92GA3'K!\8*[G@$A)59(TT(-@@)><0.)PO=D6);83V'"$8)- M0^6UWE,P7\ND02R!06SX3G3O6 )6#WX)D^>YMI1-B4AMFD"-*['4S!QH6DN" M:&V0[U[NFMIXE@QXJ,TCI6B"$/OZ]I138S@A.#W3!C5-)9=\J"U!7;5"59NC MJDDL-3-M&@*3RS_4!H<,3IX'"QD13F>"RH18:F96-!,F,!.^RIOV4/=+)BX, M MO#"R9_GLI2P"ZP8W5A<#IYPDU#84]\V0KX&!B<; Y(48Z+7;A37JM$C4UYL, MB"BQ(IH.:IY+\'@N<>&*VH.T&1POV,$!(2562--"S7/)RWDN<=\:,A8QM>?2 MX0C!IJ'R7.+A.>,4S->Z:IY+_PC/]:Y2I#X"\Z[\#"XYAX\XU#@L-=-?S6II M**OU>^J!,,_*CZ^8/=OH*>-=^?&4\Z_\3$[^7D+WYS!^S>O[4MUC5\6=JAF_ M355^Z^>_,/'\I:VV^S^A\*5JVVJ]__A0Y&HHTQ50O[^KJO;'E^ZO,AS_SL?- M_P%02P,$% @ ]4EL6<;OM> OB2T?3\^]/D?RZE'47^6.,86>BKR4UY.=4M7E M;";3'2NH?"TJ5L(O&U$75,'7>CN3578F] MRGG);FLD]T5!ZV]O6"X>KR?AY/#@,]_NE'XP6UU5=,ONF/I2W=;P;=9IR7C! M2LE%B6JVN9[A)H1"QGJ=(J*/Q[ M8&N6YUH3X/BG53KIWJD7'G\^:']OC =C[JED:Y'_Q3.UNYXL)BAC&[K/U6?Q M^"MK#9IK?:G(I?F+'AO9))Z@="^5*-K%@*#@9?.?/K6..%H >MP+<+L #Q=$ M(PM(NX 80QMDQJRW5-'552T>4:VE09O^8'QC5H,UO-1AO%,U_,IAG5I]*>D^ MXXIE:"W*#,(#G^X450Q"I202&[2F0[@EFJ(O=V_13Z]^1J\0+]$?.[&7 MM,SDU4P!%*UPEK:O?=.\%H^\=HD^B%+M)'H'+\U.U\_ A,X.?+#C#?8JO&/5 M:T2""X0#'#GPK)^_G'C@D,ZMQ.@C(_J,TS;&:9M:% C*KJ:*E]LF;[GB3%ZZ MW-:HC=QJ=4U?RHJF['H"12M9_< FJQ]_"./@%Y?-9U)VXH&H\T#DT[[Z""TH M%]*9&\W*V*S4?>9A-0U#,H>X/1S#=XDMPC#NQ$Z S3M@Z("#7GQW ^3D#>"9E)WZ*.S_%W@"^9: TY;3I MMF6&:"%JQ?\U#UR6-^KF1^$*2; A.Z))AS3Q(KTY J8[5L;N%<*EW-,R92@54CGS,K'!A7A@@$MFZ<:_Z/ O_*4BRJE)-EXJ!H%4 MB#U5NA6[,"ZL]^,@'F!TR"PC-\9EAW'IQ?B[+@QP+[BU$I+FVL]42N9VY-+A MI' TI;!P8@CPZ!GL^!YKLP9<+O/CZVBX_?'\Z$C'4))F(R /*+_)M:FF'). M[WD^W@%;I6=J@>?2=NJ"GL=#+TFN;E+31:3F"<8?Z'W.+C0[. TG5A2F>$&L MI'*(A<$R'LNKGG%#/^7>UJRB/#MD?1,MH7:LADFRKIENAJ,EV^H^J8=XV/P< M0@D>P]T359%SL&8UG0$ MJ:6J=?34-Y.$[)\]K_1>P.D#FU6G)!Y.M"ZI9*Q4<,^]V$MLT,Q%REC6QNUX M['J! =B"-JP8A\@8])XSL9\SK7)Q99T3KX,9'0YW2"5CK1[W[(FC%Y7*AI>P M6WA.J7A9^<6E- MSB4S0GRX)VGL)^E3S#!1%[!1:>#J/1_DX+[,@&O>%54NOC&&S ".#ET!W>;4 M.7MCQV8U&4YS#B& M#@>'D\0J)H?4/!KCG9[HL9_H+?P:?BD4.PPGWT7O('P<6\YWC07)6$+U?(_] M?.]$GXMR.X7]>6%.$YR8;1:WVJUK( A&1Q32$SWYSL9WV'-=[# 7S/I>W4(SW9$S_9 MFY'''!F T=WIH]-LF[=#$EA=PB5%1L[K2<_O)/Z_@2N[HU/%BI$;%>_P\.*( MG4G;J2OZN8#XYX)WAW$?5>WT& T19MG>\CUSMH#8KK@-O3K4RKB#R;IL6UG61 M=?+BD%D,>^3LZ#*U8/76W#%+9,Y6FOO([FEWCWUC;F\'S]^$E^OF-KI7TUR. M?Z U-'\)<]P&5 :O$_!QW=PW-U^4J,R5[;U02A3FXXY1"+,6@-\W J+=?M$O MZ&[]5_\!4$L#!!0 ( /5);%E'HFND) 4 '4+ 8 >&PO=V]R:W-H M965T&ULC59M;]LV$/XK!VU8-\"S72?MUBPQD/0%*[!B0;-N M'X9]H*B3Q(4B59**D_WZ/4?9BIVU6;_8DG@OS]T]=[S3C0_7L65.=-M9%\^* M-J7^9+&(NN5.Q;GOV>&D]J%3":^A6<0^L*JR4F<7J^7R^:)3QA7KT_SM,JQ/ M_9"L<7P9* Y=I\+=!5N_.2N>%KL/[TW3)OFP6)_VJN$K3A_ZRX"WQ62E,AV[ M:+RCP/59^9))+2^VMY>5N=%4L!Q)9U$@L*?S?\DJT5 M0X#Q<6NSF%R*XO[SSOJ;'#MB*57DE][^8:K4GA4_%E1QK0:;WOO-S[R-YYG8 MT][&_$N;K>RR(#W$Y+NM,A!TQHW_ZG:;AR]16&T55AGWZ"BC?*626I\&OZ$@ MTK F#SG4K UPQDE1KE+ J8%>6O\:&N7,/TI2=+I(L"C?%WJK?3%JKSZC_8+> M>9?:2*]=Q=6A_@)()CBK'9R+U:,&K[B?T]%R1JOEZO@1>T=3>$?9WM$7A#>C ME]Y%;TVE1D*XBBX#1W9I_.!K>F.<1E3 '_^^E2&1@#' MGP8@/742>Z7YK.C%5[CA8OW-5T^?+W]Z)+SC*;SCQZS_;_6^7)M><=3!]+M$ M7 P1TA&5O45O.GKK])R^32TCB5VOW-UW9"(ITK[K.$C&OH\)DE09U3@?D]%1 M#D64-JW1+?&MB[]3ET; MUZ Q4DN"H/&H#S":+AO"48\8I%1/8-(XH^5\2'#/<4Z_F(^#J<3/;_?PJ541 M?O40 E>8+O(@EJR/D6/FAN-&R<@@K6)+-<97I#KXCC 1 TX@G6>*@>](2)=F ML<@YA_,#9\HA'P8H(9A:E<@DA&,M,H03-[!D):.!U[0%,:?S*&&B)\#$DL/4 M&#-*!Y%4(T0!G1\8 =\HF\D+ U^O5O,EAH>U.]J+BI*1J(=NL(!5R20#Q#3* MOUC.G^\4YG1U&-I#[\A*[AH8,>)PS Y:#74VF/3&WD$C^*%I1\*4$-_Q3*"B M,J,%I#3.@*1,]Q](A:!<,[;B+*,/?,.2LUR,B#ASE'N@GHAK7PT:]Q5=@$L5 MP=NA0*Z\2U3NB-Y;A= ZY=3HC$JV!IZFBL61P8))J]XDD P=[8>@(9.K63(N MMUKR*/HH:3T [J%?7UK3;/.#.Y5@VH+N$-^P!=FZ<:#6WH)PXDO438R#9'@; M)YH#Q*EP-2*R>AI9<1I98)\'6K Z<49^$&4\K&"G[L Z6%(5N@3 8$J 9^<> M$?6]#V,"MG25D[TR2TWZ(<1A]-5@B*%3960F;N[F] %*0#=@!B1%13&)6]\2;[/ MBU7I$]:T_-AB+^8@ CBOO4^[%W$P;=KK?P%02P,$% @ ]4EL61"]E1:( M' E%4 !@ !X;"]W;W)KI'55K7=*3 M>56OTH:^UHMG=EWK-.=)J^+9=#R^?+9*37GT\AO^[;Y^^4W5-H4I]7VM;+M: MI?7VE2ZJS;='DR/_PSNS6#;XX=G+;];I0C_HYL/ZOJ9OS\(JN5GITIJJ5+6> M?WMT.WG^ZASC>WYVI++6-M7*328(5J:4O^DGAX=HPO7XP(2IFS!EN&4CAO)U MVJ0OOZFKC:HQFE;#!SXJSR;@3 FB/#0U/34TKWGY(,10U5P]F$5IYB9+RT;= M9EG5EHTI%^J^*DQFM/WF64/[8=:SS*W]2M:>'EC[1KVMRF9IU9LRUWE__C." M,P []<"^FCZYX(->C]39.%'3\?3\B?7.PN'/>+VS ^L-G%+]S^W,-C4QR_\. M'5C6.Q]>#P+TW*[33'][1!)B=?VHCU[^^4^3R_&+)Z ]#]">/[7ZOTBJ?]?: MZE5JC<7 >QRQ;%*1KC)7'ZS&[V]L8TA<:.C[I2:QRZK5.BVW6,24C:[-2F45 M<41I=4X25:1EII5HH)07)C(W>C73=:!U$LVPM*,FM=#P6-).-4-@&022E^SC MLBIR7=N_*/UK:YJM(M6E&@*E6=9:\["2CJ]6PIP:S#FP)P^D#V>T>6J7:D[Z MRX:U_M *_ &S:ET0\#FM4C5EU6B5&YL5E6T)E2JMM6K+M,T-AF#*,GW4:J9U MJ8B=UO0\)PPR1NN/B@L[8VC7$CWGS*EFFY MT.JN6JV,9?5Z_/#F[B3AQ[QFVA%^79LR,VNLO] E8;LHMGB.XS(\V.)#R4 _ M-$SWX[_>WMZ?J'2])IY)9P6AO@JTGYN28#=I$5%R!%:Q\?$[>@^-=R=] IEV M6;4%L1=PGC*8M.(O;2FV(.#M3GCSSW^ZGDZN7M"Z;OO!33WMY[0//=GJM':T M?ZTS1_I)XGB&D%:TN6#(T.3;LFQITCN]KNI&$0PP*FHR/OUO6J_0>0<3D0+/ MWZ9UME23:^&ED?J^)+U?DJ$$,'\AXJY-26=)>$Z'N'T1&SS+ &M50DJ;KC0, M'0DYB2-^>1(IH(0[JR+64"5L9:'2_!%8U=&# MCM=MMJZL$1US0#L(#+01+4C&>%GN18CV<2//[STT=+(K6_#UVM'W79 M"J.!*V@9HACI:4)9-X<5L"/^;=9 @WA6REC! 3VU89V<&\)'+=1NEI6-\#?J M6?7#:%VE1':GTO\($1W'"!]YB2C,BCF.J.D/6^NL(CB:H+?PPR-)*B.:W0_( M<5&5B].">3>B1PG>UG1$L&"3?O+/CF-C\)@6K?-("C+8$(L3X5.G6I26(71Z M;'48%^S4T/^+"@@0A=A:?%X:^,_(E MPF7C'0N>!B$D)\NY6E )1*5@7YPW F61:7I"'@5Q=#L#?MR^T%5] \(K,2[W MEB0&76K"7 I#K".6QM%,TS*"^&B14IKIPA ;$]NP_"XIW//'^I6(0NP+F,AD MYYHM%J1IFV /H@#TCOZ4:0B0SIT31;NUX&46%-OGTF4JNKACL)SM BDM*(I* MG H^&EF,W2/VY7V=;CT[2D2I:T&"L,AF:0AJTC=B%\GB\2-B_LGXZWW#W%0- MLZ!(-,S5/G6"1:+3ZY17MS!\L(A[QHIH2;Z0C+.[8/>@3CJM20> 8@1#$X$8 MRAY+@5OT#OD+O%_8.V/OO/KW5< QH MU=O\,14 IE/UM9I?6#F1+-R< M?* JYK\Y?J+OWKQ5IOF84 M"/=[1G]AB =@=HXT<4>ZWCE27](-'+4U-B@Y+OBHH441.D%, 8Q3PZI(9Q5I M[XH<::_S[;\-_]<"[,TNL /XSTVZ*"O2E!DC#";1 4QV3!/?K%L*75+K7<]F M4W4GZ@#^@T'X#KQ7#MZK_W-X;TOQP^N6;;7WCWC$UNU&:C201&W8+!O:OF\( M"13OZ! #DA)"3K4#2=>/)H.A?FULNEA0(!\L=:=XM--&[":RDG*^EQT6$G9= M\VY!\=[W52N9D$8OP%K'?+ZJM?38GCP?4G9].NVKO@$Z[BA"=Z#GG(,@;0SC M^Y6Z3*ZN;OCO^&9,?Z?3Y&QR3A\F5\G5]8WZ*WS%DJWQ-+D\.U/GR')"8VZN)PIKW*B;9')U00O?W-R(GW,\/5$36OQB M2MM,2/%=J/<]"T*[3I.+\14^G"7GI/R^4N<36A(?SJX)H#.%7;[W^"=CNC:T M IEZ\0.#O'+8H9MLI+!KF+ F^N(L5A?S4R*)(A^-G2#\K][L.$'OB$_(Z00% M^7FL0]BERMFLDQ\$UZ38D@--*R X)Z?%1>(=HTN6APZ+Q#V8B=@72:)M%.!$ M^H2XI8#:;]><2:>%74Q.C#S3 _Z'Y'/BO6%0.&1@ORLC>4R\0D6M@R%EGOX7CQ7H-RFKO )*US%UDZ>%-2=[$TE0SUMXIZW%V;@3! MSD_TB1]C#YS$QV,<.V+B5^/15*U,4;BD2$8: Z0^@'/] MG"A7,3B1 TJ22&8SI!+H=%7;(-[((T!)+@BU?;J3TT]S:Y:J^=MP=-IFQ\'MY=HQ.V:AR69IST%>;SE M7+$W"5B&])H8I$$LP5%!6J_/QX2[&1EVR9+LGZC+=NPMBMPWR>>BKMHU[0Z6 M);Z/1<^I99=OZM&F=.K+U9@\Y,S3'H#"N91PDK5%6HL#7R$) A3A M>[8LJZ):;,E, 14Y6?>"Z)L3DGI^HC)PP*$ $2$ZY>^DJ9^-B8*(X6059PY< M#MCY9:1>:I;%H%>QI46Z@">QVD"\/XMR8HCC8@@WI/*#VTC63 CGN#8MMH0S M\E;W )((@Q1 [JRU)[@DG:1\@(0H[(L72%$0(5TM$Z7^XWS(0!)U7#FM+C0_ M81(5(4H, X.T!FR(31NIMR'-$L9TJ3)"UKQMD*J-(/.,FWF/MJY^<:""!1ZK MHEU)%J Q5W*U:QF;6UYHP26VW';I\8@N2->X>(#PMR+QY(R/+ZR(22?P12*>P)3PC:201"8[1\G5[;J" M%^J#L@L\O+S-8C]BGQ7CRJ30D:T3A*!><.VN4X@N5=V%U.^ZE.Y 2NY@[ YS MSN6G7I'"IH40' ?T@1&1%D=PI28H;F(,KK-T^AT")2DY1WDF=Y%*3$ADV)SF M\))((Y#_:%/&R(Y&[]:E/Q_91QF" NGLI6Z)-Z%7C'6 B79?+TD*R8.#7P;3 MFI:=J].KD(G= *S/#ZY8\9ONN':@^AZU2#S /81W34ODXO1!*MY7:[)4E^/+) @-,_M= M57*CB96%[KK4;)G[G".'-X_ZU#9Z#8IDK%6K8$]UK$>8%\P*H$0%IG",_#G' MJ\[.;7T%BV'HJL]=KA6Q:F^P,ST2!L+J3 W<^*PV,Y;PH$F<;:# M9P'N&*BEC=2]2_'WY'Q&_H)$VWTE4KCJ2P;#SW::SB1%7/;&,E?Q$\XPC.QU MD6:D]9%6#IFECK-B4?PI %\LLQM2E3A33FV=@V$.,5 MD<"49')0%XIK%[^T^2*$$WXC$"I6,)V,6Z=3:]W#MU2H3H,YC.B86V]P5^GB,YYD,=42V5' WHSX/,3G. M^? "VM8U;\U%;,Y6L&O-3!7Y>!D-'*GOVEIR!-&J3C8ZF!)NP^2,1NKKH42- M-0?',0@L=^3.- 4??^0S;PQ<(/G\B_+GDN]'*N8RI&+*3CB0E:TE>&-7ZJOI MZ.+)<;M);'(?*I+^QJ?J!K"&8G=MF ?[DA$YL(?49U!T+-L$C*%@WW?(? 91 M7U 745]=1BFKI_'T-#[_L_#T?M!L&=L+[3G0*;M82OSN%06VE3"Q@I=&RL!4 M$OB.U$_# )O0:1'D:W_WJBRV7FCT)U3FD0!EO[F:23,>-\_T]!707%M./.XD M&RGP;<6/'O H)"2%/\D"' >4<>\ 4\;1+PYR;JVM41[WKD0,P^ M$QH1&4SIC!8%:4(BUX8QR"*DF$S3IJ'Y@TON^-^@[A^L;RN1E.2269_U-;ID M"A9'XY0T!^^=P6+;D;/[@C,F#EMFQ6X?_N[G59&#QU;S MMLS9,#B/'YH)B'!!#)@A:80>DNO4!O&]#"\FQW=QG+VL.'HT]EK[G5\;N M&R/<89"Y#HV;X#8U]WVRM !I#9(K\0C%H76>!]EUDF:@5SJ[Y8((=W:E2$$Y M;G*)$3HQ'6C%XE> /N)^9$5J5O;4:^)H%:\G!L)$X-#$W=.L=,4:%ZR'[0=J2?O:\RZ6ZWD!79W']2^DB18E+5>VA M_B%WPM5^9M"[E,%=C8(.-FW!*,V"_P[C\F22D=NA!).(G/SVD=O-J;R80<5) M=7K# X5&2>/TV\]Q,.9H[-.W.C0JAL[2KOH7%F$=T]9QVQ918&]1EWF,"H&B M9IZB /RRWW1=/=U5#1>N[^1CI<,! 06;%*C.VL9W_0]KP<1U)="Y@.AT1MI; MG'?R;WQQ-9M?H*UX&N,]%G)T%%?R)^] M$R.4PJ!V[;1'R882TTB_LI#8AH#"FCG:"3&9('GARU;=52&?^)$Z%NGX/#Y2 M[2/GMG$-V.#!1Y12G3>=XWK$1\V;"WF&B93NS%J%6;^#2B/7$7)X$<$3]Q#U MVY,H+CSO2O0TAW[H L O"SEWF\B^L(^J^>(S34;C_IDF75 WT.%FM>>C6O?B M%O*QQ1X[1>8:I2^*GCI,-YR-1VJ++%:UUGB>UH#"M.>7^ MI\Y![\IL71E?#*Y%Q=\GAB/O"_P@&Q^W5@(X[JCQI1L>>2*1/P>.BV5SB@N9 M/OKG+K^P+7MM.!0Q4,<]OI/+HG:[5R::CB^* ">GB597K(@F] MY(?O]/AFUOCR SH3:VDC4F7++"@U(XHW/LF]3KE6 ,W@/0I"U!NYW\G8!@/, MM6G"58^\[+A*^PZ/TU=4J$/(ZLPE[! 'K?;I&,8RZXA)\PD MP>7*['+?$(ZBZ%+VT^'9QIQ-^R%O0RSJ4Q3A2II$H9KKV2DY13Y(,*XET=5( MHARVI+\B^-UMOV$D2PW471!T<61<7T("(VZT<0#O4N/#Z(&VJ=E;W:JMP243 M9![DHIHKQ'!X1NNPNA&H.'>%.WUNBKCFB>\3Z%T*001+TDJ1L^MQ6:5P$7*4+0G[\QODJ](1ZLX6C[H?A*DNB4N#L$0<1E0W_I MR:4L^/XYGPR%861RO)G8O7B\>Q7 PLQ@=[M,:VF%Z*&'=I"4]-;O[P3 69<1 MKU7K)5Z;01*'N'SG)XEC0;RYI"S[_4[NSCQG$&>@(#E)-C^O1N^R3ZK[:ZU<3+&UYY3Z^X1N[X)Y,LP2@J?C,Q[ ND!Q.$7 M(61A"&>)F6I[,7!,0?=N BX0=PITMA4!]A(3%OT]2[E>K#WMW;.D/,OQ5-3( M&ETX]==,7YNBC<_^!0,3]F]_#[LYC=/8I[(4!^?S4Y)> MQ$C!E-D#5K(#R"&XM5)4H14*.66%SLI"].M(W4?7,7E#PZ;W *[Z?;)HN?1K!\QYQW$'Y4G? M+4U$&\6X/^B:?L\W40'7+?MNXI)B(#_&5RF]=&KP"9M! *(W/^A?N+:[]Z*^ MX*T?<3VFZU?P5O0PU;U8'Z9[A*-@XYD7;)2U7P^1T7:O\@C]?FBX\P,.4#^: M%EWP[XKT#F2W>WY0 R2T7Y;223NGH@?&J=\QV;D[R1WE!WC0866XS7SOIS/U MLV=0%( \;_;6/IM>)&=G8W4^ODDFXVN^9-1Y&,Z'O;BZ3"87$S5)QN/SY/KB M(FY*[[P=2P.N)^/D_/*:/EU<7B>3R;2+K0('"ACPN/C>T-68_YQ/70YIFEQ- MSY,+8NYIR6<+8V>1UV@Y'X:\.HI0CJN M/-*'^$$2(ZQ@[[S2JR35!J5I0_=U^!1*N6.]=.+T)3!OX;*$ANKLE/]@7 M^*J"MCO^[O;AU4G25<%"^X_/L,ZJW+?II'FUCCJNP_6#H!1=+SRRPQQF0-[% M>_X0U._?*=2F3>I&_4C.\"N/K ?\U*XMWBN Y4CY3M7QWW]\]8!?3G8*L%IZ MV[5XCJ$^ 09076?0H\(EBD7'EK,KXZGIUXE/D3 D7<_\9DV+![ZXL2 MR3 %/ZQS><71+6*@(66Z6YZ-WZ BF3+F>U<$B/P1Z;'7AED"*T?O3X*#ZRH$ M<4\^N]!I2/#[.Z=[N8'!EW9P&UZ C2^-_(,B)E:VP0(J\*IG^+I M1:I2W@!1;60R/00[QVCNWMZ"&RI,\/W6TSGW73KM%)V=&XB"+$,*HA<$H5^2 M9(WO;*9SHGMW$VMRX5\^)>6E^-U!(:OQAY8Z3T3L-&.-59&3SY5IW!N4"%C MSD77PGQ$]E="0FY("2T>W?6(Z-T[W"_D-!PS8 #@, ,*DFX2.)$5Z>KWZ2?P MCO#=U?D0WW4C#_';S3Z_1: ;F8]WSL32[ 2>;2RRC43ZPKCFA6!,W>L^$I$\ MU]M=4PQ11LM*12]LRE FCQ>\#Y1?IE(V\-#/\JOPK1V_E39O=<'E? MZ=L4-L^J0L]IZGAT=7$DZ73_I:G6_-[-6=4TU8H_HM"I:PR@YWAOG?^"#<*+ M6%_^$U!+ P04 " #U26Q9O#ZI.&0$ 7"P & 'AL+W=OD2&FV$?*[6B-J>*JK1ITY:ZW; MT^E4%6NLF9J(%AM:60I9,TU3N9JJ5B(KK5%=30//2Z8UXXTSGUG9G9S/1*+(0XKN9?"W/',\0P@H+;1 8#8]XB55E@(C& MCP'3&;&.2\J EK7*RT_-?]1HEW/"&-05G%7QM^D13Q&9331L8M6DQ M@%WT8,$K8#E\$XU>*[AN2BQ?VD^)V,@NV+&["(X"/F [@=!S(?""Z A>.'H; M6KSP_=["7^<+I26=DK\/.=[C1H=Q3>6.90:2B4C^C,/W[P$^_+$=;1 MR#HZAO[>'!T%.TSU6%SN)+:,EW#]1(U H0+6E- ;7'928J/A7"G4:M3$?4UA M-8M!D_6:A:"J5AK$$F@9EJ*BYL";%7SB#4E$I\A4?3X%.@ :ZP4A[$X!7&$Q M2'PK">&*LU4CE.8%:*2!<%37MA4G"B<0N'D8V3%+_9%C*T79%1JDV+)*&\TP M@# >UTT_TVCB@=8-WJA.VAEQM\=$@>_Z24[?+/&&@+1OCL#'#UG@!U_(B7>$ M[00BUR>29DSSE"RI.4N]M1;7/SK>UD;[A1A'\<\-^DTG&ZX[V8=GR9_,OZ&8 M9_WGEBV$9%K([1Z'R V\'&(W] .X%'7;:<)\7C902BSUAA%NX/I^:+Y9#+=( MG7>K2;4J=T811=W55,8TE]GE)+I='?)&3*:B$U_Z<7?(K=.,\_ MFS%-:#R< !<:NF1-[K+8Y#"F6/@4V6/(PYF@9$F;-+V6B%#W719-ESV4+0-C MD[1A=)I:\OF)4S5CM843;Q+1/5)5N^U(D.P$+EVSJD5[45;;"=P,NS;40]Z\ MJ?L_P=JY=(";/PE?FUG;H\ION/59JE"O[)#,YZ!K=OUM&Z?CJ M.^\?.\_J_9/Q&Y,K:LP4A"69>I,T=D#VS[!^HD5KGSX+H>DA97_7]')%:11H M?2F$WDW,!N-;>/XO4$L#!!0 ( /5);%EBW#G># P ,<@ 9 >&PO M=V]R:W-H965T[/'=KJV3.FZKR M?#&;79]74M>CV[?\[-[>OC6-+W6M[JUP355)N[U3I=F\&\U'[8.?]'+EZ<'Y M[=NU7*K/RG]9WUM\.^^DY+I2M=.F%E85[T;OYV_N+FD]+_B[5ALW^"S(DM28 MK_3E8_YN-".%5*DR3Q(D_GE0WZBR)$%0XYC6Y&(E>%;$K_D]G\145[KDA>9DK'?XM-6+MX-1)9X[RIXF9H4.DZ M_"L?HQ\&&VYF1S8LXH8%ZQT.8BT_2"]OWUJS$9960QI]8%-Y-Y33-07EL[?X M56.?O[TS%CMTO71OSSWDT=/S+.Z]"WL71_:^%M^;VJ^<^+;.5;Z[_QQ2.V46 MK3)WBY,"/ZOU5%S,$K&8+2Y/R+OHC+M@>1='Y'U0J1ED7%\<:M9:;>C9#]3MD'-;K]XQ_FU[,_G]#TLM/T\I3T9\)P M)4+ M*3SM*6F/7%JE4(I>C&GMKL0)4M:O(+S'NUDX2(9V0$(T,"L+?QR^L[/OV8"Q<-]8U$CIX(S8KG:UV]$[9 M8.P[6UQ-9RB5LD353\5[)TPQL+A-KT341L@\UP0.LH0.IJF] ] 0E)']#U*7 M,BT5G1>D"Y@ $<>UG(H?\6UM=2D6-WS.Q9YW:S@5VW0-H:?D_'ST-[&!QSP MF(,$YXG*Y+K0F?1L,.*;F;J.J,>A.7[0KG96K:6&!^>SWH/D/5H#H^I,K^&I M5)82D16 >.1?$XWS1YS7E@8 M+ C'RS*&@[/[N9 ([?A7=)V07W?2Z4S\!&D3LFTL)_S[DCUJZ='-=/9"P!Z* MP3_H.%0;]<>_FL92JL 5E0KZL,1[_LX2D:4E*F"<3L0"4I+H$^A GGVIZY=? M=4WAYS.II]*!@S3L:@Y"[C_^C8UQDZGX\HR9J*,ZYK!0OS0DR8CY].I%&[_> M;.0$N1!1DEO.[U8KQ%)D>JN(:Z!7D[NJ>-,183[?![&XOHN01.*Y5SN^!!5,;1T5B] MGU!!9+!K&)E!]"C$^RK\IO)A6R,X4.JJ.N98&V==X[RRI T.Z%/A0T:'ZPX- MV>=?ULSD6FB($2LT)?Y Q+-*[:*6)M#^I=$VQ)I\0[70UU2A.'AG\V%?^)E" M:=)2+QDW24JJ2&=RD?(M1G>.4H_@P0Z"'J)JG/+#I&L<5\+A#*J47QE 'ZBD M4!(Y'W?Z%6P*?D3*LJU/4X=#][29:.U/I3-I7HZ_] M/XY:=+V"-N/!1?L@063<.OBBW(;D)%&2F4%T02]46O)85C8YNW\ \R]K4[_, M&FNYI1C+(3,!11&PH"6ITS8G9L0GVVC,&6J@!]H5=)MWV"F7V+5D##A86=3\ MR$N]' =PRADZR?=&_("T83_/6S XH9FF&BI+:D<1B5.D-.K$.A]$$N@Y\#3^ MT,-)C2Z7DGY>HY2VW"JC"3&0?X*YSBGODNCH4*6 +\*6AIL;+GS6QV#) J<" MWBB7,]A02[(MRCSM6"R)N-TF$4"68++0Q*GDHX(2Q+4\_HBE,;GH7$MYM*1* MJUDBQ;?4%-?!#CQ(=4D.H-4&!UD"D<:&=;#C07,(L-F#[/F.(Y'^3B]K?L#B M+5**PJL>*'8)2RS0[+5;"0DG$1P03"'>@5=)E?S="$MNR9 O<- M+-HJ::G*> G21A!@]BI(U[97E\'A7:;18<0]PN]+0]X G0*I1S4(6K"[Q@)/(DF\:Q7R]4I+N4SF=:9%\""JW M?8NL90S&RG?E=K\6@T4$M' M1B+AN_Q@8JQK7:&8^_K-I%MU&-'QI$(72".D?39H2_VF8P3H2/Z/U6-;6:3H MD%%UI3ILWA/B-U2J5!^N-<@UL"<:&:*)-'!06;786>!^PMXV7>28KBG+LQJR ML LZ$5%T;?"5$AD"HI%T+##C2.HB$6,]:1,:?UDF5MO?>]1NWP >5=I3+&JU M&930NI1U8$\/ =YV,2HUTN9T<(Z\R+RQ+G)W>CXA-?K;9B +3R^$VG'/SGQ( MK!3\_BL7>,A5SH2BQ*4ND-0.JOT^LPQP,-9'O1.N%S#4N19=*'B[UA[HIVY( M4J@&>E37%&*:G:$%(I.8F^8TS>#"J!7U 9,IE8,P-ZARNFSS=:IHF,AO!_;E M*OR>;<52UY=N"<7DW\@J!JMH"PH>1"KX<=?H+0-*?1;0MOF$^7*NR3DULBERJGYAA"\T/9-]);F5_,I==:53'6CR V+#[?!D M;L0(Q-S 3]QLN7"^YI ;'; MZU5_L^A'6HR,.;4VKG$Z3P4U7*@D;>%)XB:9&KM)T#\S39DCWZ6#\U.ZZJH= MN$&^DDF:;\/$Y @'9(X.Z-K[P5-?MZ%/!I4I0B*&,"?T[,U.%I%/D2V?*A[CH87<-BUH:)L[92M8Q>]'KT?Y)O_'>!D)> M7.J#,P^4)AG85L5!PA(CVT?,V)TRE-S#R'9M\B1DS$8[QH'^RAP]0PY,>4@J M0HG&V""7JR0,[H>6I :>IJ?]&UAPOQX?*@OS2E_"1ZAIT^D"; M]B[9>T-@0J:4KTZJ#!TA=#FVOB,)>P.0EC$ >BCQ0^.^I&%9F/#0YDYI%X@% M/%@2KBY7S^H$+KZG4TS;-CN&A;B'M*DJB96X?G'CA/L+=Q\'\92]EUXU%]9*9@QY2RI0N M0L9NF8\$D6&N4;/@B*/P@C]:%#P:V%W?V6!5*7T_6@P>QO?^-"JELWD_4TA" M*9W-II?=F"$KT3[#_20RLL&D8']*$&<2-]WNIUL.#!<2)EG,0'%!XRB2(.9@ M[00#J>(&\'1T#!'[8O#(\QZ@*<@.NEU-%S)QV'Q"+(>WKM:J'PE M%LGL]:M@^F*>7,YF]!D/YE=LO;@&]G"F0O/%ZVOQ"8WWC?A2HVB1 ;^VA+N- M/_MO+_+CF]D$-1:C,;Y(7E]?3*+4WHC?D4J+6;*XNHBJW!W/Z?'E!4Z^^U]E M\)F8OTYN%A?BT)O,\\'+Y0J=GU^A$SN%R/">N7O:O:5_'UY.]\O#*_[OI5T2 MHR]5@:VSZ:NKD;#AM7GXXLV:7U6GQGM3\<>5DN@!M "_%P8U%+_0 =W_7;C] M#U!+ P04 " #U26Q9MO5Z"",) N%@ &0 'AL+W=O3QH\9.]E,TEDGGKC;?NCT M TA>D=B0 . 5M1?O^=>4!2I>-W,M%]LD0#N^YY[P/.-\Y]"1135EZ:VX6)6 MQ=B^7"Y#7E&CP\*U9+&R=K[1$8^^7(;6DR[D4%,O5T='/R\;;>SL\ES>W?K+ M<]?%VEBZ]2IT3:/]]IIJM[F8'<]V+SZ:LHK\8GEYWNJ2[BC^UMYZ/"T'*85I MR ;CK/*TOIA=';^\/N7]LN$?AC9A]%NQ)YESG_CA77$Q.V*#J*8\L@2-?_?T MBNJ:!<&,S[W,V:"2#XY_[Z2_$=_A2Z8#O7+U/TT1JXO9BYDJ:*V[.GYTF[?4 M^_.,Y>6N#O)7;=+>9ZN9RKL07=,?A@6-L>F__M+'873@Q=&?'%CU!U9B=U(D M5K[645^>>[=1GG=#&O\05^4TC#.6DW(7/58-SL7+5ZYI3$24H]*V4*^VG62MOH3:7]5-Q!0!?6++:B8GE_"LL&\U*L*UIM=VJ2@=5RR8J5*2\LJYVY58!+E072!FK#(X41I?6 MA6AR; J $?4.'5D41EHS.A4ALS$UUIPEU>IM4N7IK!C#N&% MN3=%I^N=#:-E!1_(Z[K>JM8[;",QRMG2L3_>;74=MR-5VI:\L/:N4:O%T5_8 MK.?\'Q9:P&/0,$^Y-8LKNAQ'-I7)*UB1.]\ZKR,]%(JY0HB $XA[P>$('<[L MS5RHCV()1UNC\'2>^PX[-Q59%MUY=I\SXPEZBB0D1RS%%D_W9#N),X<0IU-B MV)/\5QD[U(. M,>3%# 1( XP"GA47NO9P+9]('!P%KL5*7=4UE?!LJ]X2G*[4>XH,V^KC[O@[ MBRJ)'6+YX]7;]S_-5=OYT&D(@+84\+$Q9E0CV(!L*AR#65,SUD3L^9.CQ2F7 M6*S6O MN[Z,![5L<8%2KETKZG;2%NJN:UNT\ A^4)A778G1*,Y.:U,W*2@:;2;G#NJ/ MP456#&SDW(#(E E,AF9FZP*:W.3<1(A.DY 1T]->5 ME7I->9^-8\G&L[GHL> GZ$=P'YW5M(<03S5:L]A!8._'#P!5W=E]VC]>(1#9 MTUOOU@!)=6T<*-0G\@C050D72P:?G8':6H;$A^P M$OWHX %#C35KDZ=S9WU]R)QPS&VSUI'528*#P5[E&$E\\AZS3,#TGE#:#3; M)1DNI;LG;]EDJ-!]/.;JA@KH050A./TV"?AQ%KL*U2^6VIK_]'X _L%3V9R, M8X[_+4<&4R@HJ>[/'9LAPZ"1-'.B&(1[ 1SP_J3!I"F[&D&3F$@P66,FA1W[ M$C5>Z1@A209W7_0[$1JAB:(Y5L8CIMJSK,68,J"VT=V)90U8,9WP >!G#&,%2T#> 0N3^9"J;-U%Z)NCN"(HRSV7 M742E1YS%F)738K2>GLX(0,$JX3NT&%Q<4(9&UQ./^IF-(L#\UXB%B=N^/-!A M#8?+AWZ@1W8.I98)#(C"9%N"/(0/O[$9 =W[A1H049,MN>;H,( %9R$-/8), MLX'% KPM]H-&2PP)) O%_VEA] %')OZ-3>0^WC>N 0"B2FFW-B;CBAY(P M8> ;("3&XC+W0/^F"Y?Y*O^J<+">X]]'-PGJ(BI4!/">:>0X&)(U9ALI 8K6 M:[;7)7X)=J711FRO"XE42OD'7,Z^XCPCZLD<4GW(HV.,2R-S'!P(X)+C-AQW M-*3+-.&MORWN@,$Q.F]I^_UW+U;'S\^"^K &9M" J;A81,R3R);N24M"*Y_N9L4=8(_Z$.$^,U]K^)B^QY\'"7P=2 M@0:YHPB@E^-A\,L7QE=5(?X."9#;0*6+)**MM@%#7MN^0!]-96%"8X)0>TA3 MO+PZ.LO9+89F4&W,I;0\#R6O[ ]KFFE'\+4"L&N3:1VX M&6Y#NVN9='_Z@""WW8+;L@]]OT-XAP/7[E\SC6&:UKC=#;!W=ZI-S!E(R%<- M^@/W#2:)5!K&HV=:UP]ROC"9)F-8&OA-3EZX :YC4^8X1<$]&>U\/?60#:F(8XQ9FHGKH:Q\;UP+$=H66#L\3U0$.IN=T M5T3"\:9-7&T*LI@.#+&HF()Q1X9/FK,35)4!DC!N?HC#D^WS-!]Y_+=.QC_3 M(^C*XXXZ\R39P7.=4$87*&N4(9X27(]"/338GO A<\(70W)W#^K<%H+74R<9 M($"K9&B9TH&+!*B2Y!83-M SAHP$)=!3/NY3/$K E*8(>\E-FQ#?\"VR$%I8 MR=U5Z!A,+KUNA+-PP).?^\YX"$,7#WT%6HZ^X37D2_E2&;BS;$R?\X:WP\?0 MJ_0-<+\]?4F]T;Z$ZRBV-8X"7)_-E$]?)]-#=*U\$A)1@& !'$ &0 'AL+W=O MEV?#H4LR*J0;F)(T5I;&%M+CU:Z&KK0DTZ!4Y,/):'0R+*32 MOE7-$'\A_+ M=Q9OP]9*J@K23ADM+"TO>E?CL^L9RP>!3XK6KO,L.)*%,9_YY75ZT1LQ(,HI M\6Q!XL\=O: \9T. <5O;[+4N6;'[W%A_%6)'+ OIZ(7)_U*ISRYZ\YY(:2FK MW+\WZS^ICN.@KST0&%2:TP M";BCHX#RI?3R\MR:M; L#6O\$$(-V@"G-!?E@[=85=#SEZ^DLN*3S"L2;TFZ MRA(R[MWYT,,XBPR3VM!U-#0Y8.A4O#7:9T[\H5-*'^H/ :I%-FF074\>-?B! MRH&8COIB,IK,'K$W;2.=!GO3;T?Z4KDD-QRL$W]?+9RW(,<_^V*.)F?[37+# MG+E2)G310TO.KP[K+^N&WH-M*02JH2IVB)9$XE7A*:RF9)*;B54L)0721 M4U\@,:54J:![S!%'4=7 B06]K84U(9TC[SKZI=RPRP@(0Q!NZHUR,1;%-W2"D#N$'AVG'UVX".0:&;/!4+I*]IJ7[0FHS&S\0-PWMCI!:91*;WD.)H?#H88?[D>1BE M7)>OHCX:SP=/&XG&ZTL0(3H=!Z?3'W0Z'SS[AM/3K<2WJ_*5W[5\6(:02>19Z9I70^EXQ[)8/'3V(C%;&HO++ Y#'F? MM95B!*!_P6P,=.X'G<12JCPK,&<&W]6NL4/V<$Y(OX<#(05'X\'D89:WS90* M!3IN,XG"^D-5_7EL <5H,/]^%*^VM0V]M P5A!EV2?=))O6*8H?@$V)?FRI/ MN:'C;&)ZH%= @C!\1'RF>U6WE0@SBV>&E=HM@5NV\V:#2@<_D-2)*F7.ZH5Q M*'5Z)[7'8<94KJ%%TY^MHP=VX-78E"P:/+B2\;"R(+\FTFVK2^L5N^+I:*+W MSCP2*9($@E"2:77+$Z]R<8+50MU>*'"HX!,$R/]@@=&=,83> MV)&L](YLI*?/+-%QSL/,-01@K[$I,D56VB3;A)RD[2;,DEV W3TJ#N6VO$N3 MHQ7=63N5C\5'+=-_$1,$ZOE8#T;5G/GJ+,91J5+850F*%K>=;D70>L_;47PL M7L!K%;7Q-?8^XXL(ZJ+L MLHYA*X(D,F7(63#QBE9,[L0ZF659Z':=34SE(> M#!U(%?,C!CT-A=AE4 O6566)?3>"@KZ/J+5I8(5PN2F:?GG4=S,-/:V,55_J MH;OD#4)IB:Y$?97&^:0*_5$7Z! =,4+B\*_*NKE ,FPD(C"9[89P8C00=FJE MU1(D@NEXKCC WP@SDI8'G0^Y<347L04\G)#[L->W7]I9\%2^'6_%X MQ7XK[0K, JV74!T-GCWM"1NOK?'%FS)<%1?&X^(9'C/<],FR -:7!J#K%W;0 M_N_@\C]02P,$% @ ]4EL64=2U+EP! #0L !D !X;"]W;W)K&ULE5;;;N,V$/V5@;IHNX#6EN1+G-0VX%P6W<5>@KCM M/A1]H*61180BM205)W_?(65IY;0W+.G+E1,]\I?6\*1 N/I9!F$136 M5A?#H4D++)D9J HEG>1*E\R2J+=#4VEDF5 5"N& B,;W M/6;0F72*_76+_M[[3KYLF,$K);[QS!:+8!9 ACFKA;U3N]]Q[\_$X:5*&/\+ MN^9N0A;3VEA5[I5)+KEL_MGC/@X]A5ET0B'9*R2>=V/(L[QFEBWG6NU N]N$ MYA;>5:]-Y+AT25E;3:><].QR;55Z7RB1H3:_P,WWFMNG^= 2LCL?IGN4RP8E M.8%R#I^5M(6!&YEA=J@_)$8=K:2E=9F\"+C&:@"C*(0D2L8OX(TZ-T<>;W0" MKW$,_EYMC-54"?\<\[&!&!^'<-UQ82J6XB*@\C>H'S!8_OQ3/(U^>X'@N",X M?@G]U7GX_RAPI>Z%$'*M2K#T&(!5_C^D0Z@K)[Z))]$@HMX0PJ'1?MHX;)S#(5"R M"$83B_U&AAL+!M-:<\O1A+!C6C-IB:[,H):<7CGXXS6$88,IN0A(1/WKX@+0 M13 Y;R/H<)D0SZEJ=*\FL ?&!=L(!'ICP3!:4.C(#VH"VT"UG3" E?74/C-] M3R_VFBX;6&TU=@G\H11/O%)RF$&ZABX87%+LF#='CK<(!UE31\JA2>4SNV_I MT;(%F=BA],[NC87PZ=.5AVS->!-5K4U- 7?9VQ4\+0X(ENRIR;Q'HO=;',V_ M*1AUH0M3J]A/.Q3LP941(SY;HKFEC'7U1"7!4^Q54#\K3>I;3&Y *JKKC> . M(G/7'25PA_]!@5+;KV+*W8FL'B:H8(U-0VW\S Q5YJ&)?B2/Y&4 7VM+W2DS MY_6WMLR=@[D2]#UVV]B\$JE@QO"IAGRK8"^H? MS_[F$77*">?6Q_Z#<;QID;G$W#Q6?-];7KXZL-6R249G83P]AS<0#V9C^,AD M36,$Q+[-XNFSC61Z F9Z%D:S:8M"C43U-XKW&'WQ)$(\BEOU%962@%:[)YU4 M3J+P?#QV^N/!*(%K3)N(^?Z*9\\VDLD)F%DT#L\GC@?5;A3#QUK2@Y5XG9C: MEJ0XC"D-R2R&Z[I[4VU!M>$[2]*W \KFL]WT^['*E.JUY8#[#&>#8Y_#86]$ M*5%O_2#FJKF6MIE6NMUNUELU(\Z/Z\V@2#G:!L$H!NAJ]&L*KR M \]&61J?_+*@>16UNT#GN5*V%9R!;@)>_@M02P,$% @ ]4EL63"+^$0; M" ]Q4 !D !X;"]W;W)K&ULS5AM<^.V$?XK MM?3,T15*D7ES;,_;ETEYGDGC.N>1#IQ\@$I(P1Q(, %I6?GV>!4A*LF7G MKFDZ_2*1Q&+WV?<%+K=*?S(;(2Q[K,K:7(TVUC87X[')-Z+B)E2-J+&R4KKB M%J]Z/3:-%KQPFZIRG$31=%QQ68^N+]VW.WU]J5I;REK<:6;:JN)Z=RM*M;T: MQ:/^PP>YWECZ,+Z^;/A:W O[L;G3>!L/7 I9B=I(53,M5E>CF_CB-B5Z1_"C M%%MS\,Q(DZ52G^CE?7$UB@B0*$5NB0/'WX-X*\J2& '&SQW/T2"2-AX^]]R_ M<;I#ER4WXJTJ?Y*%W5R-YB-6B!5O2_M!;?\A.GTRXI>KTKA?MO6TZ63$\M98 M576;@:"2M?_GCYT=#C;,HQJVPUP MLB:GW%N-58E]]OK>JOP3^[YQ)KHK>7TYMF!+B^.\8W'K620OL%BP;U5M-X:] MJPM1'.\? \Z *>DQW2:O,KP73<@F4<"2*$E?X3<9=)PX?I.7^&VX%N>W\%W! M[O@.(679C=:\7@OW_*^;I;$:\?'O4\I[WNEIWI0S%Z;AN;@:(2F,T ]B=/V7 M/\73Z&^O($\'Y.EKW#_/.Z^R. WP&5^8.EZP]W4.>R!+V,V6Z\*OO*\9'&)% MM13:D07,;@2[543!"X6E(F"\+MSGMZIJ>+W[JV&&9&Q460AM&&\:K1Z(D(B< M,&(>LH^(&7W\,6#;CWL5W KB+.W!:E"4,6CT+DT M?%D*TH8(Q:.EJ'^ #401LA_Q+^LUDX;A"802U:1@R]VAF\%-'N)8J59W"%9: M52< *!V 2OLW9\D:)7I#'@T&4GKUJ@[>)T-9-!/R!AN)!Z'76D!=BA])K0!Q MON%0L$0_(:(:KH&7T0'-&7\U+4!?=:@D:K=KUA_^00IWJA.*OD-VX(-NG35]-\1O$21(DL[@W#.AR5540[E%H0;T<'(\M MMFIMBWCJ$J-]GK8A^[#/*E]@/M84UT@MWWREW1ULW%>*O>\18P:#".39#5O2 MQ'#!OAL\^9-KL:(X9]_O;1@(:WR'R!7J .* $SRDLKBDOE(8CWM4K #MFAWR-,NGR,]=)6W$5JJ@A!/PLA7U9 =MFC3O?E^<"J9OCR%]D\W:U38-;GJ-])J M,9\BBBFIXIB28AJF*85S,F=_[QR:94$61401+A;LG6\^E"_S#'4GI72)PF3* M,%&OA*0=9XL@B^>T$$_#680]U.'P?8(,RY*I6\G"=/Z;*9;-ID&#3$_*Y$.96HLD:%QHDJ[S)24DTK\];'.\+<-7*Y6@$EL%OJ MOO99H3DNX4<=I)\%.Q,)]&Z9#YN.%/2H^!"!3_%ACSHV.& 6K::T^6R#="5M MTJ?O_T#H4$>3O=#_7E'JZX!O2B2)Q@*:BVJ2&?_A=2H),?MTAO"O1_K:*#KR9V=.FE/IJ6!3T/3 M%$:6AFLK<]GTHVO3ZW,4Y_U0V/"=5FC:B(0V]W$#&[4-[4RB?O!#\HA2KB4- M5(?>]>*?S:M/Q[(7YM=]"_ ZPO'D7S\68U#O!^/B. M_BC114=/Z:FIL#Q+^J$E!,>3%&6/!S_$JC_L#A1/(J7K*#AM%222=D,2W8<8 M7P"1^UX@J@O,;52M@43SY@+!B^/9T0W0$XM_1]7RE757HEW)W#^] M1<%S,#0.@#5*,J9L:L"^A483-RW$8(0R1]- =S#UI]X"L2#I0L=5@CA.V6R1 M(%:C;([33XH>CH,*0AV!1/0%1)2J<3=!Z-,9C@_3!5K]M/,:!IR89,\7;JX) M)A/Z3X)YEK)35SSC@\NX"J=7=^5('1*QZN_EAJ_#K>:-O\S;D_LKT6^Y7M-) MN!0K;(W"63;R7NU?K&K&ULK99M;YLP$,>_BL6J:9/6\DP>EB US>.D3E&S;J]=< (JV,PV2?OM M9QM"D\J)4)_.'/@&.T*?68(0!R]YAMG02#@O^J;)H@3ED-V0 F'Q M9$UH#KF8THW)"HI@K* \,QW+"LP9:313PT+!D0RE#$I0(4MRVZ0UDFA408?VM-HW$IPY/$&&[DCV)XUY,C2Z!HC1&I89?R"[.:KS\:5>1#*FKF!7V?J^ :*2<9+7 ML(@@3W%UAR_U/AP ]BG J0'G/>"= -P:<-L"7@UX;0&_!ORV0% #05N@4P.= MMKO4K8%N6P^]&NBIGWKY8\AA.*!D!ZBT%FIRH"I(T>*=IUC6^HI3\305 M' ^7\!5L&5@BJKX;'"$P3EF4$592!*[!XVH,OEQ]!5<@Q>!70DH&<^ MI8(9U7Y&E1_GA!\7W!/,$P8F.$:QAI^?YWMG>%/DW"3N[!,?.6<%5ZBX :[U M#3B6XVGBN3N/_RCQ67Q\'K^'5.#V27S2/GA7@T_;!Z_#9^V#U^'S_]OYQ8=S M/RH$M_D"7*7G?N0+T!5Z)>?IY>39U&<%C-#0$(<[L#<'M:BQLKI!<&QU5ACY;J!=6PUT7GT;/_8:JJ-RW:/K68:JT[0?1?] M7&-EVZ[O'9LM=&9=VW[+LMI\\^!(S1'=J'Z,@8B4F%?_EF:U:?EN5:?S;GUD M]V>V9GTN6L2JHWN3K_I+\7O=I)B!#*V%*^NF(UH'6O5LU8230AWH3X2+]D - M$]'F(BH-Q/,U(7P_D0Z:QCG\!U!+ P04 " #U26Q9 'J/JT," "*!@ M&0 'AL+W=O=@,A M7VT*2,FV57/8*DJV[=G! UAK;&J;L/OO:QM"TRIAI5S -C//;XP8HD;(9U4 M:/12,JYBK]"Z6OJ^2@LHL1J)"KAYD@E98FVF,O=5)0$3EU0R/PR"N5]BRKTD MOV6-O%\?*)_=;6;6@Y8P8-@ORC11>Q]\!"!#-=,[T3S#;IZ9I:7 M"J;<%35M[.2CA])::5%VR<:@I+R]XY?N',X2#.=R0M@EA,Z[W!>ZA&:!+

TX80>*:DQNU1U"YU>AMKO9JDJG$+LF0]#@3R"E[Q_ M-YX'GP:4I[WR=(B>[&H&:!P<9O?CK?%S0KGG_6'$F3N MNJ!"J:BY;EM%O]HWVE7;7_Z&MUWZ$&ULS5QK<]LXLOTK*._4 M7KM*5FSG_:QRDDGM;$UV7/%D[H=;]P-$0A(V),$!2#N:7[^GNP&0E&3E,;NW M;M5,+)$$T.CGZ493+VZ=_Q36QG3J71NNO:9_?NA6)M:AWFKC4-[BR= MKW6'KWYU+[3>Z)('U=6]B[.S1_=J;9NC5R_XVI5_]<+U764;<^55Z.M:^\UK M4[G;ET?G1^G"![M:=W3AWJL7K5Z9:]-];*\\OMW+LY2V-DVPKE'>+%\>79X_ M>WW^F ;P$[]9'<)_KR4_GRZ(PH,I4I.II"X\^->6.JBF8"';_' M28_RFC1P_#G-_HXWC\TL=#!O7/7?MNS6+X^>'*G2+'5?=1_<[=],W-!#FJ]P M5>!_U:T\^_CAD2KZT+DZ#@8%M6WDK_X<&3$:\.3LC@$7<< %TRT+,95O=:=? MO?#N5GEZ&K/1!]XJCP9QMB&I7'<>=RW&=:^N11K*+=6U735V:0O==.JR*%S? M=+99J2M7V<*:H([3IY,7]SHL31/<*^(RKV69BSN6>:K>NZ9;!_5C4YIR.OX> M2,YT7R2Z7U\[_X=\^W;\/]<+D+GH3?_ MNV_#,M^#_?.1,3T+K2[,RR-82S#^QAR]^NM?SA^=/3] [8-,[8-#L[]ZXYK" M-*"--1NR>^--:3OUP89/2C>E^J5;&S]\_8C'?0<;[;"O?9OY#RZGWME&-X75 ME;(-^-G#IKN@NK7N5.LZ?,&M:@._L/@G3!4WC'KCZE8W&]4Y58IC>' M9/4HR^K107[^[)H5&' ^A']U>[_"GIIB0]3B3]?C@G!]@+TUO(-/"(2H1 M)_<1]LV3[+%]EN38_'T<1H:T,*:!67K>W=*[6@4(D,V8K CRX) !\91]$?40 M5@X'A:AJ*U*\&E](H3!$B^W?N I.D"YX4VE")169Y^UIZ:I*>P5'VP3-J&7+ MMH=Y\><36+V?"NB<7YL>^N(JMX+'%,*P3:A.N]X$Q#<--0WD337IGFV8"1_! M)9!Z35H8EUX;777K@I03\R^AXR!+5P&JZ:#UX,T6^_;R!!3A^9IO8M59Y?%F9)CHX;IT'T*[EBRTQJ$ (& U8N]#:#FR<*<>QL](+A_CJX+')X7?%_(2G:*$? M-! X=GF*T5-]\*+9?YA!:VW#0<^7"$Q&O-@(VT"R3:E]&3!%R6"/K>)7U]I" M/3I[-%/):%C9$?@9 69Z WC4?:B(&T);76W^(PP>&-.0V=:DDA!;A#R+DUG M/!"K8?W0-9$@NH"@!5)8_66MO(WRF3H^/U'PU"!WN>&11:1!2. KD8R9.K[8 M>A@ACS,5VKM;5';%^\OZG>;"R/LG6Q2.K([LK#!XZ,$)N0A7D,??^PQM]*O7 MI,T?/SP9MIL9<+N&FSF&NNIP5$$V!W4Z^X8#*_9D8.$D";I.ZV?-L,SLM@+S8$[X8S$ MY\%4"8XEW\Q8-)I8(. G;B&ZL6A"1$. EE MN(H :!BE>/_LRQ4[,9HP+42"&CN8P<9#]!R)OH1-!F2U!G?AOPHX4)@D^5'& MT -U R*=B3]EO?3&UHO>!\'*;4J^:*RXQB5$#.[,B'6)TV-A<'"NWO6> MJ=*C6:-M##3-N%)0*BD[ ..+--H.=R8DL-T!,W45;W^N?FJ*JH_$99''0#9% MG(8R:84\N#/U @2E9)CY@0_WU:TFP?UP-G^D:B@LB: 9C ,K( D!F9(HJ1\N MY@\//C?CB&P* 2PS@@\.UM\EL+R':R6 JK>L@U/+8.!CRD/N,SLZMFT08UT? MHI#"%QC5D%/_5CX]FE]\)9\.\_/_%Y]^W1NVX#&'M7N*%MA=]%%,#=(+59MN M[42)%:$T. /K2+,MYOUM/\'LB@?)[ ^:KJDVR6C,9RH! ,<*;G8+GI0CE)[X M*V*S#YQJCQ$%(;>^[@5'[T$4X#E /N%)-F )M>P_)T4*EDR46[;GB%G88 -Y MT)V@F]D2 YMW?8LUP7WQZ>K8SA&3"'6"[M+>V)*\P3;6G&7<.,N@<0LSSG:@ MX 0F$@R'1.<$V4;BJ &#%R(CB %6(4'+?(XBXA"T7TA@,U+8/FH9V.89 WE6 MGL;EZ-M+)K7R)OFSJ4M\707J;@7$)B.LF+,2)N4MZ34&;>9;0,+B(P[[$UUT9="#20C+S*]_8[ M'='QP3UDK[!%DN\-1TL-M);$,P4]?_W+DXOSQ\^Q0UVQW^(Z->GH&+%,D5\S MAF_,\,A!UCKX/]8V!4KR!/ :L"M!A )H(_) 7(;;)F\ZM(/@(_BDK;.IPF3SR:)?F)/6DB\1 $#T"7G8^X&4CI_AF- M?7JF2KUA!8PTSM3:W9*?F]V=- FY(PMC71II;8Z" U.CAI&'X.(B21Z.81.= MU("U"NOA30GK%50 &/*_TK$/):/7[!D&QQR+H)']KF&2,OYAY[)IF:<189', MR8@2JIY$MN60K&_!1W8&8ST]4&=ZDNM,3PZ6B"X36OXPH&5:]C)!.69F+'?_ MS!74?76H__ BDZT]S5M[^H7J5S#:%U+)?@NEJEQ+ZK*/_N^;">K!I:4M?./' MCY>CQ_D$SG*X)5LAO]($\2' #(3")3I% $0W4OT) EJW[H0!3-61H$/1H,2IZ3A?O._B%T M,;Z,Y8:2HP4\2SG>DD_Y6M^1O\6$AXS@_&PX!#P[K*$E%@.,%!Q8JO=<7:1O M+.*]YWU_:L8[5$=OC:KSJ*_0'?A>/9W/SZ9[.A\2G&WBY#0B:C?'L0'# V]*;(K1 M3/2T1#RR@<\$;[(\,@0AQ,+!)]9I2I%61B9A"DT.:O'H*/O\H,Y=KVW;)@[] M#?]4AS7XWS3;E-J+@=J+P_.S>WK-[NG-R#WM)?7[IKJK5KS/&PJTK*J)V]2W M7"NFP@N E=N8&)5+2\B*4-DDSJ^01'2G?#XVP,?AO"JP3^,G"6_1"5DNS8^Q M >F/+'SE;0_+,J:@34'A(A"FC"F> M] 4D@KN'&!=GYT_5CW'/BOFKKN((=04PJXY_O+ZZ.E&>%F=PFJO)*:&F&5]7 M&LR\+M:N,N'T/6P85!^_OGY_$HG)Q:GEV)G&@ #7_F[<;3=;+5A/K!*#I"!6IG;I,"+ UR)V^V MZF2:SE3,)E7 B+O8P=X-D.-POJ50BEEH)2I&V*;MNTEL[G8DM'4$CP29*F/$ M^-FH+N$HSZ=,8W21V,Y[I!Z!TR7Y:"3U<(A4O9:#K-_R.)+41&>'-4?U2_Q? M]((LAB6IJ%X0:F4E[!>5+4@SO2Y37>"6>X!,>:ICRCNED5U>3*>IRC@L,BA, MX$HFEW.D_$+U(TRLUIB3ZYKBE[E XGH_T6RL1U4%J&A*H$MGI!M "=Z6QL?Y M-98A$GM0O['4:T%Y\7))F5P\)N#D ?.PNQ&JN+*":)J&!/6'\6X657?:&T'Y M%:P5>1T!3CY8M&6>0;R#-%'0D4(CAUE.!9>"&[:*:&F8A#&:?R^&:CQ]Z M$D10?0.,?_SA^N/)EL\8NU!I,1B4HJAY2%PJVW?2QD05W8Y F5BU)S3: ]&$H%Z4>""&7"E@D?_[&_&K,+730$R!/ MC])76&)TXG$3H(@/M5+O3TRH7067S#NC8TNJ,Z0PD0\!XZZFQQ5EAK M+P?U$_9@!2F8;M+ZT0!B=#F(1(9FLO.#W5^OB!YOUM2\"*NEE&YO5/_62=3T M$G7TB!8MI;)'M1BI+D>Q2\00LYW%HSZZ)G(> MM2'(E<8U[A;: UM +(P= C[Z)FZ5@,T@J-=!&IN6#/] 5BPN[%(/6YM)59&, M:I9!2/(DW#M'E:_9KLYOSW4;C3UHN $1F23[ASQB!*Z?FE&JZE']K+]Z;#UX:APU1Q8XB MSEQ=C?HT>4'+8.0.7I%<)WU/>>[,N02EMU@^FP+UF?CG,>_O!.L_<8LJT77) M:%9 .CW(M^FK')4,@>% % 6!X%N3(Q*!_2&%ET( 3?:MR?SH_&3H+TBXXFZI M)[.^6^XC'F74P[H01E7V=I\8@RFHKY$/P5P/\+2@K74V/7#08PXMH>>'^S:O MC30;?&"'#"KW.LQOG$/](A4$*O;)O5B]D)8@*S%Q5)7F\ODX!NH%&!?!;^XO M*6TH/)TBC-M[AZH_-=C<:%OIU)AF"//)O>AABK4UN;Y!/M' XG#_E#(X/@;# MA_&-<0I'9XT47E,M,)<&J3 <8@:<"N93_'-#+RUPX)L<^\QBS8AR2;F=\8!M M9MS)[+8Y>5#L0W?I^>'>4*IX;[U.X $BZ.RU'C7NTD/0R1Y!1ST,:+>H9>L-O00BDO30W+ZWR^ZU(U]T_.[R^O7);#A3RLTT MJ7*\<&5J>M&1"7&!)%J=71;5[42Y)2TB(Q:T_S$[Q[_W=8M%?*=^ 7A_G:1] M39?Z-H!8/@"$:[Q0QW__Y?4U73G9.LXTI@NQ*0R68'.'$2RH-GY%=*^@$=32 ML ^,4P[%;]^($X,S&P[\.84E?"FSQDBZ= (2*\:-#/5)'KA*;0UM\<$%]3]0 MU/+&#S7N.3JQ[11"XWZ!S(\#CHY/BG2U:3DV#,>F?/=T[/' M,[7K@H^E=_3BR=G),_53374&D[NBY#'>4!KY=L0=XFF:^V2G]B4E%O+6$ITH M#9?!9G+^&!W64(.6YA&N8*T0-GVU2>6/,L7S-^R@A_#Q-OIA]9X=]/&;7]Z^ M/TGR@J^7%S?@_7@P;I(ZC]GL,T.P@@A\MY%SR5V,XE[5:._KL)\TU0/9F)VAKG&KBC:9VV[ M3NI<()9HY[Z:RGZBLP;)'+F](S=,)$&6(Z63[IOHX5@!,P%W*Z PZ>F,()Z# MK_Y5?R;=$;U[_&"?W@U/WJ5O3W?U;42ZE?$=QH^M.1H\@P2JCD+TE8VM !D- MQ+=T9F)YL5/: ^$WHVGEI#(OR<5=/)2U37")5,KC.M3!P*DU'24AG!KH&1HK'U/=[4OEH*2(GU1:;ZL,T-4R!5) M<6MBK!TI50Z*K%EW>SK"+_O\VT'$,KQXK:J'0H3^WI[)U1!L?ER^S\1KT MA-S'LS,L-?4P+AE.%N-;).-3G;(WT:]:2NOA!T^YU-O0&U,FO\0DZCT-?EK] M3 T"ZAQZFYF]W8!TZ*" VGADM87S$#9XO7T: R EBUS$@PC>K)2=AQS)_8L'XV%VX/!A3**-/779W2?7[:6,JSN9/OIZ*=X-LI_5E ?"QQAS?@"$'GBL'\=V&V*G8B/-1 M\ME\S@WZ[+/(9U .L*1V^E$380RS^2U?&EZ[T%$7!*(9DE@Z5(QJD>PS+S29 M!ZOR.VIR4)<[7%/G63)U>G.,EF*4+*N/_%$Z2S'%NK'4)Y@+,_&AL2W4?:"7 M?\%9>L&'&XVESN46=(81W\?(;HBZ*+:?[)N=9V,?-]6=3BMR9CD;'&H/@+2> M^JXV\?65#+KPY)C 452+3CF+-[[N\2Q[Y5,D3/*F QZ(_C$Z1IM^4B&_BTC+ M2NF% *>$G;%$N/\IN>)3@#3F@N@MM*C962#F61'()IHRO!^X- //[B8ST9<' M]*--%+#J+A33 ++Z*&H2] 5S9P(DS=-^=RPKZ:'H*E[ M[0Y6D7[(IN^S('8U*!-+/6MRT &B,+X3JAN7R(K]4_FER,-K[X52]T:_,D'Y M/_^6!I77X(7E!R?RU?Q['9?R*Q7#X_)C'^\UE0\0O../I =Q?.L@X?J$%\J^8O/H74$L#!!0 ( /5);%DF M:5UT@ 4 !H/ 9 >&PO=V]R:W-H965TT.:O&JBVMKQG:<-C--ZK'=YJ'3!XB$1(Q)@@% ._[['H 2+3FR MQNUS'R2"X%[.8@^PBY,'I>],(82EKU59F]-!86US/!R:K! 5-T>J$36^+)2N MN,6K7@Y-HP7/O5)5#J,@& TK+NO![,3/7>G9B6IM*6MQI2R$K61JB8M%J>#L_#X?.+DO<"? M4CR8C3&Y2.9*W;F7#_GI('" 1"DRZRQP/.[%A2A+9P@POJQL#GJ73G%SO+;^ MWL>.6.;C@EL]+80Y/AA:. MG?HP6SDY[YQ$+SB9TD=5V\+099V+?%M_", ]ZFB-^CS::_!&-$<4!XRB($KV MV(O[58B]O?@%>[O"_>ML;JP&:_[>%7!G+]EMS^VD8]/P3)P.L%6,T/=B,/O^ MNW 4_+P';=*C3?99G]U@9^9M*5S2+E2=B1HX/<^!7FGB= M;Z7WBC\*O2NL_8ZQ#TCPK""S8:OACRL/'5V%9MBM]Z)N!7%#G!JA'41L<8?/ M*LO+)P&H\6[Q#28S(>\=R5Y6W"FLO<)"E3ABS#%=KXS?%EJ(+>K1)T2T/>,8 MY/[BC=%'D2,V6#W+[WD'((KH+84I_J+0C<;XZ\6B &^QFX(%C)S8C_2;,(9L MP6L*@[='ZRUE &^-G-$G'+L@LQ757.B>T?0.(MU,R)Y!PO@M)=&F^^RABG5&GPVA\>[F+&=A6]YLB-+ MSUBS6H%C!QC>,PFZOJ$1&X^G_AE, SRCB,5A@D$X9N/)E'Y1]T+7*'.6(C:* M8TK8-$V1,Q:-1Q3&+!T'=%%*"!R$AY"93D)R-J8T9>$XA>'I=$J_8Z7T071( M(8RG$=R$8$E*MUO;#5XCE@9C-XA9 J:\H22$23>()P 4D_/R8;W^A3*-A 7# M2#D/5/*YPF&C-(Y(1L)F1^2\]@H-".%B0=U=_(24T#[FC7KFC5Y_X'%3^"S[ MP>67%ENIA$>SBWE[S>X^I9U9!N; N'@RSKQ+"%DM,T3) MZJAL+.CG$FL<;J^P< <490H]C;'^4-LB_W.:ONIDZ!?D.>:.; %.(^1VQ)*I MH^AV &C=_,]+1FO)$23W9&W<9VW\ZJQM./Y7"=SKX?\$_K<$3OH$3EZ=P#-T M1[DL6]=#(ZRLU=*Z+NGRJ]_X.2VTJOQ1W=J^)EQR76-9#%TAWIL"M6I7CO>" MV)WC*V6Q0#A@RT?J49DG5+6RZQK2IS;C9=:6/3:OAJ\U*G"I4"K1;9!Q&-$] MB8RW1J#EH%R14;A9M"6*C.M7K/QI[9$]ZSQ\^L&?"AY0@;*[C61VIE_@Q#=3 M,7WF6G/' 6!H6IT5N'ELVXZCE,5Q0$F .A!,?-7I/ZK&Q6DH'8]8F(84LB!( MV 2%98-!G6A;2[@)V00E)QE-,$I'$Q:&$5U63:D>42@[P1Y&4[JF(O*5R3W0 MC71E)F+C*&$I2A/*U#1A([1)NW@XW+BOH%(N_:W,;2OT1]W5I9_M+WYGW7WG M2;R[-7[D>BD1:"D64 V.QF@V='<3ZUZL:OSM9ZXLF@(_+'!Y%=H)X/M"@4NK M%^>@OP[/_@%02P,$% @ ]4EL60?$(SHY! Y@H !D !X;"]W;W)K M&ULK5;K;]LV$/]7#FI0M( 0ZVTI=0SDB15(L2#I MM@_#/M#2V28JD2I)Q?'^^ATI67$QQ\B&?N'S[G=/'F^VD>J;7B,:>&YJH<^] MM3'MV62BRS4V3)_*%@7=+*5JF*&M6DUTJY!5CJFI)U$09).&<>'-9^[L7LUG MLC,U%WBO0'=-P]3V$FNY.?=";W?PP%=K8P\F\UG+5OB(YK?V7M%N,J)4O$&A MN12@<'GN781GEYFE=P2_<]SHO3582Q92?K.;S]6Y%UB%L,;26 1&TQ->85U; M(%+C^X#IC2(MX_YZAW[K;"=;%DSCE:S_X)59GWNY!Q4N65>;![GY!0=[4HM7 MREJ[$38];9IX4';:R&9@)@T:+OJ9/0]^V&/(@U<8HH$A^_"5+6K4 M'V<30Y(L_:0<4"][U.@5U *^2&'6&FY$A=6/_!/2<%0SVJEY&1T%?,3V%.+ MARB(DB-X\6AV[/#B_V'VGQ<+;12ERU^'#.]QD\.X]@F=Z9:5>.[1&]&HGM"; MOW\79L&G(UHGH];),?3Y(SW)JJL1Y!+N%;:,5W#S3.]3HP8F*NC-NNJ40F'@ M0FLT^I 11\4<-F(G#_?E22>O'.0Q)P]*24]6&ZLD7<-2UO3RN5C!!R[H1':: M6/7',Z"@&FP6A+"++%QC.9R$[B2&:\Y60FK#2S!($^'HKFUK3BJ<0.07<>+F M?!J./FF5K+K2@));5AM+&4<0I^.]+58&;>S1F<&%[I3;D>XN]!I"/\P*&O,L M&-S:OMD#[]_E41A](B/@[6X[@<0/24D[3XLI',F7=,R7]#_D"Q5R9;9.@9OO M'6^IM)I#R7$4\[7DV /''?A/SH3;3@EN.M7';,F?[=KZK M#HD?!06D?AQ&<"6;MC.$^7)MH;10IW2+5^+6O*CH;RZ0DM M.262'^0%C7&8$9R@0M'UWPM91&0KTDA#D:20%O!5&BHM[6'?A(&?I(F=BFE MTK0^HR^J[)JN9@8K^EG(O52;^K^+6%DCE>%_#Z4Y]=.B^&CG:4;SX0#X(.A; MMPF5IS:Q4O)%>"RQLC&QLC-LP6MN'^"A/#LJXG">[6.>[QQ_L+4J7+-+ 4ILY*RZ@N M-8>7=)HF4YA&P? 3(=0VZT N:KYR@=;^:&%KPT^AC_(8DB* !UQV!+4S? M1 MEI$=T1 $-FBP[Y@LRZFB17D(;W/D"61^.)W2//73^'#F3/9ZCP;5RG58-@:= M,'T;,IZ.3=Q%W[N\D/<=X!>F5E2*R0E+8@U.IU2)5-]5]1LC6]?)+*2AOL@M MU]2(HK($=+^4TNPV5L#8VL[_ 5!+ P04 " #U26Q9S/)A10H# "S!@ M&0 'AL+W=OO'@^O#"^6-JA;-SNUMVMJ)_>V6TI:#@2W\#L[LQO_K,/T_E> MZ6]FAVCA9RFD600[:ZM9%)ELAR4S5ZI"22M;I4MF::B+R%0:6>Z#2A$E<3R. M2L9EL)S[N7N]G*O:"B[Q7H.IRY+I7VL4:K\(!L%AXCTO=M9-1,MYQ0I\0/NQ MNM+8#68K8?.WSM\XK@W)S:X2C9*?7.#-_DBB)T@%)A9 M1V#T]P-?HA .1#*^M\R@2^D"3^T#_=;73K5LF,&72GSFN=TM@DD .6Y9+>Q[ MM7^-;3TCQ\N4,/X7]HWO=1I 5ANKRC:8%)1<-O_L9[L/)P&3^)& I U(O.XF MD5=YPRQ;SK7:@W;>1'.&+]5'DS@NW:$\6$VKG.+LES["N\&-A1MN,J%,K1&^K#;&:KH17\\5V["&YUGNEU=6+ON.1E7<*J*#06S"+< MLU_T+JP!>I3PKK;&,IG3&<+Q-,_5=3'S^;I6Q@FAX[!8;E!W9Q+"MA%7MN)8 M)ZYJQ87 929JKXM+B\2TH5>L3A1OCO>/$8ZYF@1U"KJ.7(+=J=J0I^G/?%KH M:72=AOS[\!1&@VLW/8(DC*?>'$,R"(=Q[&R:&(R<,8'Q-7Q0E@D@Y59K3?L'E9-&?:LW3"GSB8-4 M\E^G_TC[% ;3<)*D<.ZR1B>-I$1=^'9IP".;GM+-=AUYU32BHWO3SN^8+K@T M('!+H?'5]2@ W;3(9F!5Y=O21EEJ&PO=V]R:W-H965TA6:0B-+?% NPJC;'88YXS*83?S9O9Y-5&D%EWBOP91YSO1V MCD)MID$OV!T\\%5FW4$XFQ1LA0NTWXM[3;NP04EXCM)P)4%C.@TN>^/YP/E[ MAR>.&].RP2E9*O7L-K?)-.@Z0B@PM@Z!T;+&*Q3" 1&-EQHS:%*ZP+:]0[_Q MVDG+DAF\4N('3VPV#48!))BR4M@'M?F*M9XSAQ*D^FLAQZ1YE M837=,:\1YA1B]@W@. M=TK:S, 7F6#R9WQ([!J*T8[B/#H(N,#B%/K=#D3=:' K]]([GN\_K\E7W,3 M"^54&_AYN3164Y7\VJ>Y@ASLAW2=,S8%BW$:4&L8U&L,9DL/NQ0'"@X;P MX!#Z;$&=F)0"0:7P1KX#-UPR&7,FX%82]=*]W.X5$W E#P\8EUISN8(Y,]SL M4W8P]WYECQE"J@0UM$.VKE+ (%4-#0F;@:7K*Y473&X_T5G#DC?>L-F7/H$+=>,HV8ZSK9P["]5:9A,S,D8J'0L MYDO43?W H[)$Y1NN44"O7J-Z[<.E<3K&KH1Q2WVFGVDNIB6A=8A^+$HJ:3(@ M9B8#2E(9^%)RHN*%?83>H',^[+>-HP^CJ!==M*QKC&M>/<^K_W]X]4?#MO$W MKWW5&K:F2XYZY6>H@5B5TE:#ICEMQO1E-9W>W*L9?\?TBJH !*84VCUU4U%7 M<[/:6%7X6;54EB:?-S/ZU*!V#G2?*F5W&Y>@^7C-?@-02P,$% @ ]4EL M6247;G7I @ C 8 !D !X;"]W;W)K&UL?97; MCMHP$(9?9916/4B('&&! M+N=JMVI6U7I8>+JAA:&)B^Q8F:H:I0TLE&Z8I9"O0U- MK9$57E2),(FB<5@Q+H/EW/?=Z^5<-59PB?<:3%-53/^^0J%VBR .]AV?^;:T MKB-':5N?E^PC>..W/0!I?)6JD' M%WPH%D'D#*' W#H"H[]'O$8A'(AL_.J80;^D$QZV]_1W/G?*9V M7 23 K0DWOQIN?\.K+VPMT+R>AY:60AH-((F2[ PO[?--/2\]P>LR_'&Y-E;3E?AY+,<6D1U' MN&!38XUELN!R M"]^9UDQ:<\SO>>*7$F&C!#T_Q\%V W+!C.$;C@7L.C)8!76C\Y(N.>2JJNC1 M&'<]8(>:_!R88<;9H[.Q6*U1]PS5!]%)<1(-IEGF]-DP3> MYNV.77C& MY+^.9'0",XFRP73D?$3#*(KAMI$(2>(U,7Q4%,6#F(XAF<3'+F%X4"$JU%M? M!PV=#$*0+>UKPVLJGV]62M+ MUR;)II>'S7KB[.Y#IP^T!$N:2*1*4G'R]P4IV4XZCG?WQ:9(X #$ M 4#,MD(^J@I D^>VX6KN5%IWE].IRBMHF9J(#CB>;(1LF<9/64Y5)X$55JEM MIM3SXFG+:NXL9G9O*1NFYK"41/5MR^3+-31B.W=\9[=Q7Y>5-AO3Q:QC M):Q ?^Z6$K^F>Y2B;H&K6G B83-WKOS+Z]C(6X$O-6S5JS4Q-UD+\6@^_BKF MCF<<@@9R;1 8_CW!#32- 4(W_ATQG;U)H_AZO4/_W=X=[[)F"FY$\[4N=#5W M4H<4L&%]H^_%]D\8[Q,9O%PTROZ2[2 ;A0[)>Z5%.RJC!VW-AW_V/,;AE4+J MO:- 1P5J_1X,62\_,,T6,RFV1!II1#,+>U6KC<[5W)"RTA)/:]33BY46^2/Y MU-D0+1O&R=D#6S>@SF=3C?A&:IJ/6-<#%GT'*R,?!=>5(K>\@.*M_A3]VCM' M=\Y=TY. *^@F)/!<0CT:GL +]I<-+%[P'E[%)%Q<(XD%6;(7S"U-KJ1DO 2[ M_OMJK;3$1/GGV.4'[/ XMBF>2]6Q'.8.5H<"^03.XI>?_-C[[83GX=[S\!3Z M8H7%6/0-$+$A]X!.UKG&2PSL?>8UWL.D=ZU?CGE^$ONXY_>KST/%("3ID4]) M= 7D1K0=XR^_*J3$SX:$J151V#VP0>B*K$V97Y*[OEVC"GK[U=8%%!?D4Z^5 M9KRH>>F2#Y"#%0E\2V] ?#=($S>,,O(S"2/09.I[;ABGUF28D!-,1GLFH^]F\DWQG2+P).1Q @=LT1UZWULF?YR_P^JJ M+"643,.W.,W2&$-H&/5]PT@\"4,32YJ2/T9:H\B-/,](3+*,W#Z#S&O+9AJY M/@T-5]Z$Q@1[\ 9JHW&6N9&?F@,_GB0>ZG2U-/L!TAO1V)Y$DS#])K]1$KM^ MY!MYM!&@>U%B/K*$?,$B0TQ4)O#<@:TV+<@3;O\HU,"O0AQ[-]-=CT-$U(W3 M>("(8A,LD^M^Q=^==W>"7]PP50T).#9$4]KXV#*;,!A37,.Q7#QI MYG@N/@C-&L+1:FZL*FMU;:WFKZW"8!5+.A<2GQ!3VVR,O!BC.+8#EV"'.C0' MPY.%)5TO\XH9$).M!XE#YM^NEDM2<[O.!6YSXP@FBK:O@#(1PJ%'LL$@E@=3 M6!T-%H8B9U91] HMJO-+\E!)@#?OWO^HO<, G3JWU-MB.:QNA!KVT\P6J1L$YI^Z:10>3Y^J+L:9IF#^# 1?F2RK)&!!C:HZDT2;(-RF+*& M#RTZ.]FLA<8YR2XK'$Q!&@$\WPBA=Q_&P'[47?P'4$L#!!0 ( /5);%F] M1<3[:P( -0% 9 >&PO=V]R:W-H965TYB&RKH]3'LPR858=>S4=J#;KY_MA C:%/5A M+XD_[CGWG)O<&^^%?% Y@$9/!>-JBG.MRXGGJ32'@JB>*(&;FXV0!=%F*[>> M*B60S($*Y@6^/_0*0CE.8G>VE$DL*LTHAZ5$JBH*(O_< !/[*>[CP\$=W>;: M'GA)7)(MK$#?ETMI=E[+DM$"N**"(PF;*9[U)_/(QKN 'Q3VZFB-K).U$ ]V M\R6;8M\* @:IM@S$O'8P!\8LD9'QV'#B-J4%'J\/[+?.N_&R)@KF@OVDFO M ((&$+P5$#: T!FME3E;"Z))$DNQ1])&&S:[<+5Q:..&]HDM5 O;1+?@"4@/O.WAX"O>,U=9OT/H-'%_X!K_7:"ZX$HQF MM7UC$"TE*."Z/A ;=$LYX2DE#*W,(9C_5ROT:[966IH_\'=7/6H!4;< VY43 M59(4IKBTN>0.>S(G*75%2NX#'BNX(LP7H M%::-/4;IF;L0O2!IC[C1#ZL+&=W0[RY!]02P,$% @ ]4EL69M1 MV 6! #QL !D !X;"]W;W)K&ULM9E=C^(V M%(;_BI5*JU;:3CZ!&0I(,R31KM19H4%M+ZI>F' =Y*8V@9VI/[X.A\$$H44 M=L_<0.+X?6R?USD8>W3@XE5N !3YFL2I'!L;I;9#TY31!A(J[_@64OUDQ45" ME;X5:U-N!=!E+DIBT[&LOIE0EAJ345XV$Y,1WZF8I3 31.Z2A(JW)XCY86S8 MQK'@A:TW*BLP)Z,M7<,#V8!94PY?$?;*DV8^/>($M8T5VL7OCA$Y0#ZF6\B,Y!PM+BFWXM W$FT)QV@5,*G*; NR!P2X%[;0M>*?"N;:%7"GI-0?^"H%\* M^GGLBV#ED?:IHI.1X ;%C")\1>9L MG;(5BVBJR&,4\5VJ6+HF,QZSB($D/Y,7V$.Z [)X(\_T;R[(C+Z!D.1''Q1E ML?Q)UYGF?09!ICR-(%6"YC/HAM+J1$C^/<[1 MMKG62J8@/[\55SZMV?!\O=;ZCZ@ GS,6$!)BQ$@M5Q1/3;45XC M#;:S&@O7L'N$WQI!YQ1!Y]I4>,LZLYMZ\_N"2?-1:0$J+<2BU=T^;;+8[GLE M2-0-%U2:CTH+4&DA%JUN^&G7Q>[\JW];@D3=:4&E^26MD7'=9L9%W41I;=-S M&DM/\VR_/@&QSD]6),E3:;']6956IS>/^9E%H_S)'D[MEG+?'@;%V*;_/3@@57BB?YY0;H$D1603]?<:Z.-UD# MU1G8Y#]02P,$% @ ]4EL666-M4.F!0 SB4 !D !X;"]W;W)K&ULO9I?;]LV$,"_"N$50PMTL27_SQP#B26A =HBB-/N M8=@#(]$V%TG42-INAG[XD9(B6Q;#V,$M+[8DW_U(WAV/Y%F3+>,/8D6(1#^2 M.!47K964V7F[+<(52; X8QE)U2\+QA,LU2U?MD7&"8YRI21NNYW.H)U@FK:F MD_S9#9].V%K&-"4W'(EUDF#^>$5BMKUH.:VG![=TN9+Z07LZR?"2S(G\EMUP M==>N*!%-2"HH2Q$GBXO6I7,>N+E"+O&=DJW8NT9Z*/>,/>B;Z^BBU=$](C$) MI49@];4A,Q+'FJ3Z\4\);55M:L7]ZR=ZD ]>#>8>"S)C\1\TDJN+UJB%(K+ MZUC>LNTG4@ZHKWDABT7^B;:E;*>%PK60+"F550\2FA;?^$=IB#T%UWU&P2T5 MW&,5NJ5"]T"A^UR7>J5"[]@6^J5"_UB%0:DPR&U?&"NWM(DRI0L:XE2BRS!DZU32=(EN6$Q# M2@3Z#7W%G&,=">B]1R2FL?B WB&:HKL56PN<1F+2EJI3&MT.RPY<%1UPG^E M%WUAJ5P)Y*<1B0SZGEU_;-%O*V-4%G&?+'+E6H%SDIVA;N^C] MNP^&?LV.QW0M&.\5O4&"+-7LE@:<#].KP([Q2*@PC@U3LWVWBL9NSNT^P_VJ M,M%^Z'&6JNN0Z,%^1#[F\2.ZC%B6)Z4_/RMM="U)(OXRQ5W15,_3LR%A'B3,AX0%0+":\WN5\WLV^O26",EI*$F$ M0BQ6)I<6@$$.T&OF9JI6T$E[L^\I:R.G>NJ(!GW(!@-[@S6[]BN[]E^PZX:D M:Z+V 2%3&?Y?95^5LE5G-E1E;9013IDY090TXX& M4J.YP#K45P;HH#+DP&K(RUCMP[!*1TCMZ%#(240EBID0Q&B]06/0A[9[4<)[ M4<)_42*P#NJ5)AM6)AO:319M")=4Z&Q.?JCML" F4PT;@^@U JTITXRS82.$ MG$XCSIH@IQ&,@758KS3:J#+:R&JTK^ODGG"])5,'"+WA4L8K5WR!?EH6_RLK M]]0E#Q+FC9I&/W +9',!$*SFOG'EOO&QZYC:OH9 P M'Q(6 ,%JGG4ZN]-2Y^TVJ&5;0/X'I7F@-!^4%D#1ZC&P=V)VK//;HQL:D31" MCY3$IA/KE1UPLF,A:5Y)&UNV%* -!E"TNK?0HN9J3XB#8J.>N9 M6^QZCV&L/?1(,#F'T;+-B,&X<&PU"C:J"9Q!J5C%\@Y33:#"PC^NU M=MO5*!Q[D>*IVO-33YMH'4HT8VKJI%(?)-5TN:7B0?UX^?UZ[J/9G8?NU(IH MM"Y0W:!T R3- Z7YH+0 BE;W_Z[@X@S?,'<"E4'*&("D>: T'Y060-'J,;"K M'SGV M(-X7K&Z_0IF<2Q-8F.FN>!LW'W,(N:I$;CPS1J9!T6>LRLT6$:_3]* M.,ZNAN.\5,1Y2J/S=9;%E'!S'KW;,O0%_\UX)6?^#Q2TU -*\T!I/B@M@*+5 M_PG>E7O<-RSWN*#E'E":!TKS06D!%*T> [MRCVLO]YR23%U#<>5L?)#:9D=) M>6:IX4$R/4HJL _Q5!.V]UXW20A?YB\&"91/D^*__NII]?+19?[*S<'S*^=\ MYAB>>\ZY7[Q:M,,7;SI]P7Q)4X%BLE!-='BAO)LOQEEWLF)4OR MRQ7!$>%:0/V^8$P^W>@&JE>XIO\!4$L#!!0 ( /5);%E5\-U&& 0 (8 M 9 >&PO=V]R:W-H965T M2][PWOF1LF]\B[$ WXN\Y MC*\3NVC1YLL4%XE=TATOY94-9@81\99G)=PRC MM"85N6E;EF\6B)3&!^Y)MA75 M@+F<[U"&UUA\V=TQ^69V*BDI<,D)+0'#FX5Q Z]CZ%>$&O$7P4=^]@PJ4QXH M_5:]?$H7AE6M"..H/;$MRGSN"UA-ITL[&]=ER$!%K.&3T" M5J&E6O50>[]F2W^1LMHH:\'D5R)Y8KEN-@B@&[ F64DV)$&E #=)0O>E(&4& M[FA.$H(Y^ 5$A*,L8SA#=9 EYQX?<+G'X%V$!2(Y?R]17]81>/?F/7@#2 G^ MW-(]1V7*YZ:0RZTF-9-V:;?-TNP+2W/ 9UJ*+0=QF>)4P8^F^>$$WY1NZGQE M/_KJUIX47./=%7"LGX%MV:YB/:NGTQV5.3\V>_SBV7O.<+J-X]1ZS@6]RWOA M[]\E%'P2N.#_J*+>Z+IJW2HQ7O,=2O#"D)F/8W; QO+M3]"W/JAU9P=P\G+M5@7)@'PNP#X MKW3^?9W!T2D6Z12+-8GU@A-TP0E>>OX;HG=V&OT@" ?'7P&R0FMP^L<@VW:@ M.SC]8Q0,@EFH/OVSSK[9I'V_T@-FI;RO"I6)D]SG;C"=8I%.L5B36"\ 81> M\)5.?Z@S.#K%(IUBL2:Q7G"@=;K46R\]_RVS=VQ]QQDD 7*#3UOD $4*&C9 MP? "H((Y7F"I

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end XML 55 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 179 247 1 false 57 0 false 6 false false R1.htm 0000001 - Document - Cover Sheet http://www.exagen.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - Unaudited Condensed Balance Sheets Sheet http://www.exagen.com/role/UnauditedCondensedBalanceSheets Unaudited Condensed Balance Sheets Statements 2 false false R3.htm 9952152 - Statement - Unaudited Condensed Balance Sheets (Parenthetical) Sheet http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical Unaudited Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - Unaudited Condensed Statements of Operations Sheet http://www.exagen.com/role/UnauditedCondensedStatementsofOperations Unaudited Condensed Statements of Operations Statements 4 false false R5.htm 9952154 - Statement - Unaudited Condensed Statements of Stockholders' Equity Sheet http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity Unaudited Condensed Statements of Stockholders' Equity Statements 5 false false R6.htm 9952155 - Statement - Unaudited Condensed Statements of Cash Flows Sheet http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows Unaudited Condensed Statements of Cash Flows Statements 6 false false R7.htm 9952156 - Disclosure - Organization Sheet http://www.exagen.com/role/Organization Organization Notes 7 false false R8.htm 9952157 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.exagen.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 9952158 - Disclosure - Other Financial Information Sheet http://www.exagen.com/role/OtherFinancialInformation Other Financial Information Notes 9 false false R10.htm 9952159 - Disclosure - Borrowings Sheet http://www.exagen.com/role/Borrowings Borrowings Notes 10 false false R11.htm 9952160 - Disclosure - Commitment and Contingencies Sheet http://www.exagen.com/role/CommitmentandContingencies Commitment and Contingencies Notes 11 false false R12.htm 9952161 - Disclosure - Fair Value Measurements Sheet http://www.exagen.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 9952162 - Disclosure - Stockholders' Equity Sheet http://www.exagen.com/role/StockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 9952163 - Disclosure - Stock Option Plan Sheet http://www.exagen.com/role/StockOptionPlan Stock Option Plan Notes 14 false false R15.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 15 false false R16.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 16 false false R17.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.exagen.com/role/SummaryofSignificantAccountingPolicies 17 false false R18.htm 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.exagen.com/role/SummaryofSignificantAccountingPolicies 18 false false R19.htm 9954473 - Disclosure - Other Financial Information (Tables) Sheet http://www.exagen.com/role/OtherFinancialInformationTables Other Financial Information (Tables) Tables http://www.exagen.com/role/OtherFinancialInformation 19 false false R20.htm 9954474 - Disclosure - Borrowings (Tables) Sheet http://www.exagen.com/role/BorrowingsTables Borrowings (Tables) Tables http://www.exagen.com/role/Borrowings 20 false false R21.htm 9954475 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.exagen.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.exagen.com/role/FairValueMeasurements 21 false false R22.htm 9954476 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.exagen.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.exagen.com/role/StockholdersEquity 22 false false R23.htm 9954477 - Disclosure - Stock Option Plan (Tables) Sheet http://www.exagen.com/role/StockOptionPlanTables Stock Option Plan (Tables) Tables http://www.exagen.com/role/StockOptionPlan 23 false false R24.htm 9954478 - Disclosure - Organization (Details) Sheet http://www.exagen.com/role/OrganizationDetails Organization (Details) Details http://www.exagen.com/role/Organization 24 false false R25.htm 9954479 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details) Sheet http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails Summary of Significant Accounting Policies - Revenue by Major Payers (Details) Details 25 false false R26.htm 9954480 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 26 false false R27.htm 9954481 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) Sheet http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) Details 27 false false R28.htm 9954482 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) Details 28 false false R29.htm 9954483 - Disclosure - Summary of Significant Accounting Policies - Securities (Details) Sheet http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails Summary of Significant Accounting Policies - Securities (Details) Details 29 false false R30.htm 9954484 - Disclosure - Other Financial Information - Prepaid Expenses (Details) Sheet http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails Other Financial Information - Prepaid Expenses (Details) Details 30 false false R31.htm 9954485 - Disclosure - Other Financial Information - Property and Equipment (Details) Sheet http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails Other Financial Information - Property and Equipment (Details) Details 31 false false R32.htm 9954486 - Disclosure - Other Financial Information - Narrative (Details) Sheet http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails Other Financial Information - Narrative (Details) Details 32 false false R33.htm 9954487 - Disclosure - Other Financial Information - Accrued and Other Current Liabilities (Details) Sheet http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails Other Financial Information - Accrued and Other Current Liabilities (Details) Details 33 false false R34.htm 9954488 - Disclosure - Borrowings - Narrative (Details) Sheet http://www.exagen.com/role/BorrowingsNarrativeDetails Borrowings - Narrative (Details) Details 34 false false R35.htm 9954489 - Disclosure - Borrowings - Future Minimum Payments (Details) Sheet http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails Borrowings - Future Minimum Payments (Details) Details 35 false false R36.htm 9954490 - Disclosure - Commitment and Contingencies (Details) Sheet http://www.exagen.com/role/CommitmentandContingenciesDetails Commitment and Contingencies (Details) Details http://www.exagen.com/role/CommitmentandContingencies 36 false false R37.htm 9954491 - Disclosure - Fair Value Measurements (Details) Sheet http://www.exagen.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.exagen.com/role/FairValueMeasurementsTables 37 false false R38.htm 9954492 - Disclosure - Stockholders' Equity - Narrative (Details) Sheet http://www.exagen.com/role/StockholdersEquityNarrativeDetails Stockholders' Equity - Narrative (Details) Details 38 false false R39.htm 9954493 - Disclosure - Stockholders' Equity - Outstanding Warrants (Details) Sheet http://www.exagen.com/role/StockholdersEquityOutstandingWarrantsDetails Stockholders' Equity - Outstanding Warrants (Details) Details 39 false false R40.htm 9954494 - Disclosure - Stock Option Plan - Narrative (Details) Sheet http://www.exagen.com/role/StockOptionPlanNarrativeDetails Stock Option Plan - Narrative (Details) Details 40 false false R41.htm 9954495 - Disclosure - Stock Option Plan - Restricted Stock Units (Details) Sheet http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails Stock Option Plan - Restricted Stock Units (Details) Details 41 false false R42.htm 9954496 - Disclosure - Stock Option Plan - Stock Option Activity (Details) Sheet http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails Stock Option Plan - Stock Option Activity (Details) Details 42 false false R43.htm 9954497 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details) Sheet http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails Stock Option Plan - Stock-Based Compensation Expense (Details) Details 43 false false All Reports Book All Reports exdx-20240930.htm exdx-20240930.xsd exdx-20240930_cal.xml exdx-20240930_def.xml exdx-20240930_lab.xml exdx-20240930_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 60 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "exdx-20240930.htm": { "nsprefix": "exdx", "nsuri": "http://www.exagen.com/20240930", "dts": { "inline": { "local": [ "exdx-20240930.htm" ] }, "schema": { "local": [ "exdx-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "exdx-20240930_cal.xml" ] }, "definitionLink": { "local": [ "exdx-20240930_def.xml" ] }, "labelLink": { "local": [ "exdx-20240930_lab.xml" ] }, "presentationLink": { "local": [ "exdx-20240930_pre.xml" ] } }, "keyStandard": 223, "keyCustom": 24, "axisStandard": 25, "axisCustom": 0, "memberStandard": 32, "memberCustom": 23, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 179, "entityCount": 1, "segmentCount": 57, "elementCount": 506, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 524, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.exagen.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.exagen.com/role/UnauditedCondensedBalanceSheets", "longName": "9952151 - Statement - Unaudited Condensed Balance Sheets", "shortName": "Unaudited Condensed Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "unique": true } }, "R3": { "role": "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical", "longName": "9952152 - Statement - Unaudited Condensed Balance Sheets (Parenthetical)", "shortName": "Unaudited Condensed Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations", "longName": "9952153 - Statement - Unaudited Condensed Statements of Operations", "shortName": "Unaudited Condensed Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "unique": true } }, "R5": { "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity", "longName": "9952154 - Statement - Unaudited Condensed Statements of Stockholders' Equity", "shortName": "Unaudited Condensed Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-33", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-37", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "unique": true } }, "R6": { "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows", "longName": "9952155 - Statement - Unaudited Condensed Statements of Cash Flows", "shortName": "Unaudited Condensed Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "unique": true } }, "R7": { "role": "http://www.exagen.com/role/Organization", "longName": "9952156 - Disclosure - Organization", "shortName": "Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies", "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.exagen.com/role/OtherFinancialInformation", "longName": "9952158 - Disclosure - Other Financial Information", "shortName": "Other Financial Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.exagen.com/role/Borrowings", "longName": "9952159 - Disclosure - Borrowings", "shortName": "Borrowings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.exagen.com/role/CommitmentandContingencies", "longName": "9952160 - Disclosure - Commitment and Contingencies", "shortName": "Commitment and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.exagen.com/role/FairValueMeasurements", "longName": "9952161 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.exagen.com/role/StockholdersEquity", "longName": "9952162 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.exagen.com/role/StockOptionPlan", "longName": "9952163 - Disclosure - Stock Option Plan", "shortName": "Stock Option Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R16": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConcentrationRiskCreditRisk", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConcentrationRiskCreditRisk", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.exagen.com/role/OtherFinancialInformationTables", "longName": "9954473 - Disclosure - Other Financial Information (Tables)", "shortName": "Other Financial Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.exagen.com/role/BorrowingsTables", "longName": "9954474 - Disclosure - Borrowings (Tables)", "shortName": "Borrowings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.exagen.com/role/FairValueMeasurementsTables", "longName": "9954475 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.exagen.com/role/StockholdersEquityTables", "longName": "9954476 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.exagen.com/role/StockOptionPlanTables", "longName": "9954477 - Disclosure - Stock Option Plan (Tables)", "shortName": "Stock Option Plan (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.exagen.com/role/OrganizationDetails", "longName": "9954478 - Disclosure - Organization (Details)", "shortName": "Organization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails", "longName": "9954479 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)", "shortName": "Summary of Significant Accounting Policies - Revenue by Major Payers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "c-60", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-60", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954480 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "unique": true } }, "R27": { "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails", "longName": "9954481 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)", "shortName": "Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-80", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "unique": true } }, "R28": { "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails", "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)", "shortName": "Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R29": { "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails", "longName": "9954483 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)", "shortName": "Summary of Significant Accounting Policies - Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails", "longName": "9954484 - Disclosure - Other Financial Information - Prepaid Expenses (Details)", "shortName": "Other Financial Information - Prepaid Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails", "longName": "9954485 - Disclosure - Other Financial Information - Property and Equipment (Details)", "shortName": "Other Financial Information - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails", "longName": "9954486 - Disclosure - Other Financial Information - Narrative (Details)", "shortName": "Other Financial Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails", "longName": "9954487 - Disclosure - Other Financial Information - Accrued and Other Current Liabilities (Details)", "shortName": "Other Financial Information - Accrued and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.exagen.com/role/BorrowingsNarrativeDetails", "longName": "9954488 - Disclosure - Borrowings - Narrative (Details)", "shortName": "Borrowings - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RepaymentsOfLongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-119", "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "unique": true } }, "R35": { "role": "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails", "longName": "9954489 - Disclosure - Borrowings - Future Minimum Payments (Details)", "shortName": "Borrowings - Future Minimum Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.exagen.com/role/CommitmentandContingenciesDetails", "longName": "9954490 - Disclosure - Commitment and Contingencies (Details)", "shortName": "Commitment and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-136", "name": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-136", "name": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.exagen.com/role/FairValueMeasurementsDetails", "longName": "9954491 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-141", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "unique": true } }, "R38": { "role": "http://www.exagen.com/role/StockholdersEquityNarrativeDetails", "longName": "9954492 - Disclosure - Stockholders' Equity - Narrative (Details)", "shortName": "Stockholders' Equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-5", "name": "exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.exagen.com/role/StockholdersEquityOutstandingWarrantsDetails", "longName": "9954493 - Disclosure - Stockholders' Equity - Outstanding Warrants (Details)", "shortName": "Stockholders' Equity - Outstanding Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.exagen.com/role/StockOptionPlanNarrativeDetails", "longName": "9954494 - Disclosure - Stock Option Plan - Narrative (Details)", "shortName": "Stock Option Plan - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails", "longName": "9954495 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)", "shortName": "Stock Option Plan - Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-159", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-159", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails", "longName": "9954496 - Disclosure - Stock Option Plan - Stock Option Activity (Details)", "shortName": "Stock Option Plan - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-162", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-164", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "unique": true } }, "R43": { "role": "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails", "longName": "9954497 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)", "shortName": "Stock Option Plan - Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exdx-20240930.htm", "first": true, "unique": true } } }, "tag": { "exdx_AHNCollaborationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "AHNCollaborationMember", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AHN Collaboration", "label": "AHN Collaboration [Member]", "documentation": "AHN Collaboration" } } }, "auth_ref": [] }, "exdx_AVISECTDTestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "AVISECTDTestMember", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AVISE CTD Test", "label": "AVISE CTD Test [Member]", "documentation": "AVISE CTD Test" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r43", "r687" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Net", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r630" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r832" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails", "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "totalLabel": "Accrued and other current liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r46" ] }, "exdx_AccruedPurchaseGoodsAndServicesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "AccruedPurchaseGoodsAndServicesCurrent", "crdr": "credit", "calculation": { "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued purchases of goods and services", "label": "Accrued Purchase, Goods and Services, Current", "documentation": "Accrued Purchase, Goods and Services, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedSalariesCurrent", "crdr": "credit", "calculation": { "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued\u00a0payroll\u00a0and\u00a0related\u00a0expenses", "label": "Accrued Salaries, Current", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r46", "r639" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r742" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r56", "r687", "r948" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r569", "r822", "r823", "r824", "r825", "r890", "r949" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r755" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r755" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r755" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r755" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r37", "r38", "r340" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising and Marketing Costs", "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r103" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising expense", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r383", "r675" ] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r788" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r714", "r724", "r734", "r766" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r717", "r727", "r737", "r769" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r789" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r755" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r762" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r718", "r728", "r738", "r762", "r770", "r774", "r782" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r780" ] }, "exdx_AlleghenyHealthNetworkResearchInstituteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "AlleghenyHealthNetworkResearchInstituteMember", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allegheny Health Network Research Institute", "label": "Allegheny Health Network Research Institute [Member]", "documentation": "Allegheny Health Network Research Institute" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r372", "r381" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt discount and debt issuance costs", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r301", "r659", "r660", "r816", "r901" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive securities excluded from computation (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r167" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r21" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r409" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r93", "r102", "r116", "r138", "r170", "r173", "r187", "r188", "r230", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r410", "r412", "r461", "r527", "r593", "r649", "r650", "r687", "r705", "r857", "r858", "r903" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r112", "r123", "r138", "r230", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r410", "r412", "r461", "r687", "r857", "r858", "r903" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r777" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r778" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r773" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r773" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r773" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r773" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r773" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r773" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails", "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails", "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r367", "r368", "r369", "r370", "r371" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r776" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r775" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r774" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r774" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Costs incurred, but not paid, in connection with capital expenditures", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r17", "r18", "r19" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/OrganizationDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails", "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r15", "r114", "r637" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds, included in cash and cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r892", "r893" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents and Restricted Cash", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r16" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails", "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "totalLabel": "Total cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r15", "r70", "r134" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r70" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r753" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r750" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r748" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.exagen.com/role/StockholdersEquityNarrativeDetails", "http://www.exagen.com/role/StockholdersEquityOutstandingWarrantsDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r119", "r120", "r121", "r172", "r310", "r311", "r312", "r314", "r317", "r322", "r324", "r564", "r565", "r566", "r567", "r661", "r793", "r818" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.exagen.com/role/StockholdersEquityOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.exagen.com/role/StockholdersEquityOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.exagen.com/role/StockholdersEquityOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of warrant or right, exercise price of warrants or rights (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r325" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.exagen.com/role/StockholdersEquityOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued to purchase redeemable convertible preferred stock (in shares)", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "exdx_ClientMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "ClientMember", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Client", "label": "Client [Member]", "documentation": "Client" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r754" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r754" ] }, "exdx_CollaborationAgreementAnnualCollaborationFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "CollaborationAgreementAnnualCollaborationFee", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration fee", "label": "Collaboration Agreement, Annual Collaboration Fee", "documentation": "Collaboration Agreement, Annual Collaboration Fee" } } }, "auth_ref": [] }, "exdx_CollaborationAgreementCollaborationExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "CollaborationAgreementCollaborationExpenses", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration agreement, collaboration expenses", "label": "Collaboration Agreement, Collaboration Expenses", "documentation": "Collaboration Agreement, Collaboration Expenses" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 5)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r52", "r96", "r528", "r580" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.exagen.com/role/CommitmentandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r81", "r260", "r261", "r631", "r844", "r849" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common\u00a0Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r696", "r697", "r698", "r700", "r701", "r702", "r703", "r822", "r823", "r825", "r890", "r947", "r949" ] }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r55" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r55", "r581" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r55" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical", "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r8", "r55", "r581", "r599", "r949", "r950" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value per share; 200,000,000 shares authorized as of September\u00a030, 2024 and December 31, 2023; 17,520,335 and 17,045,954 shares issued and outstanding as of September\u00a030, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r55", "r530", "r687" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r759" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r758" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r760" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r757" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Loss", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "exdx_ComputerEquipmentAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "ComputerEquipmentAndSoftwareMember", "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment and software", "label": "Computer Equipment and Software [Member]", "documentation": "Computer Equipment and Software" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r24", "r25", "r39", "r40", "r192", "r630" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r24", "r25", "r39", "r40", "r192", "r561", "r630" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r24", "r25", "r39", "r40", "r192", "r630", "r797" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk and Other Risk and Uncertainties", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r42", "r104" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percent of total revenue", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r24", "r25", "r39", "r40", "r192" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r24", "r25", "r39", "r40", "r192", "r630" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized in previous periods", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r329" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Costs of revenue", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r61", "r62", "r520" ] }, "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Cost, Depreciation and Amortization", "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service." } } }, "auth_ref": [ "r812" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r63", "r138", "r230", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r461", "r649", "r857" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Costs of revenue", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Shipping and Handling Costs", "label": "Cost of Goods and Service [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r800" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r66" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r139", "r140", "r283", "r312", "r486", "r503", "r526", "r640", "r642" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "exdx_CowenEquityDistributionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "CowenEquityDistributionAgreementMember", "presentation": [ "http://www.exagen.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cowen Equity Distribution Agreement", "label": "Cowen Equity Distribution Agreement [Member]", "documentation": "Cowen Equity Distribution Agreement" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r76", "r192" ] }, "us-gaap_CustomerRefundLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRefundLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refund liability", "label": "Customer Refund Liability, Current", "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.exagen.com/role/Borrowings" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r82", "r136", "r252", "r253", "r254", "r255", "r256", "r268", "r269", "r279", "r285", "r286", "r287", "r288", "r289", "r290", "r295", "r302", "r303", "r305", "r469" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails", "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r13", "r45", "r46", "r94", "r95", "r141", "r280", "r281", "r282", "r283", "r284", "r286", "r291", "r292", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r656", "r657", "r658", "r659", "r660", "r686", "r819", "r845", "r846", "r847", "r900", "r902" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan covenant, minimum unrestricted cash balance", "label": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance", "documentation": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance" } } }, "auth_ref": [] }, "exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease": { "xbrltype": "percentItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan covenant, increase to interest rate", "label": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)", "documentation": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)" } } }, "auth_ref": [] }, "exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet": { "xbrltype": "durationItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan, covenant, number of days to cure covenant if performance measure is not met", "label": "Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met", "documentation": "Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met" } } }, "auth_ref": [] }, "exdx_DebtInstrumentCovenantRevenuePerformancePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "DebtInstrumentCovenantRevenuePerformancePeriod", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan, covenant, revenue performance period", "label": "Debt Instrument, Covenant, Revenue Performance Period", "documentation": "Debt Instrument, Covenant, Revenue Performance Period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r293", "r460", "r657", "r658", "r893", "r894", "r895", "r896", "r897" ] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan, fee incurred upon payment of final installment", "label": "Debt Instrument, Fee Amount", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": [ "r49" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan, effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r48", "r308", "r469", "r470", "r686" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan, interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r48", "r281" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r141", "r280", "r281", "r282", "r283", "r284", "r286", "r291", "r292", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r304", "r656", "r657", "r658", "r659", "r660", "r686", "r819", "r900", "r902" ] }, "exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant": { "xbrltype": "percentItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, minimum cash balance", "label": "Debt Instrument, Minimum Cash Balance Required, Not Required To Comply With Covenant", "documentation": "Debt Instrument, Minimum Cash Balance Required, Not Required To Comply With Covenant" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails", "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r13", "r141", "r280", "r281", "r282", "r283", "r284", "r286", "r291", "r292", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r656", "r657", "r658", "r659", "r660", "r686", "r819", "r845", "r846", "r847", "r900", "r902" ] }, "exdx_DebtInstrumentNumberOfMonthlyInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "DebtInstrumentNumberOfMonthlyInstallments", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of monthly installments", "label": "Debt Instrument, Number Of Monthly Installments", "documentation": "Debt Instrument, Number Of Monthly Installments" } } }, "auth_ref": [] }, "exdx_DebtInstrumentPaidInKindLoansIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "DebtInstrumentPaidInKindLoansIssued", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan, paid in-kind loans issued", "label": "Debt Instrument, Paid In Kind Loans Issued", "documentation": "Debt Instrument, Paid In Kind Loans Issued" } } }, "auth_ref": [] }, "exdx_DebtInstrumentPrepaymentPremiumPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "DebtInstrumentPrepaymentPremiumPercentage", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan, prepayment premium percentage", "label": "Debt Instrument, Prepayment Premium Percentage", "documentation": "Debt Instrument, Prepayment Premium Percentage" } } }, "auth_ref": [] }, "exdx_DebtInstrumentStatedInterestRatePaidInKind": { "xbrltype": "percentItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "DebtInstrumentStatedInterestRatePaidInKind", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan, paid in-kind, interest rate", "label": "Debt Instrument, Stated Interest Rate, Paid In-Kind", "documentation": "Debt Instrument, Stated Interest Rate, Paid In-Kind" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r13", "r30", "r33", "r41", "r85", "r86", "r141", "r280", "r281", "r282", "r283", "r284", "r286", "r291", "r292", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r304", "r656", "r657", "r658", "r659", "r660", "r686", "r819", "r900", "r902" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "calculation": { "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unamortized debt discount and issuance costs", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r291", "r306", "r468", "r469", "r470", "r657", "r658", "r686" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r5", "r170", "r178", "r188", "r649", "r650" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r328", "r662", "r663", "r664", "r665", "r666", "r667", "r668" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r328", "r662", "r663", "r664", "r665", "r666", "r667", "r668" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r860" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.exagen.com/role/StockOptionPlan" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Option Plan", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r338", "r342", "r373", "r374", "r376", "r673" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r709" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r741" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r752" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r129", "r150", "r151", "r152", "r153", "r154", "r155", "r160", "r162", "r164", "r165", "r166", "r169", "r399", "r408", "r436", "r437", "r525", "r536", "r644" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r129", "r150", "r151", "r152", "r153", "r154", "r155", "r162", "r164", "r165", "r166", "r169", "r399", "r408", "r436", "r437", "r525", "r536", "r644" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r21", "r22", "r168" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options, unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r375" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options, cost not yet recognized, remaining weighted average vesting period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r375" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails", "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r707" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r707" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r792" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r707" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r791" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r707" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r707" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r707" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r707" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r746" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r787" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r787" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r787" ] }, "exdx_EquipmentNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "EquipmentNotesPayableMember", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails", "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment Notes Payable", "label": "Equipment Notes Payable [Member]", "documentation": "Equipment Notes Payable" } } }, "auth_ref": [] }, "exdx_EquipmentPurchasedUnderNotesPayableObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "EquipmentPurchasedUnderNotesPayableObligations", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment purchased under notes payable obligations", "label": "Equipment Purchased Under Notes Payable Obligations", "documentation": "Equipment Purchased Under Notes Payable Obligations" } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r8", "r107", "r126", "r127", "r128", "r142", "r143", "r144", "r147", "r154", "r156", "r158", "r171", "r234", "r240", "r250", "r326", "r387", "r388", "r395", "r396", "r397", "r400", "r407", "r408", "r417", "r419", "r420", "r421", "r422", "r424", "r435", "r462", "r463", "r464", "r465", "r466", "r467", "r472", "r474", "r485", "r534", "r550", "r551", "r552", "r569", "r619" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r756" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r714", "r724", "r734", "r766" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r711", "r721", "r731", "r763" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r762" ] }, "exdx_ExpirationApr12026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "ExpirationApr12026Member", "presentation": [ "http://www.exagen.com/role/StockholdersEquityOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant expiration April 1, 2026", "label": "Expiration Apr 1, 2026 [Member]", "documentation": "Expiration Apr 1, 2026" } } }, "auth_ref": [] }, "exdx_ExpirationDec72025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "ExpirationDec72025Member", "presentation": [ "http://www.exagen.com/role/StockholdersEquityOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant expiration December 7, 2025", "label": "Expiration Dec 7, 2025 [Member]", "documentation": "Expiration Dec 7, 2025" } } }, "auth_ref": [] }, "exdx_ExpirationJan192026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "ExpirationJan192026Member", "presentation": [ "http://www.exagen.com/role/StockholdersEquityOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant expiration January 19, 2026", "label": "Expiration Jan 19, 2026 [Member]", "documentation": "Expiration Jan 19, 2026" } } }, "auth_ref": [] }, "exdx_ExpirationMar312026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "ExpirationMar312026Member", "presentation": [ "http://www.exagen.com/role/StockholdersEquityOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant expiration March 31, 2026", "label": "Expiration Mar 31, 2026 [Member]", "documentation": "Expiration Mar 31, 2026" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r441", "r442", "r443", "r679" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r441", "r442", "r443", "r679" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r293", "r331", "r332", "r333", "r334", "r335", "r336", "r438", "r440", "r441", "r442", "r443", "r449", "r450", "r452", "r490", "r491", "r492", "r657", "r658", "r669", "r670", "r671", "r676", "r679" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r439", "r440", "r441", "r443", "r676", "r895", "r898" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.exagen.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r445", "r447", "r448", "r449", "r452", "r453", "r454", "r455", "r456", "r524", "r676", "r680" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a01", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r293", "r331", "r336", "r440", "r450", "r490", "r669", "r670", "r671", "r676" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a02", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r293", "r331", "r336", "r440", "r441", "r450", "r491", "r657", "r658", "r669", "r670", "r671", "r676" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a03", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r293", "r331", "r332", "r333", "r334", "r335", "r336", "r440", "r441", "r442", "r443", "r450", "r492", "r657", "r658", "r669", "r670", "r671", "r676", "r679" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r439", "r440", "r441", "r443", "r676", "r895", "r898" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r293", "r331", "r332", "r333", "r334", "r335", "r336", "r438", "r440", "r441", "r442", "r443", "r449", "r450", "r452", "r490", "r491", "r492", "r657", "r658", "r669", "r670", "r671", "r676", "r679" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r676", "r892", "r893", "r894", "r895", "r896", "r898" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease obligations, current portion", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r476" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Principal payments on finance lease obligations", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r477", "r478" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r304", "r322", "r425", "r457", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r535", "r653", "r676", "r677", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r688", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r834", "r835", "r836", "r837", "r891", "r894", "r895", "r896", "r897", "r898" ] }, "us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit losses", "label": "Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest", "documentation": "Amount excluding accrued interest, of allowance for credit loss on financing receivable. Excludes net investment in lease." } } }, "auth_ref": [ "r839" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r718", "r728", "r738", "r770" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r718", "r728", "r738", "r770" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r718", "r728", "r738", "r770" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r718", "r728", "r738", "r770" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r718", "r728", "r738", "r770" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r751" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture\u00a0and\u00a0fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on disposal of assets", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r816" ] }, "exdx_Government1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "Government1Member", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government", "label": "Government1 [Member]", "documentation": "Government1" } } }, "auth_ref": [] }, "exdx_HealthcareInsurersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "HealthcareInsurersMember", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial", "label": "Healthcare Insurers [Member]", "documentation": "Healthcare Insurers" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Long-lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r80" ] }, "exdx_IncentiveAwardPlan2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "IncentiveAwardPlan2019Member", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019 Incentive Award Plan", "label": "Incentive Award Plan, 2019 [Member]", "documentation": "Incentive Award Plan, 2019" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r251", "r257", "r259", "r444", "r446", "r451", "r545", "r547", "r604", "r634", "r678", "r917" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r257", "r259", "r444", "r446", "r451", "r545", "r547", "r604", "r634", "r678", "r917" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r815" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r799", "r815" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r815" ] }, "exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Current Other Assets", "documentation": "Increase (Decrease) in Prepaid Expense and Current Other Assets" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r718", "r728", "r738", "r762", "r770", "r774", "r782" ] }, "exdx_InnovatusLifeSciencesLendingFundMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "InnovatusLifeSciencesLendingFundMember", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Innovatus Life Sciences Lending Fund", "label": "Innovatus Life Sciences Lending Fund [Member]", "documentation": "Innovatus Life Sciences Lending Fund" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r780" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r710", "r786" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r710", "r786" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r710", "r786" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r177", "r814" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r130", "r132", "r133" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r170", "r176", "r188", "r649", "r813" ] }, "exdx_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "LaboratoryEquipmentMember", "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Laboratory equipment", "label": "Laboratory Equipment [Member]", "documentation": "Laboratory Equipment" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r79", "r479" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r13", "r45", "r46", "r47", "r50", "r51", "r52", "r53", "r138", "r230", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r411", "r412", "r413", "r461", "r579", "r645", "r705", "r857", "r903", "r904" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r60", "r97", "r532", "r687", "r820", "r838", "r899" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders' Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r47", "r113", "r138", "r230", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r411", "r412", "r413", "r461", "r687", "r857", "r903", "r904" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LicenseAgreementTermsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseAgreementTermsMember", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing Agreements", "label": "License Agreement Terms [Member]", "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lender Name [Axis]", "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r44", "r49", "r819", "r855", "r856" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Lender [Domain]", "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r44", "r49", "r819", "r855" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r44", "r49", "r269" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusAxis", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Axis]", "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r845", "r846", "r847", "r850" ] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusDomain", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Domain]", "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r845", "r846", "r847", "r850" ] }, "us-gaap_LoansPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayableMember", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan payable", "label": "Loans Payable [Member]", "documentation": "Borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails", "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total borrowings, net of discounts and debt issuance costs", "terseLabel": "Long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r13", "r95", "r292", "r307", "r657", "r658", "r686", "r913" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails", "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings-current portion", "negatedTerseLabel": "Less: Borrowings-current portion", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r117" ] }, "exdx_LongTermDebtIncludingUndiscountedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "LongTermDebtIncludingUndiscountedInterest", "crdr": "credit", "calculation": { "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Long-term Debt, Including Undiscounted Interest", "documentation": "Long-term Debt, Including Undiscounted Interest" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": { "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r141", "r297" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": { "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r141", "r297" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": { "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r141", "r297" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": { "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r141", "r297" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": { "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (remaining)", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r821" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails", "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings-non-current portion, net of discounts and debt issuance costs", "verboseLabel": "Borrowings-non-current portion, net of discounts and debt issuance costs", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r118" ] }, "exdx_LongTermDebtUndiscountedInterestAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "LongTermDebtUndiscountedInterestAmount", "crdr": "debit", "calculation": { "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest", "label": "Long-term Debt, Undiscounted Interest Amount", "documentation": "Long-term Debt, Undiscounted Interest Amount" } } }, "auth_ref": [] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermNotesPayable", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes payable, noncurrent", "label": "Notes Payable, Noncurrent", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r13" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r13", "r845", "r846", "r847" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r13", "r27", "r845", "r846", "r847" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r262", "r263", "r264", "r267", "r382", "r655", "r851", "r852" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r262", "r263", "r264", "r267", "r382", "r655", "r851", "r852" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r192", "r664", "r690", "r693", "r860", "r916", "r918", "r919", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r945", "r946" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r263", "r264", "r265", "r266", "r337", "r382", "r443", "r519", "r544", "r546", "r560", "r571", "r572", "r624", "r625", "r626", "r627", "r628", "r632", "r633", "r652", "r661", "r672", "r679", "r680", "r684", "r685", "r691", "r859", "r905", "r906", "r907", "r908", "r909", "r910" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r754" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r754" ] }, "exdx_MedicareAdvantageMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "MedicareAdvantageMember", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Medicare Advantage", "label": "Medicare Advantage [Member]", "documentation": "Medicare Advantage" } } }, "auth_ref": [] }, "exdx_MedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "MedicareMember", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicare", "label": "Medicare [Member]", "documentation": "Medicare" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r263", "r264", "r265", "r266", "r337", "r382", "r443", "r519", "r544", "r546", "r560", "r571", "r572", "r624", "r625", "r626", "r627", "r628", "r632", "r633", "r652", "r661", "r672", "r679", "r680", "r684", "r691", "r859", "r905", "r906", "r907", "r908", "r909", "r910" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r773" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds, included in cash and cash equivalents", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r862" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r781" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r192", "r664", "r690", "r693", "r860", "r916", "r918", "r919", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r945", "r946" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r755" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r131" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r131" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r70", "r71", "r72" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 }, "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows", "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations", "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r64", "r72", "r98", "r111", "r124", "r125", "r128", "r138", "r146", "r150", "r151", "r152", "r153", "r154", "r157", "r158", "r163", "r230", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r399", "r408", "r437", "r461", "r533", "r601", "r617", "r618", "r704", "r857" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncement, Early Adoption [Line Items]", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r105", "r106", "r107", "r108", "r109", "r110", "r145", "r146", "r147", "r148", "r149", "r152", "r159", "r169", "r193", "r194", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r249", "r250", "r258", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r458", "r459", "r471", "r472", "r473", "r480", "r481", "r482", "r483", "r484", "r485", "r521", "r522", "r523", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r562" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncement, Early Adoption [Table]", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle." } } }, "auth_ref": [ "r20", "r105", "r106", "r107", "r108", "r109", "r110", "r145", "r146", "r147", "r148", "r149", "r152", "r159", "r169", "r193", "r194", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r249", "r250", "r258", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r458", "r459", "r471", "r472", "r473", "r480", "r481", "r482", "r483", "r484", "r485", "r521", "r522", "r523", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r562" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements and Recently Adopted Accounting Standards", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "exdx_NoExpirationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "NoExpirationMember", "presentation": [ "http://www.exagen.com/role/StockholdersEquityOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "No expiration", "label": "No expiration [Member]", "documentation": "No expiration" } } }, "auth_ref": [] }, "exdx_NonCashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "NonCashLeaseExpense", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expense", "label": "Non-Cash Lease Expense", "documentation": "Non-Cash Lease Expense" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r754" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r718", "r728", "r738", "r762", "r770" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r745" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r744" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r762" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r781" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r781" ] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails", "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes payable", "label": "Notes Payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r13", "r95", "r913", "r914" ] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrent", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes payable, current", "label": "Notes Payable, Current", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r45", "r46" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r650", "r827" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r101", "r646", "r826", "r828", "r829", "r830", "r831" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r476" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities - non-current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r476" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r475" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.exagen.com/role/Organization" ], "lang": { "en-us": { "role": { "terseLabel": "Organization", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r73", "r74", "r75", "r90" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r46" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diagnostic\u00a0testing\u00a0supplies", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r122", "r687" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r115" ] }, "us-gaap_OtherCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCustomerMember", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Customer [Member]", "documentation": "Customer classified as other." } } }, "auth_ref": [ "r916", "r944" ] }, "exdx_OtherFinancialInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "OtherFinancialInformationAbstract", "lang": { "en-us": { "role": { "label": "Other Financial Information [Abstract]", "documentation": "Other Financial Information" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r51" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r754" ] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other prepaid expenses and other current assets", "label": "Other Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r810", "r840" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r716", "r726", "r736", "r768" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r719", "r729", "r739", "r771" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r719", "r729", "r739", "r771" ] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaidInKindInterest", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense", "label": "Paid-in-Kind Interest", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r5" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r743" ] }, "us-gaap_PaymentInKindPIKNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentInKindPIKNoteMember", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Paid in-kind note", "label": "Payment in Kind (PIK) Note [Member]", "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured." } } }, "auth_ref": [] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLegalSettlements", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement payment", "label": "Payments for Legal Settlements", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": [ "r3" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r68" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r753" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r753" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r745" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r762" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r755" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r744" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r746" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r790" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r745" ] }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock", "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r54", "r310" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r54", "r581" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r54", "r310" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r54", "r581", "r599", "r949", "r950" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value per share; 10,000,000 shares authorized, no shares issued or outstanding as of September\u00a030, 2024 and December 31, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r54", "r529", "r687" ] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r811" ] }, "exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock", "presentation": [ "http://www.exagen.com/role/OtherFinancialInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Other Financial Information", "label": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]", "documentation": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities" } } }, "auth_ref": [] }, "exdx_PrepaidMaintenanceAndInsuranceContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "PrepaidMaintenanceAndInsuranceContracts", "crdr": "debit", "calculation": { "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid maintenance and insurance contracts", "label": "Prepaid Maintenance and Insurance Contracts", "documentation": "Prepaid Maintenance and Insurance Contracts" } } }, "auth_ref": [] }, "us-gaap_PrepaidRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidRoyalties", "crdr": "debit", "calculation": { "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid product royalties", "label": "Prepaid Royalties", "documentation": "Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r638", "r654", "r840" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan borrowings", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r14", "r564" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from disposal of property and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r67" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r11" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from common stock issued under Employee Stock Purchase Plan", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Concentration Risk", "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r77" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r190", "r520", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r636", "r662", "r689", "r691", "r692", "r694", "r695", "r853", "r854", "r860", "r916", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r945", "r946" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r190", "r520", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r636", "r662", "r689", "r691", "r692", "r694", "r695", "r853", "r854", "r860", "r916", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r945", "r946" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "crdr": "credit", "calculation": { "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation and amortization", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease." } } }, "auth_ref": [ "r795", "r798", "r843" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails", "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r798", "r841" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total property and equipment", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r794", "r809", "r842" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6", "r479" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r479" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r79", "r479" ] }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationDueInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase obligation, year one", "label": "Purchase Obligation, to be Paid, Year One", "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase obligation, remainder of fiscal year", "label": "Purchase Obligation, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r743" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r743" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r263", "r264", "r265", "r266", "r330", "r337", "r368", "r369", "r370", "r382", "r443", "r493", "r502", "r519", "r544", "r546", "r560", "r571", "r572", "r624", "r625", "r626", "r627", "r628", "r632", "r633", "r652", "r661", "r672", "r679", "r680", "r684", "r685", "r691", "r698", "r848", "r859", "r895", "r906", "r907", "r908", "r909", "r910" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r263", "r264", "r265", "r266", "r330", "r337", "r368", "r369", "r370", "r382", "r443", "r493", "r502", "r519", "r544", "r546", "r560", "r571", "r572", "r624", "r625", "r626", "r627", "r628", "r632", "r633", "r652", "r661", "r672", "r679", "r680", "r684", "r685", "r691", "r698", "r848", "r859", "r895", "r906", "r907", "r908", "r909", "r910" ] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesPolicyTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable and Allowance for Credit Losses", "label": "Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r196", "r197", "r198", "r199", "r833" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r711", "r721", "r731", "r763" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails", "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal payment on long-term debt", "terseLabel": "Loan repayment", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r69", "r567" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal payment on note payable obligations", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r69" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r139", "r140", "r283", "r312", "r486", "r503", "r526", "r641", "r642" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r386", "r889" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r386", "r889" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r385", "r634", "r649", "r911" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r384" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r712", "r722", "r732", "r764" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r713", "r723", "r733", "r765" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r720", "r730", "r740", "r772" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r808", "r817", "r912", "r915" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails", "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exagen.com/role/OrganizationDetails", "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r57", "r87", "r531", "r554", "r559", "r568", "r582", "r687" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r107", "r142", "r143", "r144", "r147", "r154", "r156", "r158", "r234", "r240", "r250", "r387", "r388", "r395", "r396", "r397", "r400", "r407", "r408", "r417", "r420", "r421", "r424", "r435", "r472", "r474", "r550", "r552", "r569", "r949" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r99", "r100", "r170", "r174", "r175", "r186", "r188", "r190", "r191", "r192", "r327", "r328", "r520" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r602", "r635", "r643" ] }, "exdx_RoyaltyObligationPercentageOfSales": { "xbrltype": "percentItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "RoyaltyObligationPercentageOfSales", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty obligation, percent of net sales", "label": "Royalty Obligation, Percentage of Sales", "documentation": "Royalty Obligation, Percentage of Sales" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r781" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r781" ] }, "exdx_SaleOfStockAuthorizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "SaleOfStockAuthorizedAmount", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock offering, authorized amount", "label": "Sale Of Stock, Authorized Amount", "documentation": "Sale Of Stock, Authorized Amount" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from sale of stock", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.exagen.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "exdx_SaleOfStockRemainingAuthorizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "SaleOfStockRemainingAuthorizedAmount", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock offering, remaining authorized amount", "label": "Sale Of Stock, Remaining Authorized Amount", "documentation": "Sale Of Stock, Remaining Authorized Amount" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r192", "r796" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued and Other Current Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.exagen.com/role/StockOptionPlanTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Non-Cash Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r892", "r893" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.exagen.com/role/BorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6", "r479" ] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Cash and Cash Equivalents", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r12", "r92", "r915" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails", "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails", "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails", "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r339", "r341", "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r367", "r368", "r369", "r370", "r371" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.exagen.com/role/StockOptionPlanTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Unit Activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r88" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.exagen.com/role/StockOptionPlanTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r9", "r10", "r88" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.exagen.com/role/StockholdersEquityNarrativeDetails", "http://www.exagen.com/role/StockholdersEquityOutstandingWarrantsDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r28", "r29", "r30", "r31", "r32", "r33", "r83", "r85", "r86", "r87", "r119", "r120", "r121", "r172", "r310", "r311", "r312", "r314", "r317", "r322", "r324", "r564", "r565", "r566", "r567", "r661", "r793", "r818" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.exagen.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Outstanding Warrants", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r34" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Concentration of Risk, by Risk Factor and Significant Payer", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r23", "r24", "r25", "r26", "r39", "r91" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r706" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r708" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r189", "r191", "r647", "r648", "r651" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r65" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SettledLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SettledLitigationMember", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settled Litigation", "label": "Settled Litigation [Member]", "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval." } } }, "auth_ref": [ "r850" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares authorized, percentage", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options, vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r673" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Awards canceled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r360" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Awards canceled (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r360" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Awards granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r358" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails", "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Awards granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r358" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning of period (in shares)", "periodEndLabel": "Outstanding, end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r355", "r356" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number\u00a0of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning of period (in dollars per share)", "periodEndLabel": "Outstanding, end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r355", "r356" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails", "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of stock from vested restricted stock units (in shares)", "negatedLabel": "Awards released (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r359" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Awards released (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r359" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r369" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails", "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails", "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails", "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r339", "r341", "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r367", "r368", "r369", "r370", "r371" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum employee payroll deduction percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares that remain available for future awards (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Additional Disclosures [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r354" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r353" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails", "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r351" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning of period (in shares)", "periodEndLabel": "Outstanding, end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r347", "r348" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number\u00a0of Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning of period (in dollars per share)", "periodEndLabel": "Outstanding, end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r347", "r348" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise\u00a0Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r364" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable, end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r364" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercised, end of period (in shares), Weighted Average Exercise Price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r364" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r363" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r363" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, end of period (in shares), Weighted Average Exercise Price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r363" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails", "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails", "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails", "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r367", "r368", "r369", "r370", "r371" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r352" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expired (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r354" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r353" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r351" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r338", "r346", "r365", "r366", "r367", "r368", "r371", "r377", "r378", "r379", "r380" ] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Axis]", "label": "Supplier [Axis]", "documentation": "Information by supplier." } } }, "auth_ref": [] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Domain]", "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value, vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options, expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r674" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.exagen.com/role/StockOptionPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r35" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Outstanding, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r89" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r364" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r363" ] }, "exdx_ShelfRegistrationStatementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "ShelfRegistrationStatementMember", "presentation": [ "http://www.exagen.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shelf Registration Statement", "label": "Shelf Registration Statement [Member]", "documentation": "Shelf Registration Statement" } } }, "auth_ref": [] }, "us-gaap_ShippingAndHandlingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShippingAndHandlingMember", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shipping and Handling", "label": "Shipping and Handling [Member]", "documentation": "Packing and transport of product." } } }, "auth_ref": [ "r861" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r73", "r135" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r8", "r55", "r58", "r59", "r107", "r126", "r127", "r128", "r142", "r143", "r144", "r147", "r154", "r156", "r158", "r171", "r234", "r240", "r250", "r326", "r387", "r388", "r395", "r396", "r397", "r400", "r407", "r408", "r417", "r419", "r420", "r421", "r422", "r424", "r435", "r462", "r463", "r464", "r465", "r466", "r467", "r472", "r474", "r485", "r534", "r550", "r551", "r552", "r569", "r619" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r142", "r143", "r144", "r171", "r474", "r520", "r563", "r570", "r573", "r574", "r575", "r576", "r577", "r578", "r581", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r594", "r595", "r596", "r597", "r598", "r600", "r602", "r603", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r619", "r699" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r142", "r143", "r144", "r171", "r195", "r474", "r520", "r563", "r570", "r573", "r574", "r575", "r576", "r577", "r578", "r581", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r594", "r595", "r596", "r597", "r598", "r600", "r602", "r603", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r619", "r699" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r715", "r725", "r735", "r767" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of stock under Employee Stock Purchase Plan (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r8", "r54", "r55", "r87" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails", "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options (in shares)", "negatedTerseLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r8", "r54", "r55", "r87", "r352" ] }, "exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet": { "xbrltype": "sharesItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "StockIssuedDuringPeriodSharesWarrantsExercisedNet", "presentation": [ "http://www.exagen.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of common stock warrants (in shares)", "label": "Stock Issued During Period, Shares, Warrants Exercised, Net", "documentation": "Stock Issued During Period, Shares, Warrants Exercised, Net" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of stock under Employee Stock Purchase Plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r8", "r54", "r55", "r87" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r8", "r55", "r58", "r59", "r87" ] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock options", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r698" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets", "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r55", "r58", "r59", "r78", "r583", "r599", "r620", "r621", "r687", "r705", "r820", "r838", "r899", "r949" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.exagen.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r84", "r137", "r309", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r323", "r326", "r426", "r622", "r623", "r629" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.exagen.com/role/StockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of non-cash items:", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplierConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierConcentrationRiskMember", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Concentration Risk", "label": "Supplier Concentration Risk [Member]", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services." } } }, "auth_ref": [ "r76" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r761" ] }, "exdx_Term2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "Term2017Member", "presentation": [ "http://www.exagen.com/role/BorrowingsNarrativeDetails", "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2017 Term loan", "label": "Term 2017 [Member]", "documentation": "Term 2017" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r753" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r760" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r780" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r782" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.exagen.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.exagen.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r304", "r322", "r425", "r457", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r535", "r676", "r677", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r688", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r834", "r835", "r836", "r837", "r891", "r894", "r895", "r896", "r897", "r898" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r783" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r784" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r784" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r782" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r782" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r785" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r783" ] }, "exdx_TwoMajorSuppliersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "TwoMajorSuppliersMember", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Two Major Suppliers", "label": "Two Major Suppliers [Member]", "documentation": "Two Major Suppliers" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r409" ] }, "exdx_USDepartmentOfJusticeCaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exagen.com/20240930", "localname": "USDepartmentOfJusticeCaseMember", "presentation": [ "http://www.exagen.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Department Of Justice Case", "label": "U.S. Department Of Justice Case [Member]", "documentation": "U.S. Department Of Justice Case" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r779" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r749" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase common stock", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r696", "r697", "r700", "r701", "r702", "r703" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of shares used to compute net loss per share, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r161", "r166" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of shares used to compute net loss per share, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r160", "r166" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r747" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r793": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org/705/tableOfContent" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 61 0001274737-24-000092-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001274737-24-000092-xbrl.zip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end XML 62 exdx-20240930_htm.xml IDEA: XBRL DOCUMENT 0001274737 2024-01-01 2024-09-30 0001274737 2024-11-08 0001274737 2024-09-30 0001274737 2023-12-31 0001274737 2024-07-01 2024-09-30 0001274737 2023-07-01 2023-09-30 0001274737 2023-01-01 2023-09-30 0001274737 us-gaap:CommonStockMember 2023-12-31 0001274737 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001274737 us-gaap:RetainedEarningsMember 2023-12-31 0001274737 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001274737 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001274737 2024-01-01 2024-03-31 0001274737 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001274737 us-gaap:CommonStockMember 2024-03-31 0001274737 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001274737 us-gaap:RetainedEarningsMember 2024-03-31 0001274737 2024-03-31 0001274737 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001274737 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001274737 2024-04-01 2024-06-30 0001274737 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001274737 us-gaap:CommonStockMember 2024-06-30 0001274737 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001274737 us-gaap:RetainedEarningsMember 2024-06-30 0001274737 2024-06-30 0001274737 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001274737 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001274737 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001274737 us-gaap:CommonStockMember 2024-09-30 0001274737 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001274737 us-gaap:RetainedEarningsMember 2024-09-30 0001274737 us-gaap:CommonStockMember 2022-12-31 0001274737 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001274737 us-gaap:RetainedEarningsMember 2022-12-31 0001274737 2022-12-31 0001274737 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001274737 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001274737 2023-01-01 2023-03-31 0001274737 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001274737 us-gaap:CommonStockMember 2023-03-31 0001274737 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001274737 us-gaap:RetainedEarningsMember 2023-03-31 0001274737 2023-03-31 0001274737 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001274737 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001274737 2023-04-01 2023-06-30 0001274737 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001274737 us-gaap:CommonStockMember 2023-06-30 0001274737 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001274737 us-gaap:RetainedEarningsMember 2023-06-30 0001274737 2023-06-30 0001274737 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001274737 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001274737 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001274737 us-gaap:CommonStockMember 2023-09-30 0001274737 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001274737 us-gaap:RetainedEarningsMember 2023-09-30 0001274737 2023-09-30 0001274737 exdx:MedicareAdvantageMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001274737 exdx:MedicareAdvantageMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001274737 exdx:MedicareAdvantageMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001274737 exdx:MedicareAdvantageMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001274737 exdx:MedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001274737 exdx:MedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001274737 exdx:MedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001274737 exdx:MedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001274737 exdx:MedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001274737 exdx:MedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001274737 exdx:MedicareAdvantageMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001274737 exdx:MedicareAdvantageMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001274737 exdx:AVISECTDTestMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-07-01 2024-09-30 0001274737 exdx:AVISECTDTestMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001274737 exdx:AVISECTDTestMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-09-30 0001274737 exdx:AVISECTDTestMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001274737 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember exdx:TwoMajorSuppliersMember 2024-07-01 2024-09-30 0001274737 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember exdx:TwoMajorSuppliersMember 2023-07-01 2023-09-30 0001274737 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember exdx:TwoMajorSuppliersMember 2024-01-01 2024-09-30 0001274737 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember exdx:TwoMajorSuppliersMember 2023-01-01 2023-09-30 0001274737 exdx:HealthcareInsurersMember 2024-07-01 2024-09-30 0001274737 exdx:HealthcareInsurersMember 2023-07-01 2023-09-30 0001274737 exdx:HealthcareInsurersMember 2024-01-01 2024-09-30 0001274737 exdx:HealthcareInsurersMember 2023-01-01 2023-09-30 0001274737 exdx:Government1Member 2024-07-01 2024-09-30 0001274737 exdx:Government1Member 2023-07-01 2023-09-30 0001274737 exdx:Government1Member 2024-01-01 2024-09-30 0001274737 exdx:Government1Member 2023-01-01 2023-09-30 0001274737 exdx:ClientMember 2024-07-01 2024-09-30 0001274737 exdx:ClientMember 2023-07-01 2023-09-30 0001274737 exdx:ClientMember 2024-01-01 2024-09-30 0001274737 exdx:ClientMember 2023-01-01 2023-09-30 0001274737 us-gaap:OtherCustomerMember 2024-07-01 2024-09-30 0001274737 us-gaap:OtherCustomerMember 2023-07-01 2023-09-30 0001274737 us-gaap:OtherCustomerMember 2024-01-01 2024-09-30 0001274737 us-gaap:OtherCustomerMember 2023-01-01 2023-09-30 0001274737 us-gaap:ShippingAndHandlingMember 2024-07-01 2024-09-30 0001274737 us-gaap:ShippingAndHandlingMember 2023-07-01 2023-09-30 0001274737 us-gaap:ShippingAndHandlingMember 2024-01-01 2024-09-30 0001274737 us-gaap:ShippingAndHandlingMember 2023-01-01 2023-09-30 0001274737 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001274737 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001274737 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001274737 us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001274737 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001274737 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001274737 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001274737 us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0001274737 us-gaap:EmployeeStockMember 2023-01-01 2023-09-30 0001274737 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001274737 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001274737 exdx:LaboratoryEquipmentMember 2024-09-30 0001274737 exdx:LaboratoryEquipmentMember 2023-12-31 0001274737 exdx:ComputerEquipmentAndSoftwareMember 2024-09-30 0001274737 exdx:ComputerEquipmentAndSoftwareMember 2023-12-31 0001274737 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001274737 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001274737 us-gaap:ConstructionInProgressMember 2024-09-30 0001274737 us-gaap:ConstructionInProgressMember 2023-12-31 0001274737 exdx:Term2017Member exdx:InnovatusLifeSciencesLendingFundMember us-gaap:LoansPayableMember 2017-09-01 2017-09-30 0001274737 exdx:Term2017Member exdx:InnovatusLifeSciencesLendingFundMember us-gaap:LoansPayableMember 2024-09-30 0001274737 exdx:Term2017Member exdx:InnovatusLifeSciencesLendingFundMember us-gaap:LoansPayableMember 2023-04-28 2023-04-28 0001274737 exdx:Term2017Member exdx:InnovatusLifeSciencesLendingFundMember us-gaap:LoansPayableMember 2023-04-28 0001274737 exdx:Term2017Member exdx:InnovatusLifeSciencesLendingFundMember us-gaap:LoansPayableMember 2024-01-01 2024-09-30 0001274737 exdx:Term2017Member exdx:InnovatusLifeSciencesLendingFundMember us-gaap:PaymentInKindPIKNoteMember 2023-07-01 2023-09-30 0001274737 exdx:Term2017Member exdx:InnovatusLifeSciencesLendingFundMember us-gaap:PaymentInKindPIKNoteMember 2024-07-01 2024-09-30 0001274737 exdx:Term2017Member exdx:InnovatusLifeSciencesLendingFundMember us-gaap:PaymentInKindPIKNoteMember 2024-01-01 2024-09-30 0001274737 exdx:Term2017Member exdx:InnovatusLifeSciencesLendingFundMember us-gaap:PaymentInKindPIKNoteMember 2023-01-01 2023-09-30 0001274737 exdx:EquipmentNotesPayableMember 2024-09-30 0001274737 srt:MinimumMember us-gaap:LicenseAgreementTermsMember 2024-09-30 0001274737 srt:MaximumMember us-gaap:LicenseAgreementTermsMember 2024-09-30 0001274737 exdx:AlleghenyHealthNetworkResearchInstituteMember 2021-05-01 2021-05-31 0001274737 exdx:AHNCollaborationMember 2024-07-01 2024-09-30 0001274737 exdx:AHNCollaborationMember 2023-07-01 2023-09-30 0001274737 exdx:AHNCollaborationMember 2024-01-01 2024-09-30 0001274737 exdx:AHNCollaborationMember 2023-01-01 2023-09-30 0001274737 2024-08-31 0001274737 exdx:USDepartmentOfJusticeCaseMember us-gaap:SettledLitigationMember 2023-10-01 2023-10-31 0001274737 exdx:Term2017Member us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001274737 exdx:Term2017Member us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001274737 exdx:EquipmentNotesPayableMember 2023-12-31 0001274737 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001274737 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001274737 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001274737 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001274737 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001274737 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001274737 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001274737 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001274737 exdx:ShelfRegistrationStatementMember 2023-11-17 0001274737 exdx:ShelfRegistrationStatementMember 2024-09-30 0001274737 exdx:CowenEquityDistributionAgreementMember 2022-09-15 2022-09-15 0001274737 exdx:ExpirationJan192026Member 2024-09-30 0001274737 exdx:ExpirationMar312026Member 2024-09-30 0001274737 exdx:ExpirationApr12026Member 2024-09-30 0001274737 exdx:ExpirationDec72025Member 2024-09-30 0001274737 exdx:NoExpirationMember 2024-09-30 0001274737 us-gaap:EmployeeStockOptionMember exdx:IncentiveAwardPlan2019Member 2024-01-01 2024-09-30 0001274737 us-gaap:EmployeeStockOptionMember exdx:IncentiveAwardPlan2019Member 2024-09-30 0001274737 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001274737 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001274737 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001274737 us-gaap:EmployeeStockOptionMember 2023-12-31 0001274737 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001274737 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001274737 us-gaap:EmployeeStockOptionMember 2024-09-30 0001274737 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001274737 us-gaap:EmployeeStockMember 2024-09-30 0001274737 us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0001274737 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001274737 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0001274737 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001274737 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0001274737 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001274737 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0001274737 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001274737 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001274737 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001274737 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001274737 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 shares iso4217:USD iso4217:USD shares pure exdx:segment exdx:installment 0001274737 --12-31 2024 Q3 false 10-Q true 2024-09-30 false 001-39049 EXAGEN INC. DE 20-0434866 1261 Liberty Way Vista CA 92081 760 560-1501 Common Stock, par value $0.001 per share XGN NASDAQ Yes Yes Non-accelerated Filer true true false false 17637278 22035000 36493000 9387000 6551000 4135000 4797000 35557000 47841000 4855000 5201000 2630000 3286000 563000 616000 43605000 56944000 1105000 3131000 6177000 7531000 1065000 976000 430000 264000 8777000 11902000 19823000 19231000 1952000 2760000 185000 357000 30737000 34250000 0.001 0.001 10000000 10000000 0 0 0 0 0 0 0.001 0.001 200000000 200000000 17520335 17520335 17045954 17045954 18000 17000 303420000 301893000 -290570000 -279216000 12868000 22694000 43605000 56944000 12507000 13416000 41986000 38783000 5526000 5710000 17351000 17472000 10163000 11375000 31169000 35212000 1481000 1400000 3719000 3789000 17170000 18485000 52239000 56473000 -4663000 -5069000 -10253000 -17690000 562000 557000 1671000 1769000 197000 211000 570000 1343000 -5028000 -5415000 -11354000 -18116000 -0.28 -0.28 -0.31 -0.31 -0.63 -0.63 -1.03 -1.03 18254937 18254937 17692603 17692603 18127549 18127549 17626686 17626686 17045954 17000 301893000 -279216000 22694000 217056 54605 104000 104000 326 553000 553000 -3360000 -3360000 17317941 17000 302550000 -282576000 19991000 62998 636 560000 560000 -2966000 -2966000 17381575 17000 303110000 -285542000 17585000 13155 41443 1000 71000 72000 84162 22000 22000 217000 217000 -5028000 -5028000 17520335 18000 303420000 -290570000 12868000 16549984 17000 297970000 -255527000 42460000 113378 93335 27000 27000 70317 152000 152000 986000 986000 -7688000 -7688000 16827014 17000 299135000 -263215000 35937000 31180 978000 978000 -5013000 -5013000 16858194 17000 300113000 -268228000 31902000 14424 59276 127000 127000 890000 890000 -5415000 -5415000 16931894 17000 301130000 -273643000 27504000 -11354000 -18116000 1309000 1661000 112000 119000 206000 294000 -111000 -209000 656000 717000 1330000 2854000 2836000 10967000 -662000 -727000 -50000 120000 -720000 -767000 -2028000 -1422000 -1140000 2000000 -13642000 -22811000 369000 722000 0 2000 -369000 -720000 22000 27000 176000 279000 379000 541000 266000 177000 0 10000000 -447000 -10412000 -14458000 -33943000 36693000 62591000 22235000 28648000 1307000 1336000 706000 250000 20000 81000 Organization<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exagen Inc. (the Company) is a commercial-stage diagnostics company which exists to provide clarity in autoimmune disease decision making with the goal of improving patients' clinical outcomes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses. As of September 30, 2024, the Company had cash and cash equivalents of $22.0 million and had an accumulated deficit of $290.6 million. Since inception, the Company has financed its operations primarily through a combination of equity financings, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it may need to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div> 22000000.0 -290600000 Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed balance sheet as of September 30, 2024, condensed statements of operations and stockholders' equity for the three and nine months ended September 30, 2024 and 2023, cash flows for the nine months ended September 30, 2024 and 2023 and the related footnote disclosures are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. These unaudited condensed financial statements and related footnote disclosures should be read in conjunction with the Company’s audited financial statements for the fiscal year ended December 31, 2023, included in its Annual Report on Form 10-K filed with the SEC on March 18, 2024. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all normal adjustments necessary for the fair presentation of the Company's financial position as of September 30, 2024 and its results of operations for the periods presented. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the recoverability of its long-lived assets and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable, Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2024 and 2023, approximately 93% and 89%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test. Revenue related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test for the nine months ended September 30, 2024 and 2023 was approximately 91% and 88%, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on key suppliers for certain laboratory materials. For the three months ended September 30, 2024 and 2023, approximately 98% and 98%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. For the nine months ended September 30, 2024 and 2023, approximately 97% and 97%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the Company's revenues as disaggregated by payor and customer category (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,090 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,314 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,955 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,507 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,416 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,986 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,783 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an arrangement with a financial institution with which it has an existing banking relationship, whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a certificate of deposit with this financial institution in the amount of $0.2 million as collateral for the balances borrowed on these cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,035 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,235 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,693 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, the Company combines its intangible assets and other long-lived assets, into groupings, a determination which is made principally on the basis of whether the assets are specific to a particular test offered or technology being developed. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset’s carrying amount. Management’s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (hospitals, other laboratories, etc.) and patient self-pay. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and follows a five-step process to determine the amount and timing of revenue recognized: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligation is satisfied. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are generally billed at the Company's list price unless a separate pricing contract is in place. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the three months ended September 30, 2024 and 2023 was a $0.6 million net revenue increase and a $2.5 million net revenue increase, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. Included in revenues for the nine months ended September 30, 2024 and 2023 was a $6.2 million net revenue increase and a $2.6 million net revenue increase, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company’s balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information, along with any requested medical or other claims-related information to the healthcare insurers. This generally occurs within 30 to 90 days of billing, however, the amount and timing of any reimbursements or collections for the Company's billed tests may vary by payor and other circumstances. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue an allowance for credit losses against our accounts receivable based on management’s current estimate of amounts that will not be collected. Management’s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was zero as of September 30, 2024 and 2023. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense; materials; laboratory supplies; consulting costs; costs associated with setting up and conducting clinical studies; depreciation; amortization and allocated overhead, including rent and utilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.4 million and $0.5 million for the three months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024 and 2023, total advertising and marketing costs were approximately $1.0 million and $1.2 million, respectively. These costs are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and were approximately $0.9 million and $0.6 million for the three months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024 and 2023, shipping and handling costs were approximately $2.5 million and $1.9 million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method, as we have concluded that our stock option exercise history does not provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each restricted stock unit (RSU) is determined on the grant date using the closing price of the Company's common stock on that date. The Company's RSUs generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of the RSU is subject to the holder's continued service with the Company. The Company issues new shares of common stock to satisfy the RSUs upon vesting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, RSUs outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three and nine months ended September 30, 2024 and 2023, there is no difference in the number of shares used to calculate basic and diluted shares outstanding, as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325,330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576,151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,004,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,810,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,568,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,724,519 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,994,617 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, Accounting Standards Updates (ASU) not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company's financial statements or disclosures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2023-07), which requires public entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (CODM) and details of how the CODM uses financial reporting to assess the performance of a segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU will likely result in additional required disclosure when adopted.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2023-09), which requires additional income tax disclosures in the rate reconciliation table for federal, state and foreign income taxes, in addition to more details about the reconciling items in some categories when items meet a certain quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 with early adoption permitted. The Company does not expect that this standard will have a material impact on its financial statements.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.</span></div> For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable, Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div> 0.22 0.15 0.21 0.17 0.20 0.37 0.24 0.35 0.23 0.42 0.22 0.16 0.93 0.89 0.91 0.88 0.98 0.98 0.97 0.97 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the Company's revenues as disaggregated by payor and customer category (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,090 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,314 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,955 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,507 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,416 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,986 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,783 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> 6779000 6090000 22314000 17789000 2633000 4955000 10276000 13570000 2981000 2319000 9175000 6999000 114000 52000 221000 425000 12507000 13416000 41986000 38783000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.</span></div> 200000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,035 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,235 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,693 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,035 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,235 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,693 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 22035000 36493000 200000 200000 22235000 36693000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div>The Company’s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, the Company combines its intangible assets and other long-lived assets, into groupings, a determination which is made principally on the basis of whether the assets are specific to a particular test offered or technology being developed. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset’s carrying amount. Management’s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (hospitals, other laboratories, etc.) and patient self-pay. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and follows a five-step process to determine the amount and timing of revenue recognized: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligation is satisfied. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are generally billed at the Company's list price unless a separate pricing contract is in place. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the three months ended September 30, 2024 and 2023 was a $0.6 million net revenue increase and a $2.5 million net revenue increase, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. Included in revenues for the nine months ended September 30, 2024 and 2023 was a $6.2 million net revenue increase and a $2.6 million net revenue increase, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company’s balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information, along with any requested medical or other claims-related information to the healthcare insurers. This generally occurs within 30 to 90 days of billing, however, the amount and timing of any reimbursements or collections for the Company's billed tests may vary by payor and other circumstances. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div> 600000 2500000 6200000 2600000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div>We accrue an allowance for credit losses against our accounts receivable based on management’s current estimate of amounts that will not be collected. Management’s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was zero as of September 30, 2024 and 2023. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses. 0 0 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense; materials; laboratory supplies; consulting costs; costs associated with setting up and conducting clinical studies; depreciation; amortization and allocated overhead, including rent and utilities.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.4 million and $0.5 million for the three months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024 and 2023, total advertising and marketing costs were approximately $1.0 million and $1.2 million, respectively. These costs are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div> 400000 500000 1000000.0 1200000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div>Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations 900000 600000 2500000 1900000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method, as we have concluded that our stock option exercise history does not provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each restricted stock unit (RSU) is determined on the grant date using the closing price of the Company's common stock on that date. The Company's RSUs generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of the RSU is subject to the holder's continued service with the Company. The Company issues new shares of common stock to satisfy the RSUs upon vesting.</span></div> 0 P4Y <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, RSUs outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three and nine months ended September 30, 2024 and 2023, there is no difference in the number of shares used to calculate basic and diluted shares outstanding, as the inclusion of the potentially dilutive securities would be antidilutive.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325,330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576,151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,004,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,810,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,568,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,724,519 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,994,617 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 325330 409108 576151 1004855 1810468 1568112 12570 12542 2724519 2994617 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div> 1 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, Accounting Standards Updates (ASU) not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company's financial statements or disclosures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2023-07), which requires public entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (CODM) and details of how the CODM uses financial reporting to assess the performance of a segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU will likely result in additional required disclosure when adopted.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2023-09), which requires additional income tax disclosures in the rate reconciliation table for federal, state and foreign income taxes, in addition to more details about the reconciling items in some categories when items meet a certain quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 with early adoption permitted. The Company does not expect that this standard will have a material impact on its financial statements.</span></div> Other Financial Information<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                     </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic testing supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,934 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,871 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,860 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,135 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,797 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,089 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,454 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,970 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,599)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,855 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,201 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the three months ended September 30, 2024 and 2023 was approximately $0.4 million and $0.6 million, respectively. For the nine months ended September 30, 2024 and 2023, depreciation and amortization expense was approximately $1.3 million and $1.7 million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Other Current Liabilities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued payroll and related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,413 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,738 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease obligations, current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Refund liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,177 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,531 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                     </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic testing supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,934 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,871 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,860 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,135 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,797 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div> 2934000 2871000 32000 35000 1169000 1860000 0 31000 4135000 4797000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,089 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,454 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,970 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,599)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,855 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,201 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div> 98000 98000 4209000 5312000 2113000 2185000 3089000 3316000 945000 59000 10454000 10970000 5599000 5769000 4855000 5201000 400000 600000 1300000 1700000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued payroll and related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,413 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,738 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease obligations, current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Refund liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,177 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,531 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div> 4413000 4738000 547000 720000 283000 490000 266000 302000 668000 1281000 6177000 7531000 Borrowings<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Term Loan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), as amended (the Amended Loan Agreement), pursuant to which the Company borrowed $25.0 million. As of September 30, 2024, no additional amounts remained available to borrow under the Amended Loan Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 28, 2023, the Company entered into the Amended Loan Agreement. The Amended Loan Agreement was treated as a modification. In connection with the Amended Loan Agreement, the Company repaid $10.0 million of the principal balance outstanding, for which the prepayment premium was waived. Pursuant to the Amended Loan Agreement, the interest rate on all borrowings under the Amended Loan Agreement is the sum (the Basic Rate) of (a) the greater of 8.0% or The Wall Street Journal prime rate (the Prime Rate), plus (b) 2.0%, which is paid-in-kind in the form of additional term loans (PIK Loans). Under the Amended Loan Agreement, an amount equal to 1.5% of the Basic Rate will be payable in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until April 1, 2026, after which interest is scheduled to accrue at the Basic Rate. The maturity date of the loan was extended to December 31, 2026. The Company estimated the effective interest rate of this loan to be approximately 10.6% as of September 30, 2024. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest under the Amended Loan Agreement is to be repaid in ten equal monthly installments commencing in April 2026. Upon repayment of the final installment under the Amended Loan Agreement, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of the loan using the effective interest method. For each of the three months ended September 30, 2024 and 2023, the Company issued PIK Loans totaling $0.1 million. For the nine months ended September 30, 2024 and 2023, the Company issued PIK Loans totaling $0.2 million and $0.3 million, respectively. The issuances of the PIK Loans are included in borrowings-non-current portion on the accompanying balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Loan Agreement requires a prepayment premium of 1% of the aggregate outstanding principal for any prepayments made prior to November 1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Loan Agreement is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Amended Loan Agreement require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis, however the Company is not required to comply with the revenue covenant for any quarter during which it maintains a minimum aggregate cash balance equal to fifty percent of the aggregate principal amount of the Amended Loan Agreement (excluding any capitalized interest paid-in-kind) at all times during such quarter. The consequences of failing to achieve the performance covenants, when applicable, will be cured if, (i) within thirty days of failing to achieve the performance covenant, the Company submits a new financial plan approved by the Company's board of directors (the Board) to Innovatus under which the Company is expected to break even on a cash flow basis prior to the maturity date, and (ii) within thirty days of the submission of such financial plan, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined in the Amended Loan Agreement. The Amended Loan Agreement requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative covenants provide, among other things, that without the prior consent of Innovatus, subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Amended Loan Agreement provides that an event of default will occur if, among other triggers, (i) the Company defaults in the payment of any amount payable under the agreement when due, (ii) there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii) the Company becomes insolvent, (iv) the Company undergoes a change in control or (v) the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, the Company was in compliance with all covenants of the Amended Loan Agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an event of default in any of the Amended Loan Agreement covenants, the repayment of the 2017 Term Loan may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the 2017 Term Loan can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the Amended Loan Agreement due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equipment Notes Payable</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the Company purchased additional laboratory equipment using notes payable. At September 30, 2024, the total notes payable balance related to the financed equipment was $1.2 million, with $0.4 million classified within borrowings-current portion and $0.8 million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. The notes related to the financed equipment are subject to a 5.28% effective interest rate and will mature between October 1, 2026 and April 1, 2028.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Minimum Payments on the Outstanding Borrowings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,296 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,963)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,253 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Borrowings-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,823 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 25000000 0 10000000 0.080 0.020 0.015 0.106 10 1000000 100000 100000 200000 300000 0.01 P12M 0.50 P30D P30D 2000000.0 0.040 1200000 400000 800000 0.0528 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,296 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,963)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,253 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Borrowings-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,823 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 517000 2097000 21400000 215000 67000 24296000 80000 3963000 20253000 430000 19823000 Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements, individual license agreements generally provide for ongoing royalty payments ranging from 2.0% to 7.0% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when incurred and recorded in costs of revenue in the accompanying condensed statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Obligations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a master research collaboration agreement with Allegheny Health Network Research Institute (AHN), pursuant to which the Company is required to pay AHN a collaboration fee of $0.4 million per year. Collaboration expenses under the master research collaboration agreement were $0.1 million for each of the three months ended September 30, 2024 and 2023. For each of the nine months ended September 30, 2024 and 2023, collaboration expenses under the master research collaboration agreement were $0.3 million. Collaboration expenses under the AHN collaboration are included in research and development expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supply Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company amended a supply agreement with one supplier for reagents, which includes pricing terms and minimum purchase commitments, through December 31, 2025, for new consumable products related to the Company's launch of the RA Sub-Profile Biomarkers. Aggregate minimum annual purchase commitments related to such agreement for the years ending December 31, 2024 and 2025 are $8.4 million and $10.4 million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including for subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities. The Company does not believe the outcome of any such matters will have a material effect on its financial position or results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in October 2023, the Company resolved an investigation with the U.S. Attorney’s Office for the District of Massachusetts that was initiated by a qui tam lawsuit. Pursuant to a settlement agreement entered into by and between the Company and the U.S. Department of Justice (the Settlement Agreement), the Company made a single lump-sum remittance to the government in the amount of $0.7 million, including interest, in connection with specimen processing arrangements that Exagen historically had with physicians. The U.S. Attorney’s Office dismissed this “covered conduct” in the qui tam lawsuit with prejudice, while non-covered conduct was dismissed without prejudice. The Department of Justice excused itself from the case in connection with the settlement. In November 2023, the complaint was unsealed by the court and served on Exagen by the relator. Exagen filed a motion to dismiss the complaint. In December 2023, the Company's insurance carrier provided reimbursement for certain defense costs the Company incurred in the October 2023 qui tam lawsuit. In February 2024, the relator filed a motion for leave to amend the complaint. Exagen opposed this motion, and all motions are still pending. The Company cannot predict when these matters will be resolved, the outcome of these matters, or their potential impact, which may materially and adversely affect the Company’s business, prospects, and financial condition. The Company intends to vigorously defend against the claims being asserted in the complaint.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's participation in federal healthcare programs is not affected by the Settlement Agreement.</span></div> 0.020 0.070 400000 100000 100000 300000 300000 8400000 10400000 700000 Fair Value Measurements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature, which are determined to be a Level 1 measurement. The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for the same or similar issues. As of September 30, 2024, the 2017 Term Loan had a carrying value of $19.0 million and a fair value of $18.5 million. As of December 31, 2023, the 2017 Term Loan had a carrying value of $18.7 million and a fair value of $19.7 million. The estimated fair value of the 2017 Term Loan was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The carrying value of the Company's other long-term borrowing at September 30, 2024 was $1.2 million and approximated its fair value. At December 31, 2023, the carrying value of the Company's other long-term borrowing was $0.8 million and approximated its fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -    Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -    Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -    Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,963 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,963 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,386 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,386 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's money market funds is based on quoted market prices.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature, which are determined to be a Level 1 measurement. The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for the same or similar issues. As of September 30, 2024, the 2017 Term Loan had a carrying value of $19.0 million and a fair value of $18.5 million. As of December 31, 2023, the 2017 Term Loan had a carrying value of $18.7 million and a fair value of $19.7 million. The estimated fair value of the 2017 Term Loan was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The carrying value of the Company's other long-term borrowing at September 30, 2024 was $1.2 million and approximated its fair value. At December 31, 2023, the carrying value of the Company's other long-term borrowing was $0.8 million and approximated its fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -    Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -    Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -    Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div>The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. 19000000.0 18500000 18700000 19700000 1200000 800000 The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,963 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,963 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,386 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,386 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 14963000 14963000 0 0 14386000 14386000 0 0 Stockholders' Equity<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shelf Registration Statement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2023, the Company filed a registration statement on Form S-3, as amended (the 2023 Shelf Registration Statement), covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units. The 2023 Shelf Registration Statement became effective on November 29, 2023, and all $150.0 million remain available for sale as of September 30, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At The Market Sales Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the Company entered into a sales agreement, as amended on November 17, 2023 (the Sales Agreement) with Cowen and Company, LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $50.0 million. The Company is not obligated to sell any shares of Company common stock in the offering. As of September 30, 2024, the Company has not sold any shares of its common stock pursuant to the Sales Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Warrants</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following equity classified warrants to purchase common stock were outstanding as of September 30, 2024:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237,169</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,086</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,951</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,130,281</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2024, no warrants to purchase common stock were exercised.</span></div> 150000000 150000000 50000000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following equity classified warrants to purchase common stock were outstanding as of September 30, 2024:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237,169</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,086</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,951</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,130,281</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 237169 1.84 67086 1.84 131 1.84 20944 14.32 804951 0.001 1130281 0 0 Stock Option Plan<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Incentive Award Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Board adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board and is generally four years from the date of grant or, for grants to new hires, date of hire. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) 4% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board. As of September 30, 2024, 2,122,271 shares of common stock remained available for future awards under the 2019 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,387,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,287,225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(293,209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(571,007)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, September 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,810,468 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, all of the outstanding RSUs were unvested. The fair value of RSUs vested in the nine months ended September 30, 2024 and 2023 was $0.5 million and $0.4 million, respectively. The weighted average grant date fair value for RSUs granted in the nine months ended September 30, 2024 and 2023 was $2.09 and $2.42, respectively. As of September 30, 2024, total unrecognized compensation cost related to RSUs was $3.7 million, which is expected to be recognized over a remaining weighted-average vesting period of 3.0 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the 2019 Plan is set forth below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(371,526)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, September 30, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576,151 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, September 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576,151 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, September 30, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552,686 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were 55,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 73,500 stock options granted in the nine months ended September 30, 2024 and 2023, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The aggregate intrinsic value of options exercised during the nine months ended September 30, 2024 was $0.3 million. The aggregate intrinsic value of options exercised during the nine months ended September 30, 2023 was $0.2 million. As of September 30, 2024, total unrecognized compensation cost related to option awards was less than $0.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.29 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Board adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Board. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the lesser of (i) 1% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board. As of September 30, 2024, 523,744 shares of common stock remained available for issuance under the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted, RSUs granted and stock purchase rights granted under the ESPP in the condensed statements of operations is as follows (in thousands):</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">890 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,330 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,854 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P10Y P4Y 0.04 2122271 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,387,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,287,225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(293,209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(571,007)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, September 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,810,468 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1387459 4.24 1287225 2.09 293209 5.87 571007 4.16 1810468 2.47 500000 400000 2.09 2.42 3700000 P3Y <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the 2019 Plan is set forth below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(371,526)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, September 30, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576,151 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, September 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576,151 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, September 30, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552,686 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 986819 11.87 P6Y5M8D 228000 55500 1.99 85124 0.26 9518 16.70 371526 15.48 576151 10.23 P6Y6M25D 197000 576151 10.23 P6Y6M25D 197000 552686 10.56 P6Y5M12D 177000 55500 73500 300000 200000 100000 P2Y3M14D 0.20 0.01 523744 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted, RSUs granted and stock purchase rights granted under the ESPP in the condensed statements of operations is as follows (in thousands):</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">890 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,330 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,854 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 47000 45000 103000 161000 114000 792000 1058000 2497000 56000 53000 169000 196000 217000 890000 1330000 2854000 false false false false

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